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Summary of thesis 
Schizophrenia is a disabling mental disorder, which imposes a great economic and non-
economic burden on family and society. Economic burden mainly comes from the cost of 
treatment of schizophrenia, which is directly related to its prevalence. Non-economic burden is 
related to negative outcomes of schizophrenia, which includes co-morbidities and adverse 
impacts on family members. The current thesis therefore aims to contribute to elucidate the 
nature of the overall burden of schizophrenia. Therefore, we studied demographic and genetic 
risk factors of schizophrenia, which indirectly determine schizophrenia prevalence; we also 
studied the negative outcomes of schizophrenia, including comorbidity tardive dyskinesia and 
adverse impacts on offspring poor school performance. In identifying demographic risk factors, 
we found that male gender and positive family history were associated with a significant earlier 
onset of schizophrenia. These findings clarify the inconsistencies on the effects of gender and 
family history on schizophrenia onset age in an Asian population. In identifying genetic risk 
factors, we found that the underlying gene for the advancement of onset age was CNTN5, a 
gene involving in axon development. We also found that CAMs and ARVC pathway were the 
most significant pathways for schizophrenia development. These findings improve the current 
understanding of the genetic mechanism for schizophrenia development. Besides these findings 
in risk factors of schizophrenia, we also found out that senior age, rather than antipsychotic 
usage, was the major risk factor of a negative outcome of schizophrenia: tardive dyskinesia. 
These findings clarify the possible confounding effects between age and antipsychotic usage on 
tardive dyskinesia. We also found out that the negative influence of schizophrenia on offspring 
school performance was not due to the schizophrenia associated family environments, but rather 
the genes that run in schizophrenia families. These findings relieve schizophrenia patients from 
blaming themselves for not taking care of their children. In summary, our findings contribute to 
the knowledge of risk factors of schizophrenia and also enhance the understanding of the 
negative outcomes of schizophrenia, which help to elucidate the nature of the economic and 
non-economic burden of schizophrenia.  
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Chapter 1 Introduction  
In the past 200 years, there has been a great improvement in treatments of human diseases. 
Especially, numerous infectious diseases that were lethal in the past are curable now, and 
thousands of lives have been saved. In the past several decades, however, the focus of medical 
and clinical research has been moved to complex disorders. Complex disorders are the disorders 
caused by multiple genetic and environmental factors. These disorders are usually difficult to be 
treated. Great efforts have been made to understand the risk factors, etiology, outcomes, 
treatments and impacts of complex disorders. However, the improvements in these areas are 
generally inadequate considering the great burden of the disorders on family and society. 
Schizophrenia is one type of complex disorder and has gained a great of attentions since the 
early of last century due to its disabling nature. A large number of studies have been conducted 
to understand the risk factors and outcomes of schizophrenia so that the burden of schizophrenia 
could potentially be reduced. This chapter therefore describes the clinical features of 
schizophrenia, the determinants of its burden on family and society, and the risk factors and 
negative outcomes of the disorder, which pave the road to the research studies in this thesis.  
1. 1 Schizophrenia symptoms, diagnosis and treatments 
Schizophrenia is a chronic, severe and disabling mental disorder characterized by thoughts, 
behavior and social dysfunctions. Patients with schizophrenia usually have a variety of 
observable symptoms. These symptoms can be classified into two broad categories: positive 
symptoms and negative symptoms. Positive symptoms are symptoms that healthy individuals do 
not normally experience but are present in people with schizophrenia. They include delusion, 
hallucinations, disorganized speech and non-goal orientated behaviors. Negative symptoms are 
deficits of aspects of functioning that healthy individuals normally have but are either absent or 
diminished in people with schizophrenia. Examples include poverty of speech, reduction of 
emotional expression, inability to experience pleasure, and a lack of desire to establish a 
relationship. Because of these symptoms, patients with schizophrenia are unable to 
communicate effectively or maintain goal orientated work, which usually results in 
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unemployment. In addition, schizophrenia patients are unable to take care of themselves and 
maintain personal hygiene. Because of these consequences, schizophrenia is considered one of 
the most disabling mental disorders.  
Since there is no biological marker for schizophrenia, the diagnosis of schizophrenia is based on 
the symptoms. To avoid subjectivity in assessing the symptoms in diagnosis, a number of 
diagnostic systems have been developed. These systems include Schneider’s First-rank System, 
New Haven Schizophrenia Index, Flexible System, Feighner Criteria, Research Diagnostic 
Criteria, and Diagnostic and Statistical Manual of Mental Disorders (DSM). DSM was 
developed by the American Psychiatric Association (APA), and it has become the most 
commonly used diagnostic criteria for mental disorders, including schizophrenia. Clinicians can 
follow its structured diagnostic criteria in assessing the symptoms of patients and determine 
which mental disorder the patients have. In such a way, the subjectivity of diagnosis is reduced. 
DSM diagnostic system is constantly under review and revision, and the latest edition is DSM-
IV text revision (DSM-IV-TR) published in 2000. The fifth edition (DSM-V) is currently in the 
consultation, planning and preparation stage and is due for publication in 2013 (Stein et al., 
2010).  
There is no cure for schizophrenia. However, the symptoms of schizophrenia are treatable. The 
most common treatments are antipsychotic medication treatments. Antipsychotics are small 
chemical compounds that have serotonin-dopamine antagonism functions. To date, two 
categories of antipsychotics have been developed: typical antipsychotics and atypical 
antipsychotics. Typical antipsychotics mainly block receptors in dopamine pathways and can 
effectively reduce the severity of positive symptoms of schizophrenia (e.g. hallucinations and 
delusions). However, they may also give rise to extra-pyramidal side effects (EPS), which is 
characterized by unsteady movements (e.g. Parkinson's disease like movement), body rigidity or 
involuntary tremors. Unlike typical antipsychotics, atypical antipsychotics are relatively weaker 
antagonists of dopamine receptors and potent serotonin antagonists, which have been postulated 
to their relative lack of EPS inducing effects. Currently, both typical and atypical antipsychotics 
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are used in clinical practice (Harrow et al., 2012). Patients need to take the treatments when they 
get a relapse. Since schizophrenia is not curable and relapse frequently happens, a lifetime 
treatment is common for schizophrenia patients. 
1. 2 Cost of schizophrenia on family and society   
Because of the disabling and chronic course of schizophrenia, the cost of schizophrenia on 
family and society is high. It has been reported that the cost of schizophrenia to society is as 
high as 62.7 billion yearly in U.S. and £5.1 billion in U.K. (McEvoy, 2007, Wu et al., 2005). It 
has also been estimated that 8% of all hospital beds in Canada and one third of all psychiatric 
beds
 
in U.S. are occupied by patients with schizophrenia. In addition to these economic burdens, 
negative outcomes of schizophrenia also impose an additional non-economic burden on 
themselves and their family. The following paragraphs introduce the economic and non-
economic burden of schizophrenia.  
The high economic cost of schizophrenia is directly determined by two factors:  the prevalence 
of schizophrenia and the severity of the symptoms. The higher the prevalence and the more 
severe the disorder, the higher would be the economic cost. Prevalence is the proportion of 
schizophrenia patients at a time point in a population. It is determined by the incidence rate, 
exiting rate, and duration of illness.  
                                                             
Incidence rate is the rate at which healthy people get schizophrenia. Exiting rate is the rate at 
which schizophrenia patients get cured or die. Since schizophrenia is not curable at present, the 
existing rate is largely determined by mortality rate. The last determinant of prevalence, 
duration of illness, is the duration of time period from onset of schizophrenia to cure of 
schizophrenia or death. For the same reason as exiting rate, duration of illness is largely 
determined by onset age. Earlier onset age implies longer duration of illness, and thus higher 
prevalence. Therefore, given mortality rate, the prevalence is largely determined by the age at 
onset and the incidence rate. To reduce the prevalence, onset could be delayed and incidence 
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rate could be reduced. The current worldwide prevalence for schizophrenia ranges from 
0.6/1000 to 17/1000 (Jablensky, 1986, Eaton, 1985, Beiser and Iacono, 1990). This prevalence 
is much higher than that of Alzheimer disease, multiple sclerosis and insulin independent 
diabetes. As a result, schizophrenia is not considered as a very rare disease. Therefore, reducing 
of prevalence could potentially reduce the overall burden of the disorder on family and society.  
Besides prevalence, the severity of schizophrenia could also influence the total economic 
burden of schizophrenia on family and society. Severity of symptoms represents how severe the 
symptoms are. More severe symptoms are directly associated with longer duration of 
hospitalizations, more frequent re-hospitalizations, and heavier medication treatments. It also 
indirectly indicates that more time of medical staffs and family members are taken and more 
hospital beds are occupied. As a result, relieving the severity of the symptoms of schizophrenia 
could potentially reduce the economic burden of schizophrenia on family and society.  
In addition to the high economic cost, schizophrenia also impose non-economical burden on 
family and society by negatively affecting the quality of life of the patients and their family 
members in a number of ways. Schizophrenia affects the life of the patients. For examples, co-
morbidities get developed during the treatments of schizophrenia, marriages break up, and 
social life and relationships are damaged. These negative outcomes make schizophrenia patients 
feel miserable, upset, depressed, and guilty, which, in extreme cases, are translated to suicides. 
It has been reported that the rate of attempting suicide is 8 times higher for schizophrenia 
patients than general population (Harris and Barraclough, 1997). It has also been estimated that 
40% of schizophrenia patients have attempted suicide at least once and 10%-13% of them have 
managed to kill themselves (Caldwell and Gottesman, 1990, Landmark et al., 1987). This 
premature death is a great loss to the society, and causes a great pain to their family members. 
Schizophrenia also affects the life of the family members. For example, family members have to 
spend extra time in taking care of the patients. More importantly, offspring in schizophrenia 
families are adversely affected. Children have well defined needs for nurturing, such as 
language learning, socialization, and perception skills. However, schizophrenia patients are 
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unable to satisfy adequately the needs of their children due to the disorder, which may lead to 
various social and behaviour disadvantages of their offspring (Hoghughi and Long, 2004). This 
is potentially a great non-economic burden to the society, because children are the future of 
community. Therefore, if the negative outcomes (e.g. co-morbidities, adverse impact on 
offspring) are controlled, the non-economic burden of schizophrenia could potentially be 
reduced.    
It can therefore be seen that the burden of schizophrenia is related to 1) the factors that 
determine the prevalence and severity and 2) the negative outcomes of schizophrenia on patients 
and on their family members. Therefore, the determinants of these factors need to be understood 
to potentially reduce the burden of schizophrenia. Prevalence of schizophrenia, as introduced, is 
largely determined by onset age and incidence rate, which are in turn affected by the risk factors 
of schizophrenia. The negative outcomes are related to, but not limited to, co-morbidities and 
negative influence on family members. Therefore, understanding risk factors of schizophrenia 
and understanding the negative outcomes on co-morbidities and on family members could 
potentially help in reducing the burden of schizophrenia. The following two subsections 
therefore introduce the risk factors of schizophrenia and its negative outcomes on patients’ co-
morbidities and on the life of their family members.  
1.3 Risk factors of schizophrenia   
Risk factors are conventionally defined as the factors that can increase the incidence rate of a 
disorder. In current thesis, since the focus is the burden of schizophrenia on family and society, 
factors that can increase the prevalence, which is one of the two major determinants of the 
economic burden of schizophrenia (the other determent is severity of symptoms), are considered 
as the risk factors. For schizophrenia, as introduced in 1.2, age at onset and incidence rate are 
the determinants of prevalence. As a result, factors that can advance the onset age or increase 
the incidence rate are considered as risk factors for schizophrenia. This definition of risk factor 
governs all the studies in this thesis.  
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Risk factors are usually identified through association studies, in which the association of the 
hypothesized factors and schizophrenia risk is examined. If the association is statistically 
significant, the hypothesized factors will be considered as risk factors for schizophrenia. There 
are two major designs in examining the association. 1) Cases control design: Schizophrenia 
patients and healthy controls are recruited, and the extent of exposure to the factors is compared 
between cases and controls. A significant difference in extent of exposure between the 
comparison groups would suggest that the factors under study are risk factors. 2) Cohort design: 
A group of subjects are recruited, and the prospective rate of newly onset of schizophrenia after 
a period of following up among the subjects with exposure to risk factors is compared to the rate 
among the subjects with no exposure. A significant difference between the two comparison 
groups could suggest that the factors under study are risk factors.  
A large number of risk factors for schizophrenia have been reported based on these two 
association design in the past century. These risk factors can generally be classified into three 
groups: 1) genetic risk factors, 2) environment risk factors and 3) demographic risk factors.  
Genetic composition is thought as risk factors for schizophrenia for a long time, because 
schizophrenia is highly inheritable. Offspring of schizophrenia patients have a much higher 
chance to get schizophrenia than the offspring of general population, indicating that inherited 
genetics could increase the life time incidence of schizophrenia (Gottesman and Wolfgram, 
1991). Moreover, numerous studies have also shown that patients with positive psychiatric 
family history have an earlier onset (Albus and Maier, 1995, Gorwood et al., 1995, Adachi et al., 
2008), further suggesting that genetic factors are risk factors of schizophrenia. Since meaningful 
genetic factor is composed by genes, a large number of genes have been reported as risk genes 
for schizophrenia. However, results from genetics studies are generally inconsistent and difficult 
to be replicated. Moreover, the effect sizes (i.e. odds ratio or risk ratio) of discovered risk genes 
are usually small and are usually less than 2.0 (Harrison and Weinberger, 2005), suggesting that 
effects of individual gene in contributing the development of schizophrenia are not substantial. 
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Nonetheless, when considering the cumulative evidence from all studies, some genes have been 
implicated and these include DISC1, DTNBP1, NRG1, and RGS4.  
Environmental factors are also believed to be risk factors for schizophrenia. This is because 
even the identical co-twin of a schizophrenia patient has only 48% chance (i.e. less than 100%) 
to develop schizophrenia (Gottesman et al., 1987), which suggests that some of the risk for 
schizophrenia occurrence is attributed to environmental factors. Previous studies have shown 
that advanced paternal age, obstetric complications (e.g. infections, pre-mature rupture of 
membrane, hypoxia immediately after delivery), childhood trauma, and cannabis consumption 
are all associated with higher risk of getting schizophrenia (Torrey et al., 1997, Byrne et al., 
2007, Marcelis et al., 1998, Sipos et al., 2004, Dohrenwend, 1975, Andreasson et al., 1987, 
Read et al., 2005). The consistency and replication power of these environmental factors are 
generally higher than genetic risk factors. However, like genetic risk factors, the effect sizes of 
the environmental factors are not large and the odds ratios are usually around 2.0 (Leask, 2004). 
The mechanism on how environmental factors increase the risk of schizophrenia is largely 
unknown. Hypothesis that environmental factors alter the development of brain at childhood has 
been proposed, but the evidence has not been consolidated (Owen et al., 2011).  
Demographic factors are those that are related to the demographic characteristics of a 
population and cannot be changed. A number of demographic factors, including gender, family 
history, urbanicity birth and living, and winter birth, have been reported as risk factors of 
schizophrenia since they are associated with increased incidence rate and earlier onset age 
(Krabbendam and van Os, 2005, Castle et al., 1998, Lewis, 1989, Ritsner et al., 2005). The 
effects of these factors on schizophrenia as reported in the literature are relatively more 
consistent comparing with genetic and environmental risk factors. However, inconsistencies and 
disagreements are still common, especially for the effects of family history and birth seasonality.  
Although a large number of genetic, environmental and demographic risk factors have been 
identified, inconsistencies on their significance and their effect sizes have constantly been 
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reported. There are a few possible reasons for the inconsistencies in literature. 1) Diagnostic 
criteria may vary between studies. The diagnosis of schizophrenia is based on symptoms and 
thus is potentially subjective. Although structured and standardized diagnostic criteria (e.g. 
DSM) are available, local diagnostic criteria or clinical diagnosis in a country may be still used 
in some of these studies. The adoption of local criteria makes it difficult to compare and 
interpret the results from different countries. 2) Sample populations used in different studies 
may be different. Risk factors, particularly genetic risk factors, may be population specific. 
Thus, different populations may have different risk factors, which make discoveries inconsistent 
across studies. 3) There may be variations in sample size and analysis methods. The effect size 
of risk factors for schizophrenia is usually small. Therefore, genuine risk factors with small 
effect sizes might not be identified due to the lack of statistical power. Moreover, the effects of 
a risk factor may be different when different covariates are adjusted in modeling. Therefore, 
different studies may result in different conclusions regarding the same risk factor. 4) It is also 
possible that there are numerous genuine risk factors for schizophrenia, each of which 
contributes a small portion of the risk of schizophrenia. Each individual study may only find a 
subset of the risk factors, which may contribute to the inconsistencies across studies. The 
potential variations listed in the first three reasons are controllable to some extent. For example, 
a standardization of diagnostic criteria could improve the homogeneity of the study sample and 
enhance the comparability across studies. Recruiting the subjects with the same ethnicity could 
potentially avoid possible population effects. And the sample size can always been enlarged to 
increase the power of detecting risk factors with small effect sizes. However, regarding to the 
last possibility, it is not easy to be addressed. The best way, yet not efficient way, to overcome 
the potential limitation is to increase the number of studies on risk factors. Each study could 
contribute a portion to the understanding of risk factors, and a complete picture of risk factors 
can be attained by integrating all the studies together.  
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1.4 Outcomes of Schizophrenia 
In addition to economic burden, schizophrenia also imposes a great non-economic burden on 
themselves and their families due to its negative outcomes. Patients with schizophrenia usually 
suffer from various co-morbidities, which affect their quality of life. The life of their family 
members is also adversely affected because schizophrenia patients might not be able to take 
care of themselves or take care of other members in the family. The following paragraphs 
introduce the negative outcomes of schizophrenia on co-morbidities and on family members.  
Schizophrenia patients usually develop a variety of co-morbidities as the disorder progresses. 
Two common co-morbidities of schizophrenia are: 1) Depression and 2) Tardive dyskinesia. 
Depression is a chronic mental disorder characterized by feelings of sadness, loneliness, despair, 
low self-esteem and self-reproach. The incidence of depression during or immediately following 
an acute episode of psychosis can be as high as 75% (Oliver et al., 2008). As a result of 
depression, the suicide rate of schizophrenia patient is correspondingly very high. The risk of 
attempting suicide is 8 times higher for patients with schizophrenia than the general population 
(Harris and Barraclough, 1997). It has also been estimated that 40% of schizophrenia patients 
have attempted suicide at least once and 10%-13% eventually kill themselves (Caldwell and 
Gottesman, 1990, Landmark et al., 1987). Tardive dyskinesia is a form of dyskinesia that is 
difficult to be treated, and is commonly observed in old schizophrenia patients. It is 
characterized by repetitive, involuntary, purposeless movements (e.g. grimacing, tongue 
protrusion, lip smacking, puckering rapid eye blinking). It is usually associated with prolonged 
and high dosage use of antipsychotics, but the exact mechanism is poorly understood. Since 
schizophrenia patients are usually under life time treatment of antipsychotics, the tardive 
dyskinesia incidence among schizophrenia is very high. It has been reported that 31% 
schizophrenia patients get tardive dyskinesia after 43 weeks cumulative antipsychotic 
treatments, and 29% would develop tardive dyskinesia after 12 months treatments (Jeste et al., 
1999, Saltz et al., 1991). Because of the symptoms of tardive dyskinesia, the life of 
schizophrenia patients has been adversely affected and becomes more difficult for them. As 
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reported, the quality of life of schizophrenia patients with tardive dyskinesia is significantly 
lower than the schizophrenia patients without tardive dyskinesia (Browne et al., 1996).  
Schizophrenia also negatively influences the life of their family members. Schizophrenia 
patients are unable to take care of themselves and to maintain a personal hygiene during illness. 
Therefore, family members need to spend time in looking after them. In addition, in order to 
prevent relapse of schizophrenia, family members are encouraged to play an active role in the 
family treatment of schizophrenia. The role requires them to monitor the symptoms, to think of 
solutions to improve the situations, and to implement the solutions (Pitschel-Walz et al., 2001). 
More importantly, children in schizophrenia families may also be adversely affected. The living 
environment of schizophrenia families (i.e. families with schizophrenia patients) is usually 
unfavourable for children. For instance, schizophrenia families usually have higher divorce rate 
(Thara and Srinivasan, 1997, Salokangas et al., 2001), which may cause psychological and 
social stress on the offspring (Wallerstein, 1991). Moreover, schizophrenic parents are unable to 
deliver adequate cares to their offspring and satisfy their physical, social and emotional needs 
(Hoghughi and Long, 2004). As a result, offspring of schizophrenia patients may have a number 
of disadvantages compared with their peers as they grow up, such as poorer school performance, 
attention deficient, low intelligent quotient, speech impairment, and difficulties with social 
adjustment (Kremen et al., 1998, Erlenmeyer-Kimling and Cornblatt, 1992, Sohlberg, 1985, 
DeLisi et al., 1991, Bearden et al., 2000). These disadvantages have long lasting effects for 
children and imply a potential burden to the family and society since children are the future of 
the community. The mechanism for the disadvantage of the children could be intuitively 
attributed to the unfavourable familial environment. However, the unfavourable family 
environment could also be confounded by the associated genetics factors run in schizophrenia 




1.5 Overall aim and organization of this thesis 
As described in previous sections, schizophrenia imposes a great economic and non-economic 
burden to family and society. Therefore, the overall aim of this thesis is to contribute to 
elucidate the nature of the burden of schizophrenia, so that the overall burden could potentially 
be reduce by developing preventive and therapeutic strategies. 
The economic burden of schizophrenia is directly determined by its prevalence and its severity. 
Higher prevalence and more severe symptoms are associated with higher treatment cost. The 
non-economic burden of schizophrenia is related to the negative outcomes of schizophrenia 
including co-morbidities and negative impacts on family members. Co-morbidities adversely 
affect the life quality of patients with schizophrenia and may even increase premature death 
from suicide and other causes. Life of family members of schizophrenia, particularly the 
offspring of schizophrenia patients, is also adversely affected because schizophrenia patients are 
not able to take care of themselves or their family members.   
Therefore, to contribute to elucidate the nature of the burden of schizophrenia, we need to 
identify and understand:   
1) the factors that increase the prevalence and exacerbate the symptoms of schizophrenia, and  
2) the factors that lead to co-morbidities and the negative influence on family members.  
Since the scope of these areas is far too extensive for this thesis, the risk factors were limited to 
demographic and genetic factors for the purpose of this thesis. The co-morbidity was limited to 
tardive dyskinesia and the negative influence of schizophrenia on family member was limited to 
the impacts on offspring the school performance in this thesis. By elucidating the demographic 
and genetic risk factors of schizophrenia, and by understanding the factors leading to tardive 
dyskinesia and poor offspring school performance, the overall aims in contributing to elucidate 
the nature of the burden of schizophrenia could be achieve.    
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As shown in Figure 1.1, the organization of current thesis consists of four main chapters, with 
chapter 2 and 3 studying the demographic and genetic risk factors for schizophrenia and chapter 
4 and 5 studying the factors leading to tardive dyskinesia and poor offspring school 
performance. Specifically, Chapter 2 examined the effects of demographic risk factors and their 
interaction on onset age of schizophrenia and on clinical presentations. Chapter 3 investigated 
the risk SNPs, genes and pathways for schizophrenia and its onset age based on genome-wide 
scanning approach. Chapter 4 studied the development of tardive dyskinesia and examined the 
factors that contribute to tardive dyskinesia risk. Chapter 5 investigated the impact of 
schizophrenia on offspring school performance and investigated the mechanism for the effect. 
Chapter 6 reviewed the results from each study, explored their implications and limitations, and 
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Figure 1.1 Flow Chart of the overall organization of this thesis. 
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Chapter 2 Demographic risk factors of schizophrenia: Gender, 
family history and birth season  
2.1 Introduction 
2.1.1 Background  
In Chapter 1, we defined risk factor of schizophrenia as the any factor that is associated with 
higher prevalence of schizophrenia. As discussed in 1.3 Chapter 1, in addition to factors that 
could increase the incidence of schizophrenia, factors that are associated with earlier onset are 
also considered as risk factors, since they could potentially increase the prevalence of 
schizophrenia. A large number of studies have been conducted to identify the risk factors of 
schizophrenia since early of 20
th
 century. And numerous risk factors have been identified 
through observational studies. More reliable risk factors include advanced paternal age, 
cannabis usage, obstetric complications, trauma at childhood, urban living, winter birth, male 
gender, and positive family history (Compton, 2004, Andreasson et al., 1987, van Erp et al., 
2002, Read et al., 2005, Kelly et al., 2010, Lewis, 1989, Hafner, 2003, Ritsner et al., 2005). 
Among these risk factors, gender, birth season and family history are more related to 
characteristics of the population itself and cannot be modified. These factors are considered as 
demographic risk factors in this thesis. Higher incidence rate and earlier onset age imply a 
potentially higher prevalence of schizophrenia in a population assuming exiting rate (i.e., death 
or cure) is not changed, which is directly related to the economic burden of schizophrenia. In 
addition to their effects on prevalence, demographic risk factors have also been reported to be 
associated with clinical presentations of schizophrenia (Angermeyer et al., 1990), which in this 
thesis mainly refer to the symptoms of schizophrenia, but also include medication profile and 
hospitalization recodes. More severe symptoms indicate longer hospitalization and heavier 
treatments of antipsychotics, which could result in higher economic burden on family and 
society. Because of these effects of demographic risk factors on prevalence and severity of 
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symptoms, understanding their role on schizophrenia could help in assessing the potential 
economic burden of schizophrenia in a population. 
There have been a large number of studies researching on the effects of demographic risk 
factors on schizophrenia incidence rate, but research on onset age and on symptoms severity are 
relatively rare, especially in Asian population, although they are also important determinants of 
the economic burden of schizophrenia. The subsequent section reviews the studies on 
demographic risk factors, including gender, family history, and birth seasonality. The focus is 
on the understanding of their effects on age at onset and. However, since these risk factors may 
also have effects on symptoms severity of schizophrenia, which directly related to burden of 
schizophrenia on public, we also aimed to examined these effects and thus also reviewed the 
literature on the effects of these risk factors on severity of schizophrenia, which is reflected by 
symptom severity, medication profile and hospitalization.  
2.1.2 Literature review  
2.1.2.1 Gender 
The effects of gender on onset age was first reported by Kraepelin during 1909-1915 showing 
that males had an earlier age at first admission compared to females (Hafner, 2003). Since then, 
numerous studies on western populations have replicated this finding (Hafner, 2003, DeLisi, 
1992, Lewine, 1980, Seeman, 1982, Angermeyer and Kuhn, 1988). The World Health 
Organization (WHO) conducted a similar study in ten countries
1
 in 1992, and found that 
females develop schizophrenia 0.3 to 5.1 years later than males, with the mean difference in 
onset age being 3.4 years (Jablensky et al., 1992). However, some studies failed to find a 
significant difference in onset age between males and females, especially in Asian countries. A 
Japanese study in 1988 found nearly no difference between males and females: the mean age at 
onset difference was less than 1 years (Shimizu et al., 1988a). A Pakistani and an Indian study 
also failed to find a significant difference across gender in their population (Naqvi et al., 2010, 
                                                     
1
 The ten countries are Aarhus in Denmark, Agra and Chandigarh in India, Cali in Columbia, Dublin in 
Ireland, Honolulu in and Rochester in US, Ibadan in Nigeria, Moscow in Russia, Nagasaki in Japan, and 
Nottingham in UK. 
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Murthy et al., 1998). It has been stated that the insignificance could be due to the adoption of 
their own definition of onset, such as first consultation of doctors, first appearance of symptoms 
or first admission to hospitals. However, different definitions of onset would not eliminate 
gender difference as long as the same definition was applied to both males and females. This is 
because patients with earlier onset will generally have earlier appearance of first symptoms, 
earlier consultation of doctors, and earlier hospitalization. Therefore, lack of a significant 
difference could more likely reflect that the gender difference is small in their study population. 
Similar studies on gender effects in Chinese population are rare, despite the fact that Chinese 
population represent 19.7% of the global human population. A few studies on age at onset of 
schizophrenia have been published in Chinese journals. However, the sample sizes were usually 
small (N<170), and the diagnostic criteria were usually not standardized (Chen and Li, 1995, 
Shang et al., 2001, Bao, 1995). Therefore, the generalization power of the studies is limited. A 
recent study conducted in Beijing attempted to overcome these limitations by adopting DSM-IV 
diagnostic criteria and by recruiting a larger sample (N=542) (Tang et al., 2007). Their results 
showed that males developed schizophrenia on average 5 years earlier than females. However, 
this study comprised mainly of a selected population of Northern Chinese who were resident of 
Beijing and most of the patients were chronic schizophrenia patients at the time of assessment, 
which limit the generalizability of their findings.  
Gender has also been found to be associated with clinical presentations and clinical outcomes of 
schizophrenia. Angermeyer et al. (1990) reviewed 102 studies with follow-up period ranging 
from less than 5 years to more than 10 years after onset. About half of the studies found 
significantly more favourable clinical outcomes in females, such as less severe symptoms, lower 
relapsing and re-hospitalization rate, shorter hospitalization duration, better psychopathology 
status, and better social adaption. The other half of the reviewed studies, however, did not find a 
difference between males and females in clinical presentations. These findings, on one hand, 
suggest possible effects of gender on clinical presentations, but, on the other hand, reveal the 
controversies in this study area. More recent studies suggested that the difference between 
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males and females lay more on social courses and social outcomes (e.g. maintaining social 
contact, employment status, and marriage) rather than clinical courses and clinical outcomes 
(Hafner, 2003). In terms of medication profile, a few studies have reported that females required 
lower dosages of antipsychotics than males (Seeman, 1983, Seeman, 2004, Dickson et al., 2000), 
but negative studies have also been reported (Jeste et al., 1996b). In general, no congruence on 
the gender difference in antipsychotic dosage has been reached at present stage.  
2.1.2.2 Family history 
Patients with positive family history of psychiatric disorders also tend towards an earlier age of 
onset than patients with no family history. Alda et al. (1996) recruited samples from three 
centres (Berlin, Prague and Ottawa) and found that patients with positive family history had 
earlier onset than those with no family history in all the three centres. The mean onset age 
difference between patients with and without family history ranged from 1.7 years in Prague to 
2.0 years in Berlin. Ritsner et al. (2005) also reported an average of 3.6 years earlier onset for 
patients with positive family history based on 148 patients in Israel (69 patients with family 
history and 79 sporadic schizophrenia patients). Several other studies in Germany, France and 
Japan have also found a significant younger age at onset for patients with family history (Albus 
and Maier, 1995, Gorwood et al., 1995, Adachi et al., 2008). In addition, one study in Germany 
found that the effect of family history of schizophrenia on the age of onset was more 
pronounced in females than in males (Konnecke et al., 2000), suggesting that there could be a 
possible gender and family history interaction. However, studies that have specifically 
investigated the interaction of gender and family history are rare. Not all studies have found a 
significant effect of family history on age at onset. Kendler & Hays (1982) reported that there 
was no significant difference in age at onset based on 113 subjects in U.S. between patients with 
and without schizophrenic relatives. Studies conducted by Malaspina et al. (2000) and Roy et al. 
(1994) in New York and Iowa in U.S. did not find a significant difference in age at onset either. 
One large study in Japan with 2,471 patients also failed to find a significant difference in mean 
age onset, although they found that the proportion of early onset (<25 years old) among those 
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with positive family history was higher than those with no family history (Shimizu et al., 1988b). 
In general, the studies with positive findings have larger samples size, particularly larger 
number of patients with positive family history; while the sample size of negative finding is 
usually small (maximum number of cases for the cited negative finding study is 63). Moreover, 
positive findings are usually from Europe and Japan population, while negative findings are 
usually from American population. These tendencies suggest that there might be a genuine, but 
not large, difference in onset age between patients with and without family history, and this 
difference might be affected by geographic area or population origins.  
Positive family history has also been reported to be associated with different clinical 
presentations. Positive symptoms including hallucination and delusion have been found to be 
more severe among patients with family history (Arajarvi et al., 2006), but this observation is 
still controversial as negatives studies have also been reported (Kendler and Hays, 1982, Martin 
Reyes et al., 2004). On the other hand, the effects of family history on negative symptoms are 
relatively more consistent in literature. Numerous twin, adoption and sibling pair studies have 
shown that family history was associated with negative symptoms (Dworkin and Lenzenweger, 
1984, Cardno et al., 2002, Burke et al., 1996). A meta-analysis based on 12 selected qualified 
studies has shown that family history has a small but significant effect on negative symptoms 
(Esterberg et al., 2010), suggesting that negative symptoms is influenced by family history. 
However, there are also a few studies that found no significant difference in negative symptoms 
between patients with and without family history (Feldmann et al., 2001, Norman et al., 2007).  
Studies on the effects of family history on hospitalization and medication have seldom been 
done, and the relationship is not known.  
2.1.2.3 Birth seasonality  
Birth seasonality was first reported as a risk factor for schizophrenia as early as 1929 when 
Tramer (1929) reported that more schizophrenia patients were born during the winter and early 
spring seasons (i.e. Dec-Feb) than other seasons. Similar observations were then reported in 
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various countries of the world, including England, Germany, Japan, Philippines, and U.S. (Hare, 
1975, Diebold, 1975, Shimura et al., 1977, Parker and Balza, 1977, Torrey et al., 1977). It is 
interesting to note that Philippines is located in the tropic region with no real seasons but people 
born in Dec-Feb are still found to have higher incidence of schizophrenia (Parker and Balza, 
1977). This observation suggests that factors other than temperature may play as the mediator 
for schizophrenia risk. The studies on the effects of birth seasonality on clinic aspects of 
schizophrenia, such as age at onset and clinical presentations, are rare. Among the few 
published studies in these areas, the findings have been conflicting and inconclusive (Tam and 
Sewell, 1995).  
2.1.2.4 Analysis methods in literature 
In analyzing the effects of these risk demographic factors on age at onset, two methods are 
generally used in literature. The first method is to compare the proportion of schizophrenia 
patients with early onset (e.g. <25 years old) between males and females. This method has two 
limitations. 1) There is no congruence on what should be the cut-off age for early onset, and 
different cut-off ages have been used in literature. 2) By classifying the patients as early onset 
and late onset schizophrenia, information on the exact onset age is lost in this process. Therefore, 
this method still can be improved to further utilize the collected information. The second 
method is to compare the mean age at onset between males and females. Mean comparison is 
best for distribution with no skewness. However, numerous studies have shown that the 
distribution of age at onset is skewed to right with mode of the distribution occurring between 
15-25 years old (Hafner et al., 1993, Angermeyer and Kuhn, 1988, Castle et al., 1998). 
Therefore, simply comparing the mean age at onset might not be an optimal measure of the 
effects of risk factors. Moreover, using one figure (i.e. mean age at onset) to represent the whole 
distribution of age at onset is insufficient. Therefore, instead of comparing the mean, 
comparison of the overall distribution curve of age at onset would be more appropriate.  
2.1.2.5 Mechanism and hypotheses  
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The mechanism of demographic risk factors on onset of schizophrenia is largely unknown. 
However, a few hypotheses have been proposed for the effects of gender. The most popular 
hypothesis is that estrogen hormones in females have antipsychotic effects and can delay the 
onset of schizophrenia, which explains the gender effects on onset age of schizophrenia 
(Seeman, 1983, Seeman, 2004, Dickson et al., 2000). Animal model have shown that dopamine 
receptor D2 density were reduced during short term treatments of estrogens (Hruska, 1986). 
Riecher-Rossler et al. (1994a, b) examined the relationship between estrogens level in blood and 
psychopathology score among 32 female schizophrenic patients and found a reverse association, 
suggesting that estrogens have some antipsychotic effects in human. An epidemiological 
observation that the incidence rate of female schizophrenia patients increases abruptly at 
menopause (i.e. 45-50 years old) provides further support for this hypothesis (Hafner and an der 
Heiden, 1997). However, regarding to this epidemiological observation, since most studies 
group patients according to 5-year age category (i.e. 0-5, 5-10, 10-15…), the second peak at 
menopause among females is not obvious in their histogram of age at onset. A narrowed age 
category (e.g. grouping patients according to 2-year age category) or computing the distribution 
according to a sliding window of 5-years age category (i.e. 0-5, 1-6, 2-7,…) could increase the 
resolution of the second peak.  
2.1.3 Objectives and scope 
Understanding of the effects of gender, family history and birth seasonality could help in 
understanding and assessing the burden of schizophrenia on a population. However, as reviewed 
in 2.1.2, there are a few deficiencies and limitations in literature in this research area. Firstly, 
similar studies on the effects of these demographic risk factors in the Chinese population are 
rare. Secondly, there are still some inconsistencies on the effects of these risk factors on age at 
onset and clinical presentations. These inconsistencies could be due to small sample size, non-
standardized diagnostic criteria, and variation in population origins. Thirdly, the common 
statistical analyzing methods used in the literature could be further improved. In view of these 
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deficiencies and limitations, the objectives of this part of thesis were to assess the effects of 
gender, family history and birth seasonality on  
1) age at onset of schizophrenia and  
2) clinical presentations of schizophrenia  
using carefully phenotyped large study sample and adapted analysis methods.   
The scope of this part of thesis is limited to the effects on age at onset and clinical presentations 
(i.e. symptoms, medication profile and hospitalization). Incidence rate, which is an important 
determinant of prevalence of schizophrenia, is not considered in current thesis. This is because 
study of incidence rate requires follow up of high risk non-schizophrenic subjects and regular 
assessment of the conversion which is prohibitive in time and costs.  
2.2 Methods  
2.2.1 Study design and data collections 
2.2.1.1 Study site 
This study was conducted at Institute of Mental Health (IMH) of Singapore. Singapore is an 
island country with a multi-ethnic population of about 5.0 million and a land area of 710.2 sq 
km. The Chinese ethnic group forms about 77% of the resident population. The Institute of 
Mental Health is the only psychiatric hospital in the country and provides various levels of 
psychiatric services. It provides psychiatric care to approximately 1,500 inpatients and 20,000 
outpatients with schizophrenia. 
2.2.1.2 Recruitments and data collections 
Schizophrenia patients were recruited during the year 2005 – 2008 by invitation from clinical 
service of IMH. Patients who consented to participate in the study were scheduled for a 3-hour 
interview conducted by trained clinicians or psychologists in IMH Research Division. The 
reimbursement was S$50 for each patient. During the interview, the diagnosis of schizophrenia 
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was confirmed using the DSM-IV diagnostic criteria, and the severity of the symptoms was 
assessed using the instrument Positive and Negative Syndrome Scale (PANSS) by the clinicians 
and psychologists who have been trained and certified in the use of the instrument. PANSS is an 
instrument for measuring symptom severity of patients with schizophrenia. The patient was 
rated from 1 to 7 on 30 different items in assessing the severity of the symptoms (7 positive 
symptom items, 7 negative symptom items, and 16 other general symptom items) based on the 
interviews and reports from family members and attending clinicians. 
The demographic information including birth date, age, gender, ethnicity and familial 
psychiatric history was collected using standard data collection form during the interview. Other 
information on the patients including medication profile, hospitalization, and medical history 
was collected from their hospital records. The age of onset of schizophrenia was defined as the 
earlier of the hospital recorded date of first appearance of symptoms or recalled date of first 
appearance of symptoms during interview. Patients were included into the study if they were of 
Chinese ethnicity and if they met the DSM-IV diagnostic criteria for schizophrenia. Patients 
were considered as Chinese ethnicity if all their parents and grandparents were declared as 
Chinese. Patients were excluded if they had organic brain disorder, epilepsy or mental 
retardation.  
A total of 1515 patients were approached, and 1331 patients (87.9%) were eligible for our study, 
among which 903 (response rate: 67.8%) consented to participate in the study. An additional 20 
non-overlapped patients with the same inclusion and exclusion criteria were collected through 
collaboration with another clinician (Dr Sim Kang) in IMH. As a result, a total of 923 patients 
were included in analysis.  
This study was approved by Independent Review Board (IRB) of Singapore. Patients more than 
14 years old gave consent by themselves, and the parents or legal guarantor of participants 
under 14 years old gave consent for them. All participants had to consent before participating 
into this study.  
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2.2.2 Statistical analysis  
2.2.2.1 Data coding and processing 
The data in data collection forms and assessment sheets were typed into computer. The 
identifications of subjects were coded in a systematic way such that they were not identifiable. 
Male gender, positive family history (patients’ first or second degree of relatives had psychosis 
disorder) and winter birth (Dec – Feb) were coded as 1 and the other category was coded as 0. 
In processing the data, antipsychotics dosages were standardized by converting them into 
equivalent chlorpromazine dosage. The conversion ratio is shown in Table 2.1. In addition, the 
duration of hospitalization and the number of times of rehospitalisation were standardized by 
the duration of illness since first onset of schizophrenia (i.e., duration of hospitalization, or 
number of times of rehospitalisation, was divided by the cumulative duration of illness since 
first onset). After the standardization, the duration of hospitalization represented the 
hospitalized duration if the patient is in illness for one year, and the number of re-hospitalization 
represented the number of times of rehospitalisation if the patient is in illness for one year 
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2.2.2.2 Data quality control 
To ensure that the data used for analysis was accurate and free from errors, a data validation 
procedure was performed. The procedure included two steps. Firstly, the outliners of each 
variable were identified, and the corresponding subject ID was recorded. Secondly, the inter-
relationships of collected variables were established (e.g. birth year + age at onset ≤ assessment 
year). All the relationships were checked by written program scripts and the ID of subjects who 
did not follow the relationship was recorded. The subjects identified in these two steps were 
marked as suspicious entries and the all the information in these entries were checked against 
the recorded data in the subjects’ data folders. If the inconsistency of data was due to typing 
errors in transferring the data to computer, the data in computer was corrected. If the 
inconsistency was due to writing ambiguity in the hard copy data sheets, the person who signed 
the data collection sheets were consulted and corrections were made correspondingly.  
2.2.2.3 Tests 
Gender, family history status, and birth season were treated as categorical variables. Age, age at 
onset, duration of hospitalization, number of rehospitalisation, antipsychotics dosage, and 
severity of symptoms (PANSS score) were treated as continuous variables. In testing for 
significance, student’s T-test (equal or unequal variance) was used. To control the effect of 
potential confounders in testing, analysis of covariance (ANCOVA) or two-way analysis of 
variance (ANOVA) was used depending on whether the covariates were continuous or 
categorical.  
2.2.2.4 Modeling and charting 
In assessing the effects of gender, family history and birth seasonality on age at onset, onset age 
was treated as the duration of years of life before the occurrence of schizophrenia. In this 
framework, all patients could be viewed as being followed up since their birth, and an onset of 
the schizophrenia triggered an event. Therefore, the age at onset could be considered as the 
following up time before the occurrence of the event (i.e. schizophrenia). As a result, Kaplan 
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Meier test (i.e. logrank test) and Cox Proportion Hazard modeling (PHM) could be used to 
assess the effects of gender, family history and birth seasonality while controlling for covariates. 
Moreover, after this treatment, all participants could be considered as born in the same year 
since only the duration of living after birth was used in analysis. 
In plotting the distribution of age at onset, two techniques were used. Firstly, cumulative 
proportion of schizophrenia patients was plotted against age, which could be viewed as the 
following up time since birth. Therefore, the curve was a monotonic increasing, with Y-axis 
standing for the cumulative proportion of schizophrenia patients in the sample. Secondly, a 
smoothing 5-year category chart was plotted. Traditionally, the number or the proportional of 
schizophrenia patients in each of a fixed 5-year category (i.e. 0-5 years old, 5-10 years old, 10-
15 years old …) was plotted. In smoothing 5-year category chart, a sliding 5-year category was 
used (i.e. 0-5 years old, 1-6 years old, 2-7 years old), and the proportion of schizophrenia 
patients in each of the category was plotted. In such a way, the change of proportion of 
schizophrenia along age category was clearer and smoother.   
2.2.2.4 Software 
Data quality controls and tests were performed using Stata SE 10.0. Modelling and charting 
were performed in R 2.10.1.   
2.2.3 Role played in this study 
I participated in this study since the beginning, and was involved in study design, data collection, 
data management, data analysis, and manuscript writing. In study design, I performed literature 
review to propose what variables to be collected during data collection and contributed to the 
design of questionnaire and data collection sheets. In data collection, although I was not the 
person who directly collected the data from patients as I was not a psychologist, I was present in 
some of the data collection site to assist data collection such as data recoding and blood 
processing. In data management, I designed the soft copy database, assisted the data 
transcription from the hard copy to the softcopy, I wrote Stata programs to perform rigorous 
26 
 
data control and I audited the data in the hard copy to change all errors and discrepancies. In 
data analysis, I performed all the data processing and statistical analyses. In manuscript writing, 
I wrote part of the introduction, full section of methods and results, and part the of discussion.      
 
2.3 Results 
2.3.1 Sample descriptions 
The descriptive statistics of the study sample are shown in Table 2.2. A total of 923 subjects 
were used for analysis, among which 67.0% were male, 24.2% had positive family history, and 















Table 2.2 Descriptive statistics of 923 schizophrenic patients. 
Variable/Subcategory Units N(%) 
1
 Mean SD 
Age (years) 923 48.9 (range 18-83) 13.2 
BMI (kg/m
2
) 901 23.0 4.6 
Age of onset (years) 923   27.8 9.76 
Duration of illness (years) 923 21.0 13.4 
Number of 
hospitalization 
(times) 921 9.4 10.3 
Cumulative 
hospitalization 
(years) 849 6.6 4.8 
Cumulative neuroleptics 
exposure            
 
 
 expexposure  
(years) 902 18 11.9 
Gender     
Male  618 (67.0%) - - 
Female  305 (33.0%) - - 
Family history     
Yes  223 (24.2%) - - 
No  700 (75.8%) - - 
Birth season     
Winter  198 (21.5%) - - 
Other   725 (78.5%) - - 
Diabetes     
Yes  71 (7.7%) - - 
No  847 (92.3%) - - 
Antipsychotics 
2
     
Typical     
User (mg) 576 (37.6%) 445.1 527.4 
Non-user  347(62.4%) - - 
Atypical     
User (mg) 258 (72.0%) 342.4 218.2 
Non-user  665 (28.0%) - - 
Antidepressants              
User (mg) 175 (19.0%) 60.7 48.4 
Non-user  748 (81.0%) - - 
Anticholinergics              
User (mg) 621 (67.3%) 3.7 3.7 
Non-user  302 (32.7%) - - 
Mood stabilizer      
User  212 (23.0%) 770.7 394.2 
Non-user  711 (77.0%) - - 
Benzodiazepine           
User (mg) 265 (28.7%) 11.3 31.8 
Non-user  658 (71.3%) - - 
PANSS score     
Positive  923 10.0 3.7 
Negative   923 11.8 5.1 
General   923 21.3 5.2 
1
 The number of subjects with non-missing information (%: percentage of subjects in subcategory). The 
difference between the total number of subjects (923) and the number of subjects for the corresponding 
variables were the number of missing data for the corresponding variables.  
2 




2.3.2 Effects of gender, family history and birth season on age at onset  
2.3.2.1 Comparison of mean age at onset 
The mean age at onset in different comparison groups is shown in Table 2.3. Males had a 
significantly earlier onset than females (difference=2.0 years, p=0.004). Patients with family 
history of psychosis developed schizophrenia 1.7 years earlier than those with no family history 
(p=0.023). However, no significant difference in age at onset was found between patients born 
in winter season (i.e. Dec-Feb) and patients born in other seasons (i.e. Mar-Nov). These results 
suggest that male gender and positive family history could advance the onset of schizophrenia, 
but birth seasonality have no effects on age at onset. 
Table 2.3 Comparison of mean age at onset. 
Comparison groups Age at Onset  
 
N 1 Mean SD 
Nominal p 
value 2 
Male  618 27.1 9.4 
0.004 
Female 305 29.1 10.4 
+ family history 223 26.5 8.5 
0.023 
- family history 700 28.2 10.1 
Winter season 261 28.3 10.1 
0.282 
Other seasons 662 27.6 9.6 
1 The number of subjects in each group. 2 Student’s t test 
 
2.3.2.2 Overall distribution of age at onset  
The distribution of age at onset of the sample is shown in Figure 2.1. Both cumulative 
distribution of age at onset (solid line: each point in the line represents the cumulative 
proportion of subjects whose onset is before the corresponding age of the point), and the 
moving 5-year age category schizophrenia proportion distribution (dotted line: each point in the 
line represents the proportion of subjects who developed schizophrenia in the next 5 years from 
the corresponding age of the point) were plotted. The peak for the onset of schizophrenia was 
observed in 18-23 years old category, and one quarter of the patients in study sample have their 
onset within this 5 years period. This curve suggests that most patients have the onset of 
schizophrenia during their young adulthood. By the age of 40, almost 90% of the subjects had 
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developed schizophrenia, and the proportion of patients in moving 5-year category dropped to 
less than 4%, suggesting that relatively few people developed schizophrenia after the age of 40.  
However, it seems that the moving 5-year category proportion for females increased slightly at 
~50 years – giving a second but small peak in the age at onset distribution curve. This second 
peak occurred at 47-52 years old category, and 3.4% of patients developed schizophrenia during 
this 5-year period (Figure 2.1).  
Figure 2.1 Distribution of age at onset of 923 schizophrenia patients. 
 
2.3.2.3 Comparison of distribution of age at onset 
The distributions of age at onset in different comparison groups are shown in Figure 2.2. The 
distribution for males was visually steeper than that of females (p=0.008, Figure 2.2A), 
suggesting that males developed schizophrenia at an earlier age than females. Higher proportion 
of males developed schizophrenia during the15-25 age periods than females as shown in the 5-
year percentage curve. Particularly, the distribution of onset age was a peak for males while the 
distribution was a plateau for females. In addition, females had a distinct second peak within the 




























































































5-y ear category  percentage
First peak, 18-23 
years old, 25% 
Second peak, 47-52 
years old, 3.4% 
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family history also had a different distribution curve from that of patients with no family history 
(logrank p= 0.012, Figure 2.2 B), but the difference was not as distinct compared to gender. 
Moreover, it seems that patients with positive family history have no evidence of a second peak, 
which was observed in the overall distribution the 45-50 age range (Figure 2.1). For birth 
seasonality, the distribution of age at onset was essentially the same for patients born in winter 
season and patients born in other seasons in Singapore (logrank p = 0.323, Figure 2.2 C), 
suggesting that birth seasonality plays no roles in onset age.     
Figure 2.2 Comparison of distribution of age at onset. 
 













































































































































































































































































































































































2.3.2.4 Assessing the effects of gender, family history and birth seasonality 
The effect sizes of the gender, family history and birth seasonality on age at onset were 
quantified by Cox PHM modeling (model: S(age)=S0(age)^exp(β1× risk factors + error)). As 
shown in Table 2.4, the likelihood of developing schizophrenia for a unit of following up time 
for males was 1.20 times higher than females (p=0.011). Similarly, subjects from families with 
psychiatric history were 1.20 times more likely to develop schizophrenia in a unit of follow up 
time than those with no family history (p=0.016). Birth seasonality showed no significant effect 
on age at onset (p=0.343). We further examined the interaction between gender and family 
history using interaction Cox model (model: S(age)=S0(age)^exp(β1×gender+ β2×history+ 
β3×gender×history)). Both gender and family history had a significant effect in the interaction 
model (p=0.008 for gender, p=0.031 for family history), but the interaction term was not 
significant (p = 0.423), suggesting that gender and family history did not significantly interact 
with each other. However, since the coefficient of the interaction term (i.e., hazard ratio) was 
less than 1, it implies that gender and family history counter interact with each other (e.g. 
presence of either factor reduces the effects of the other factor) in influencing the age at onset.  
Table 2.4 Assessing the significance gender, family history and birth season. 
Notes: Confidence interval referred to 95% confidence interval.   
2.3.2.5 Interaction of gender and family history 
To further examine the interaction of gender and family history, we performed a classification 
analysis by examining the difference of distribution of age at onset in each subcategory. As 
Table 2. nalysis of gender, psychiatric familial history and birth season on age at onset. 
Single variable analysis   
Variable  Logrank Test p 
value  
Hazard ratio (CI) P value for hazard 
ratio 
Gender  0.008 1.20 (1.04-1.37) 0.011 
Familial History 0.012 1.20 (1.03-1.40)  0.016 
Birth Season  0.323 0.93 (0.81-1.08)  0.343 
 
Interaction Cox model  
Gender   1.24 (1.06-1.46) 0.008 
Familial History  1.32 (1.03-1.70) 0.031 




shown in Figure 2.3, the difference in distribution of age at onset between males and females 
was visually obvious among patients with no family history (p=0.006, Figure 2.3 A), but the 
difference became negligible among patients with psychiatric family history (p=0.432, Figure 
2.3 B). This result suggests that a positive family history may eliminate the gender effects on 
schizophrenia onset age. On the other hand, the difference in age at onset distribution between 
subjects with family history and those without family history was visually obvious among 
female patients (p=0.021, Figure 2.3 C), but the difference became less among male patients 
(p=0.129, Figure 2.3 D). This result suggests that the effect of psychiatric family history alone 
on age at onset among males is small. Moreover, the second peak (45-50 years old) of the 
distribution among females was only present among patients without family history (Figure 2.3 
C). When all groups were considered together by superimposing their distributions, it was found 
that the distribution was similar for male subjects with family history, male subjects without 
family history, and female subjects with family history (Figure 2.3 E). The only distinct 
difference was female subjects with no family history, which showed a lower rate of 
schizophrenia at the age range of 15-25 years and a distinct second peak (Figure 2.3 E). 
Figure 2.3 Comparison of distribution of age at onset in each subcategory. 
 


























































































female w ith no familial history (N=220)
male w ith no familial history (N=480)
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male w ith no familial history (N=480)
logrank p = 0.006
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female w ith no familial history (N=220)
female w ith familial history (N=85)
female w ith no familial history (N=220)
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logrank p = 0.021





























































































































































































male w ith no familial history (N=480)
male w ith familial history (N=138)
male w ith no familial history (N=480)
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logrank p = 0.129

















































































































































































Male w ith no familial history
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Female w ith no familial history
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2.3.3 Effects of gender, family history and birth season on clinical presentations  
2.3.3.1 Hospitalization and re-hospitalization 
Hospitalization and re-hospitalization after adjusting for duration of illness reflect the severity 
of schizophrenia. Patients with more severe symptoms usually would have more frequent 
hospitalizations and longer hospitalization stay each time. The effects of gender, family history 
and birth seasonality on hospitalization and re-hospitalization are presented in Table 2.5. 
Covariates that were existed before the existence of the dependent variables and which could 
possibly influence the dependent variables were adjusted in the analysis. As shown in Table 2.5, 
the duration of hospitalization for males was 3.02 months for one year of illness, which was 
significantly higher than that of females (2.56 months). However, after adjusting for covariates 
(i.e., age at onset, family history, birth season), the difference in duration of hospitalization 
between males and females was not significant. Neither family history nor birth seasonality had 
a significant effect on duration of hospitalization. However, regarding on re-hospitalization, 
family history exerted a significant effect on re-hospitalization. For patients with positive family 
history, they had 1.18 episodes of hospitalization in one year of illness compared to 
0.81episodes of hospitalization for patients without a positive family history. The difference 
remained significant after adjusting for age at onset, gender and birth seasonality, suggesting 



























Male 603 3.02 0.154 









Male 617 0.87 0.084 
0.530 0.856 




Yes 215 2.85 0.258 








Yes 221 1.18 0.195 
0.038 0.035 





Winter 258 2.97 0.203 
0.584 0.587 








Winter 260 0.68 0.092 
0.064 0.102 
Other 661 0.99 0.098 
1 Number of subjects with non-missing information. Missing data were deleted and were not included in analysis.  
 
2.3.3.2 Severity of symptoms 
PANSS measure the severity of the positive and negative symptoms of schizophrenia. The more 
severe the symptoms are, the higher the scores will be. As shown in Table 2.6, patients with 
positive family history had more severe positive symptoms compared with patients without 
family history (10.5 vs. 9.8, p=0.015). However, after controlling for covariates that existed 
before the assessment of symptoms and that could possibly influence the severity of symptoms 
(e.g. antipsychotics dosage), the difference became insignificant (p=0.251). Neither gender nor 
birth seasonality showed significant influence on positive symptoms. When examining negative 
symptoms, however, males was found to have significantly more severe symptoms than females 
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(12.1 vs. 11.6, p=0.013). The difference remained significant even after controlling for 
covariates (p=0.046). This result indicates that negative symptoms of males are more difficult to 
be alleviated than females.    



































Male 618 12.1 0.211 
0.013 0.046 





Yes 223 10.5 0.256 
0.015 0.251 











Yes 223 11.6 0.343 
0.548 0.403 






Winter 261 9.63 0.216 
0.083 0.273 










Winter 261 12.3 0.350 
0.055 0.223 
Other 662 11.6 0.195 








2.3.3.3 Medication profile 
Medication treatments are the most common practice to treat schizophrenia symptoms. 
Therefore, medication profiles reflect the overall symptoms of the patients. Medicines used 
prescribed to schizophrenia patients include typical/atypical antipsychotics, antidepressants, 
mood stabilizers, anticholinergics, and benzodiazepines. The medication profiles of patients in 
different comparison groups are shown in Table 2.7. Compared with females, more males were 
prescribed typical antipsychotics and less of them were prescribed of atypical antipsychotics 
(p=0.005 for typical antipsychotics, p<0.001 for atypical antipsychotics). These differences 
remained highly significant (p=0.003 for typical antipsychotics, p<0.001 for atypical 
antipsychotics) even after adjusting covariates which were existed before the assessment of 
medication profile and which could possibly influence the medication of patients (e.g. gender, 
family history, birth season, age at onset, and duration of illness). Males, however, used 
antidepressants less commonly than females (19.1% vs. 28.2%, p=0.002), indicating that males 
may be less depressed than females. Results also showed that significantly higher proportion of 
patients with family history used antidepressants and mood stabilizers, implying that those 
patients are likely to be more depressed and mood disturbed than those without family history. 
However, after adjusting covariates, the difference became insignificant (p=0.127 for 
antidepressants, p=0.106 for mood stabilizer). No difference was found in medication profile 









Table 2.7 Comparisons of medication profile. 
Dependent 
variables 
Comparison groups % of users 
1












Age at onset 
Birth season 
Family history 
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Age at onset 
Birth season 
Family history 












1 The percentage of subjects in the subcategory with treatment of the medication. 2 The covariate that was the 




2.4.1 Study design and analysis 
The design of the study is to recruit a group of schizophrenia patients and to investigate the 
effects of gender, family history and birth seasonality on age at onset and on clinical 
presentations. There are a couple of strengths in the study design. Firstly, the sample size of this 
study is large with 923 schizophrenia patients. Although it is small proportion of the total 
schizophrenia patients in Singapore, which is estimated to be 50, 000 based on 1% prevalence, 
this is the largest study sample among all known Chinese studies. The large sample size 
enhances the power of testing and modeling, such that small difference can be detected. In 
addition, the large sample size makes it applicable to perform classification analysis by ensuring 
sufficient number of subjects in each subcategory. Secondly, the diagnosis of all patients was 
established by trained clinicians or psychologists using a structured instrument that is based on 
the DSM-IV diagnostic criteria. As a result, the disease status of the study sample may be more 
homogenous compared with other Chinese studies using local diagnostic criteria (Chen and Li, 
1995, Shang et al., 2001, Bao, 1995). The standardization of diagnostic criteria also makes the 
current study a good benchmark to be compared with by other research groups. Thirdly, all 
subjects are Chinese patients in Singapore. The ethnicity of the patients was to ensure that their 
parents and grandparents are Chinese. Since the Chinese population in Singapore originated 
mainly from Southern China, the study population is likely to be more genetically homogenous.  
Despite the strengths, the study also has certain limitations. Firstly, onset age is defined as the 
earlier of hospital recorded date of first appearance or recalled date of first appearance of 
symptoms during the interview. The actual onset age might still be earlier than this onset age. 
This limitation is partially compensated by employing of proportional hazard modeling (PHM) 
in analysis, since PHM does not rely on the actual onset age but only the rank of onset age. 
Secondly, the medication profiles of patients were collected during the assessment. As a result, 
the medication profiles reflect only the medication status at the time of the assessment, which 
limits the utilization and interpretation of the medication data as no temporal relationship can be 
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established.  Thirdly, in this study, no healthy controls were available to study the risk factors of 
schizophrenia in tradition definition, which are the factors that are associated with higher 
incidence rate of schizophrenia. However, the theme of this thesis is to contribute to the 
knowledge of burden of schizophrenia on public, and both earlier on set and more severe 
condition could increase the burden of schizophrenia on public, we also considered factors that 
are associated with earlier onset and more severe conditions as risk factors of schizophrenia. 
The study of these risk factors do not require healthy controls and thus can be studied in current 
design. However, in order to understand the burden of schizophrenia better, traditional risk 
factors have to be studied and healthy controls have to be recruited. In the analysis of the effects 
of risk factors on age at onset, logrank tests were used in addition to simple testing of mean 
onset age. Logrank test compares the overall distribution of age at onset (i.e.cumulative 
proportion of schizophrenia patients curve) and tests whether the distribution curves are 
significantly different from each other. This test does not require a non-skewness of the 
distribution of onset age, whereas the conventional test on mean (e.g., student t test) is best for 
distribution with no skewness. Covariates were also controlled in the analysis. The choices of 
covariates to adjust were based on two criteria. Firstly, the covariates existed before the variable 
under study (e.g. family history exists before onset of schizophrenia). Secondly, the covariates 
might have an effect on the dependent variable under study or the covariates that were of 
interest in this thesis (e.g. birth season was of our interest). In such a way, the significance due 
to the risk factors themselves can be examined. Charting was also employed to compare the 
distribution of age at onset. In plotting the proportion of patients in 5-year age category chart, a 
sliding window of 5-year age category was used (e.g. 1-5, 2-6, 3-7, …) instead of the 
conventional way of fixed age category (e.g. 1-5, 6-10, …). In such a way, the trend of changing 
proportion of patients in each age category might be visualized more clearly.  
2.4.2 Distribution of age at onset 
The distribution of age at onset was found to skew to the right, with the majority of patients 
developing schizophrenia at a relatively young age (15-25 years old) (Figure 2.1) and almost 90% 
43 
 
patients experiencing their illness before 40 years old, indicating that only a minority of patients 
have a relatively late onset of schizophrenia (>40 years old) (Figure 2.1). This finding is 
consistent with findings in Caucasian population (Hafner and an der Heiden, 1997). Particularly, 
in current study, 25% of patients got schizophrenia within 18-23 years old, suggesting that 
special attentions should be given to colleague students to prevent or delay the onset of 
schizophrenia. There is a second small peak between 45-50 years old age periods in current 
study sample. This observation is consistent with previous reports that women had a second 
peak of onset after menopause (Castle and Murray, 1993, Hafner and an der Heiden, 1997).   
2.4.3 Effects of gender, family history and birth seasonality on age at onset  
The results from testing of mean (t test) of onset age, testing of distribution curve of onset age 
(logrank test), and PHM modeling all agree with each other, suggesting significant effects of 
gender and family history on age at onset (Table 2.3, Figure 2.2). Male gender was found to be 
significantly associated with earlier onset of schizophrenia (Figure 2.2). This result is consistent 
with previous studies conducted in Caucasian and Chinese population (Hafner, 2003, DeLisi, 
1992, Lewine, 1980, Seeman, 1982, Angermeyer and Kuhn, 1988, Tang et al., 2007). The mean 
age difference between males and females was found to be 2.0 years old (Table 2.3). This 
difference is smaller than the 5 years gender difference in the recent study conducted in Bejing, 
China (Tang et al., 2007). There are two reasons that might contribute to the difference. Firstly, 
Singapore Chinese mainly originated from Southern China whereas the Chinese study was 
based on the population in Beijing which mainly originated from Northern China. Secondly, all 
the patients in the Beijing study were inpatients (hospitalized patients), whereas the study 
sample of current study includes both inpatients and outpatients.  
When comparing the distribution of age at onset, females had a lower proportion of onset at a 
young age and they have a second peak of onset during 45-50 years period (Figure 2.2A), which 
coincides with menopause. It has been suggested that mean age onset difference between males 
and females is due to estrogens antipsychotic-like effects (Hafner et al., 1993), which delays the 
onset of schizophrenia in females. At a younger age, estrogen antipsychotic-like effects in 
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females prevent or delay the onset of schizophrenia. Following menopause, the reduction of 
estrogen level reduces the protection effects, and causes a surge in cases of schizophrenia. 
Therefore, our observations on the distribution of age at onset of females are explained. 
Patients with positive family history also have an earlier onset of schizophrenia, with mean 
onset age being 1.7 years earlier than those with no family history. This finding is consistent 
with previous studies on family history in Europe (Alda et al., 1996). The family history 
difference was also reflected in distribution of age at onset curves, with the cumulative 
percentage of schizophrenia curve among patients with no family history consistently lies below 
the curve of patients with family positive history (Figure 2.2B). The effects of family history on 
age at onset could be due to either genetic risk factors or due to unfavourable familial 
environments that patients were exposed to. This study, however, is unable to distinguish these 
two possible causes at present stage.  
Unlike gender and family history, birth seasonality did not show any significance effects on age 
at onset. Even when different definitions of winter seasonality (e.g. define Oct-Dec as the winter 
season) were used, no significant effects were found (results are not shown). The lack of effects 
could be due to the facts that Singapore is located in a tropic region with no obvious climate 
change throughout the year.  
We also found that gender and family history counter interacted with each other, as the 
coefficient of the interaction term was less than 1.0 (Table 2.4). The distribution curves of age at 
onset in subcategory also confirmed the counter interaction. The gender difference in 
distribution curve disappeared when both males and females were from families with 
psychiatric history (Figure 2.3B). Assuming that the gender difference is caused by estrogens, 
these results suggest that the protective effects of estrogens on onset can be negated by family 
history. Therefore, no difference in distribution curve is present when comparing males with 
females if all of them have family history.  
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2.4.4 Effects of gender, family history and birth seasonality on clinical presentations  
Gender had no significant effects neither on duration of hospitalization nor on the number of re-
hospitalizations (Table 2.5). Together with the results from age at onset study, the results 
suggest that the effect of gender is greater on onset of schizophrenia rather than on the overall 
severity of symptoms. However, in terms of sub-category of symptoms, males were found to 
have significantly more severe negative symptoms (Table 2.6). This finding is consistent with 
previous reports that negative symptoms rather positive symptoms in males are more severe 
than in females (Goldstein et al., 1990, Kay et al., 1987).  
Patients from families with psychiatric history were also found to have significantly more re-
hospitalizations (Table 2.5), suggesting that they are more likely to get more severe form of 
schizophrenia (mild symptoms does not require hospitalization). In agreement with this finding, 
patients with family history also had significantly more severe positive symptoms (Table 2.6). 
These findings indicate that family history, unlike gender, still exerts effects on schizophrenia 
even after onset. 
In comparing the medication profile across gender, the most distinct finding was that higher 
proportion of males was prescribed typical antipsychotic medications and less of them were 
prescribed atypical antipsychotics as compared to females (Table 2.7). One possible explanation 
for this observation is that females have more extrapyramidal side effects (EPS) than males at 
the time of assessments. Since atypical antipsychotics have less EPS, more atypical 
antipsychotics are prescribed to females to reduce EPS, and consequently, less typical 
antipsychotics are prescribed to them. This possibility will be further examined in chapter 4. 
Another finding on medication profile difference was that significantly higher proportion of 
females use antidepressants than that of males (Table 2.7), suggesting that more females than 
males have depression co-morbidities. This finding is consistent with widely reported 
observation that females have higher incidence and prevalence of depression (Piccinelli and 
Wilkinson, 2000). However, considering that medication profiles were collected at the time of 
assessments, they reflected solely the medication status at the time point of assessments. Since 
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medication profiles change as time goes by, the implication on depression in females is only 
suggestive but not conclusive. A follow-up study with regular assessment is required to 
establish the relationship.  
 
2.5 Conclusions 
This chapter has assessed the effects of gender, family history and birth seasonality on onset age 
and clinical presentations of schizophrenia. Females were found to have a significantly delayed 
onset of schizophrenia compared with males. We also found that this gender effect could be 
overridden by family history in patients. These discoveries verity the effects of gender on onset 
age in Chinese population and extend the current understanding of gender effects by examining 
its interactions with family history. With respect to clinical presentations, females were found to 
have less severe negative symptoms and were more likely to be prescribed atypical 
antipsychotics. However, since both symptoms severity and medication profile were only 
measured at one time point (i.e. at assessment), cautious is needed in interpretation and 
generalization of these observations. To consolidate the evidence for symptoms and 
hospitalizations, a follow up study with multiple assessments is required. The second risk factor, 
family history, was found to be associated with an earlier age of onset, which is consistent with 
previous studies, but this effect of family history was more obvious among females rather on 
males. This finding extends the current understanding of the effects family history on age at 
onset. Patients with family history were also more likely to get hospitalized and they had more 
severe positive symptoms, suggesting family history has a prolonged effect on schizophrenia. 
Unlike gender and family history, birth seasonality did not show any effect on age at onset, 
hospitalization, severity of symptoms and medication profile. Although it is a negative finding, 
it fills the gap in literature where studies on birth seasonality in Chinese population are limited.  
Our study is an association study, which aims to identify the possible causal relationships. 
However, the mechanisms underlying the association are never investigated due to the nature of 
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association study. Particularly, estrogens can be the mediating factor for the gender effects 
found in our study. However, although our results support the hypothesis, our study is unable to 
prove this hypothesis. Experimental studies to investigate the biological functions of estrogens 
on onset of schizophrenia are required to further elucidate the punitive antipsychotic effect. 
However, due to the lack of good schizophrenic animal model, the biological experiments in 
this field are limited (Marcotte et al., 2001). We also found that family history was associated 
with an earlier onset of schizophrenia. The effects of family history on onset age can be either 
exerted by inherited genetic factors or by adverse schizophrenia family environment. However, 
our study cannot distinguish which one is the mechanism. A similar question has been 
attempted in chapter 5, where familial structure has been establish to examine whether it is the 
inherited genetic factor or the unfavorable family environments that affect offspring behavior in 
schizophrenia families. Even if the earlier onset of schizophrenia among patients with positive 
family history is mediated by inherited genetics, current study has not attempted to identify the 
genes that are the responsible for earlier onset. To identify the specific genes, a whole genome 












Chapter 3 Genetic risk factors of schizophrenia: SNPs, genes and 
pathways  
3.1 Introduction  
3.1.1 Inheritability of schizophrenia  
People with positive family history of psychosis have substantially higher risk of developing 
schizophrenia than the general population. Heston (1966), one of the earliest pioneers in this 
area, reported that the rate of schizophrenia was 11% among adopted away children of 
biological schizophrenic mother, while the rate was 0% among control adoptees with non-
schizophrenic mother. Subsequent twin studies conducted by Shields & Slater (1975) confirmed 
this finding by showing that the risk of developing schizophrenia for monozygotic (MZ) co-twin 
of schizophrenic probands was 58% while the risk was only 1% in general population. The 
same twin sample was evaluated again by Gottlesman et al. (1987) using standardized DSM-III 
diagnostic criteria and similar results were found (47.5% for MZ). Gottesman (1987) also 
reviewed all high quality family based studies on schizophrenia in Europe between 1920 -1978 
and found that the risk for relatives of schizophrenic probands to develop schizophrenia is 
determined by their kinship distance from the probands. The closer the kinship of a subject to 
the schizophrenic probands, the higher the risk of developing schizophrenia would be for the 
subject. Taking all evidence into consideration, it is suggested that schizophrenia is a disorder 
with high inheritability. Since inheritability is achieved by inheritance of genetic information, a 
large body of studies have been conducted to identify the responsible genetic risk factors for 
schizophrenia at the molecular level. The design of these studies can be classified into three 
groups: linkage study, association study and genome wide association study. Genome wide 
association study is a type of association study in nature, but it is classified into a separated 
group due to its high through-put and hypothesis free nature. The subsequent section reviews 
the design, strengths and limitations of each of these three study design. 
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3.1.2 Linkage study, association study and genome-wide association study  
3.1.2.1 Linkage study design  
Linkage study is a method adopted in early days when the number of genetic markers (e.g. 
Tandem repeats) was limited. The disease status and genetic marker information for members in 
pedigree families are required for linkage study. If a specific genetic marker is present in 
schizophrenic parent and is also present in all the affected offspring but not in the unaffected 
offspring, then the genetic marker, or its linked genetic region, would be responsible for 
schizophrenia development. In reality, due to chromosome cross over during meiosis, some of 
the unaffected offspring may also have the genetic marker, while some of the affected offspring 
may not have the marker. As a result, a test is needed to determine whether the discordance is 
due to cross over or due to the fact that the genetic marker (or its linked genetic region) are not 
important for schizophrenia development. The test employed is LOD test, which compared the 
likelihood of observing the actual offspring genetic marker pattern and disorder status pattern if 
the genetic marker is in linkage with the causal marker with the likelihood if the genetic factors 
are not in linkage with the causal marker. The formula is 
          
                                                       
                                                          
       
          
         
 ,        
where NR stands for the number of offspring with no recombination (offspring with 
marker and trait or offspring with no marker and no trait), R stands for the number of 
offspring with recombination (offspring with marker but with no trait or offspring with 
trait but with no marker), and theta stands for the observed recombination rate, which is 
 
      
.  
High LOD score (score ≥ 3) is usually considered as significant. In early days when only about 
400 genetic markers were known (Riley, 2004), some or all of the markers are measured and 
tested one by one to examine the significance of the association between markers and 
schizophrenia in schizophrenic pedigree families. In such a way, once a marker is found, the 
regions liable for schizophrenia can be identified. However, the regions found in this way are in 
scale of centimorgan, which is a chromosome level scale and represents a length of 
50 
 
chromosome such that the chance of cross over within the region is 1%, and the results are 
usually expressed in terms of chromosome and band (e.g. 11q22). Since there might be 
hundreds of genes in each centimorgan or chromosome band, the resolution of linkage study is 
low.  
A large number of linkage studies on schizophrenia have been conducted. However, there is a 
severe lack of consistency and replication power in most of the studies in the literature. 
Mednick et al. (1988) reviewed 31 genome-wide linkage studies and found that no region had 
been replicated in more than 4 studies and more than half of all genome regions (58%) had been 
reported as risk regions at least once. This severe inconsistency has been attributed to a number 
of factors. Firstly, the penetrance of genes responsible for schizophrenia is low. Penetrance is 
the probability that a person display a trait, in this case schizophrenia, given that a gene is 
mutated (e.g. a change of sequence of a gene). 
                                            
                                                  
                                     
                 
For schizophrenia, the probability for identical co-twin of schizophrenia probands to develop 
the disorder is only around 50%, indicating that the penetrance cannot be 100%. Secondly, the 
etiology of schizophrenia might not be entirely triggered by genetic. The fact that almost 2/3 of 
schizophrenia patients are sporadic schizophrenia (i.e. having no family history) clearly 
suggests a role of environmental factors. Lastly, it is plausible that two or more genes are 
contributing to the susceptibility in a family such that affected parental probands and affected 
offspring have different risk genetic profile (Riley, 2004). In such scenarios, linkage 
methodology is not appropriate to identify the risk genes. Due to these considerations, linkage 
studies are not common nowadays, but these considerations can help still in interpretations of 
the genetic results of schizophrenia using any approach.  
3.1.2.2 Association study design 
Association study design has also been used to identify the risk genes. One type of association 
study is the case control association study where genotype of independent cases and controls are 
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compared to identify significant genetic risk factors. It has become popular in the past few 
decades because of a number of advantages. Firstly, unlike linkage study design, association 
study design does not require pedigree families, which is difficult to recruit in practice. Instead, 
independent cases (i.e. schizophrenia patients) and controls (i.e. healthy patients) are recruited. 
Since a large number of cases and controls can be recruited, the power in detecting small effect 
markers is greater, and thus more risk genetic risk factors could be identified. Secondly, unlike 
the large size and relatively rare genetic markers (e.g. tandem repeats) used in linkage study 
design, small and frequent genetic markers (e.g. single nucleotide polymorphism, or SNP) are 
used in association study. Therefore, the resolution of association study design is much higher 
than linkage study. Because of these two reasons, thousands of association studies have been 
performed to date. To identify significant genetic markers, the frequency of a specific variant of 
a marker (i.e. allele) is compared between the cases and controls. The significance of the 
difference in allele frequency is then assessed by the test statistics z, which is 
  
       
    
 
   
 
   
          
         
     
        
n1 stands for the number of case and n2 stands for the number of controls, p1 stands 
for the allele frequency in cases, p2 stands for the allele frequency in controls. 
By assuming normal distribution of z, the significance (i.e. p value) can be computed. 
Conventionally, in a single test, p value less than 0.05 is considered significant. Once a genetic 
marker is identified (e.g. SNP), it is presumed that there is an underlying causal genetic variant 
that is in linkage disequilibrium (LD) with the SNP.  Two genetic variants are said to be in LD 
if they are physically close to each other and no crossover happens between them in history 
evolution. In such a way, a causal genetic can possibly be found by identifying the significant 
markers.  
Another type of association study is family-based association study, which requires a population 
of independent trios. Each trio consist two parents and one affected offspring. Alleles are 
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genotyped in both parents and the affected offspring, and the transmission of the allele from 
heterozygous parents to offspring is examined. If the allele is independent of disease status, then 
both allele variants in a heterozygous parent should have equal chance to be transmitted to the 
affected offspring. On the other hand, if a specific allele variant is associated with disease status, 
then the allele should be heavily transmitted to affected offspring compared with the other allele 
in heterozygous parents. Transmission disequilibrium test (TDT) is used to test the significance 
of the extent of over transmission of an allele to the affected offspring. The test statistics is:  
   
      
   
   
where b stands for the number of heterozygous parents who transmit allele variant M1 but 
not allele variant M2 to their affected offspring; c stands for the number of heterozygous 
parents who transmit allele variant M2 but not allele variant M1 to their affected offspring. 
The notions follow the notions used in original articles of the test (Spielman et al., 1993).   
By assuming a Chi-square distribution of the test statistics 
2
, the significance of the extent of 
over transmission could be calculated. Conventionally, in a single test, p value less than 0.05 is 
considered significant.  
3.1.2.3 Genome wide association study 
Recently, technology developments make it affordable to scan a large number of SNPs quickly 
using DNA probes embedded arrays. As a result, genome-wide association studies (GWAS) in 
the form of case/control design or trios design become applicable, and a number of GWAS have 
been performed. In GWAS, a large number of SNPs (up to 1 million) across the whole genome 
are tested one by one for association with a disorder. Thus, it is a hypothesis free approach. 
However, due to this multiple testing nature, the false positive is inflated to an unacceptable 
level if 0.05 is still set as the cut off criteria for significance. To control the rate of false positives, 
two statistical methods are commonly used. The first method, which is termed family-wide error 
rate (FWER), is to reduce the p value criteria from 0.05 to 5.0×10
-8
 in GWAS (Watson et al., 
1984), so that the chance to make at least one false positive in 1 million tests is reduced to 5%. 
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The other method is false discovery rate (FDR) methods. The chance that a reported positive is a 
false positive is calculated (i.e. q value) by the method. Only if the chance is low enough 
(usually ≤ 0.05) will the allele be considered as significant. FDR is rarely used in GWAS, but is 
frequently used in pathway analysis based on GWAS data. In addition to these statistical control 
methods, the false positive can also be controlled at study design level. Incorporation of 
replication in the study design has been widely recommended in GWAS to increase the validity 
of reported genes/SNPs. It is said that the top significant SNPs reported in initial GWAS (first 
stage) should be replicated in an independent association study (second stage). Only if the 
significant SNPs in first stage also display a nominal significance (p<0.05) in the second stage 
would the SNPs be considered as significant. Most GWAS studies followed this two stage 
design to improve the validity of the results.   
3.1.3 Review of genetic risk factors of schizophrenia  
3.1.3.1 GWAS on schizophrenia  
In early simple association studies, researchers have to hypothesize the risk genetic factors for 
testing. Since the hypothesis is usually based on poorly understood biological mechanisms, the 
findings are often not replicated (Hirschhorn et al., 2002). More than 1,100 association studies 
have been performed, and more than 1,000 genes have been reported to be associated with 
schizophrenia (http://www.schizophreniaforum.org/res/sczgene, accessed on 17 Aug 2011). 
Although these findings significantly enhance our understanding of genetic risk for 
schizophrenia, the high diversity of these findings also reflects the controversies and 
disagreements in literature. Moreover, the effect sizes of the identified risk genes/SNPs in early 
association studies are usually small, and odds ratios are usually less than 2.0. Because of these 
inconsistencies and small effect sizes, no congruence regarding the causing genes has been 
reached to date. As a result, a number of GWAS on schizophrenia have been performed in past 




There are at present four large research groups working on GWAS of schizophrenia actively. 
They are International Schizophrenia Consortiums (ISC), SGENE Consortium in Europe, 
Molecular Genetics of Schizophrenia (MGS) consortium in U.S., and Clinical Antipsychotic 
Trials of Intervention Effectiveness (CATIE) in U.S.. A total of seventeen case control based 
GWAS studies have been published by these and other research groups (up to Aug 2011), 
among which three studies come from Asian population (two Japanese studies and one Chinese 
study). The sample sizes range from as small as 230 cases/336 controls (Djurovic et al., 2010) to 
as large as 4,999 cases/ 15,555 controls (Stefansson et al., 2009). The reported SNPs and genes 
in different studies, however, are completely different from each other, and no single study has 
detected a genome wide significant SNP (p<5.0×10
-8
). Until now, the only emerging genome 
wide significant locus (meta-analysis) is the MHC region at chromosome 6p based on a 
combined sample consisting 8,008 cases and 19,077 controls conducted by ISC. The reported 
combined p value of the most significant SNP (rs13194053) was 9.5×10
-9
, but the p value of the 
allele in individual study was only at the scale of 1.0×10
-3
 (Duan et al., 2010). 
 
Moreover, the 
odds ratios of the detected SNPs in MHC region were small, with effect size ranging between 
1.14-1.16 (Duan et al., 2010). In addition, the interpretation of the discovery of MHC region is 
also difficult. The gene density in MHC region is very high and the recombination rate in this 
region is very low. As a result, the LD region, where the detected SNPs locate in, covers more 
than one hundred of genes (Duan et al., 2010). Therefore, it is difficult to know which genes in 
the LD region are the causal genes for schizophrenia. Besides MHC region, some other genes 
have also been reported in GWAS of schizophrenia, though none of them have reached genome 
wide significance. These genes include CSF2RA and SHOX (p=3.7×10
-7
) (Lencz et al., 2007), 
AGBL1 (p=1.71×10
-6
) (Sullivan et al., 2008), ZNF804A (p=1.61×10
-7
) (O'Donovan et al., 2008), 
MYO18B (p= 3.4×10
-7









) (Shi et al., 






) (Athanasiu et al., 2010). 
None of these genes have been replicated by other research groups.  
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Besides these case control based GWAS on schizophrenia, a family-based (trio family) GWAS 
on schizophrenia in Japan has been reported (Yamada et al., 2011). The group validated its 
findings from family based GWAS using another two independent case control based 
association studies. A novel gene ELAVL2 (p=0.0008) was found, but it did not reach genome 
wide association significance in each of the individual studies. 
3.1.3.2 Inconsistency of GWAS results and possible reasons 
Considering all evidence together, the results from GWAS on schizophrenia display some 
common characteristics. Firstly, there is no convergence on risk SNPs/genes. Different studies 
have reported different risk SNPs/genes, and the reported genes do not seem to have related 
functions with each other either. Even within a study, the consistency of results from the first 
stage and results from the second stage is low. In the Japanese study conducted by Yamada et al. 
(2011), only 84 SNPs (5.7%) out of the 1,472 SNPs that were nominally significant in first 
GWAS stage showed a nominal significance in the replication stage of the same population. In 
the two stage designed European GWAS study conducted by Need et al. (2009), only 8 SNPs 
(8%) out of the top 100 SNPs found  in the first stage showed nominal significance (p<0.05) in 
the second stage. The low consistency (~10%) in the significant SNPs of the two stages is a 
general phenomenal in schizophrenia GWAS studies. Secondly, most of the reported genes do 
not have apparent relationship with neuron system and brain functions. Except for gene NRGN 
(Stefansson et al., 2009), which encodes postsynaptic protein kinase substrate, and ElAVL2 
(Yamada et al., 2011), which encodes neuro-specific RNA-bind protein, all reported genes are 
not directly related to neuron system or brain functions. In addition, none of the genes reported 
in GWAS have been widely reported in hypotheses driven association studies or linkage studies 
before. As a result, it is largely unknown how the genes identified in GWAS contribute to risk 
of schizophrenia. Thirdly, the effect sizes (i.e. odds ratios) of the reported genes are usually 
small. Except for the gene AGBL1 found by Sullivan et al. (2008), which had an odds ratio 6.01, 
other reported odds ratios are generally less than 1.2, indicating a small effect on schizophrenia. 
56 
 
As a result of these characteristics, the original objective to identify novel genes with high 
replication power has not been achieved with GWAS approach yet.  
There are a few reasons that have been frequently cited for the inadequacies of convergence in 
evidence of GWAS. Firstly, commercial genotyping arrays are manufactured based on the 
common disease common variant (CD-CV) hypothesis, which premises that the genetic risk for 
common disease is attributable to common allelic variants (> 5% among population) (Pritchard, 
2001). As a result, most of the embedded SNPs in the commercial arrays are common SNPs, 
with minor allele frequency more than 5% in population. Therefore, most rare SNPs have never 
been genotyped and their association with schizophrenia are not known. If most of the genetic 
risk to schizophrenia is attributed to rare variants, results derived from current commercial 
arrays are not likely to yield positive findings and will not likely to converge since their 
emergences are simply due to random effects. Therefore, it has been proposed that rare variants 
(i.e. minor allele frequency < 5%) should be studied (Gershon et al., 2011). However, when 
using traditional method to test rare variants, the sample size would be very large in order to get 
reasonable power to achieve significance. Considering that schizophrenia is not a very common 
disorder, pending new analyzing methods would be developed, testing rare variants is 
challenging at this present time. Secondly, SNPs variation may not account for all genetic 
variations, and non-SNP variation (e.g. copy number variation, inversions, and DNA 
methylation) may account for a greater portion of genetic variation. Some non-SNP variations 
(e.g. copy number variations) have been studied in schizophrenia research, and results look 
promising (Cook and Scherer, 2008, St Clair, 2009). However, more recent study showed that 
the proportion of phenotype variations explained by common variants have been under 
estimated due to imperfect tagging of SNPs (Yang et al., 2011), suggesting that there is still 
scope for improvement in common SNPs based GWAS. Thirdly, population structure difference 
may contribute to the inconsistency. The LD structures for different population are different. 
Therefore, it is possible that different SNPs are reported in different studies though all of them 
are in LD with the same underlying causal variant. Besides these three explanations, there are 
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some less frequently cited reasons for inconsistency in literature. One of them is the use of case 
control designs in elucidating the causal variants. Controls might have similar genetic risk 
profile as cases but the disorder has yet to emerge, in which case the significant risk SNPs 
emerging from GWAS are simply due to random effects and findings from different studies will 
not converge.  
3.1.3.3 Deficiency in GWAS study scope  
There are also some deficiencies in the scope of the studying objectives in GWAS at present. 
Currently, GWAS generally focus on the risk of schizophrenia (case control based GWAS) and 
aim to identify the risk genes/SNPs that can increase the risk of developing schizophrenia. Other 
features of schizophrenia, such as severity of symptoms and onset age, have never been studied. 
Age at onset has been shown in chapter 2 to be associated with family history, suggesting that 
genetic factor may play a role in determining the onset age. Previous twin and family studies 
have also suggested that genetic factors might substantially influence onset age of schizophrenia. 
It has been reported that the age of onset within sibling pairs and Dizygotic twins displayed 
some correlations (r=0.3) (DeLisi et al., 1987, Suvisaari et al., 1998, Cardno et al., 1998), but 
the correlation was much higher within monozygotic twins (r=0.7) (Kendler et al., 1987, 
Cannon et al., 1998). This observation indicates that the onset is substantially affected by 
genetic components. Recently, the expression of gene AHI1 in early onset of schizophrenia was 
found to be higher than those of late onset of schizophrenia (Slonimsky et al., 2010). The 
polymorphism of gene Val66Met BDNF was also found to be associated with onset age of 
schizophrenia, with higher frequency val-val BDNF genotype in early onset schizophrenia 
patients (Pakhomova et al., 2010). In despite of these findings, the underlying genetics for the 






3.1.3.4 Deficiency in GWAS data utilization  
In addition to the deficiency of the scope of study scope in GWAS, there is also a deficiency in 
utilizing the GWAS data. Current GWAS generally focus on individual SNPs and test each SNP 
one by one. However, the SNPs may not contribute to the risk of schizophrenia independently, 
but as a group. In such a scenario, testing all the genes/SNPs that are dependent on each other as 
an entire group could have higher power than the conventional way of testing each SNP 
individually. For schizophrenia, it has been suggested that the risk genes may concentrate in 
some particular biological pathways (Levinson, 2003). As a result, pathway analysis by 
grouping all SNPs or genes in biological pathways and treating them as one unit could have 
higher power and consistency in finding the risk pathways. In such a way, GWAS data is also 
further utilized in generating more insights on genetic risk factors (i.e. pathways) of 
schizophrenia. To date, only one study has specifically investigated the risk biological pathways 
of schizophrenia based on GWAS data (Jia et al., 2010). In the study, Glutamate metabolism 
pathway was found to be the most significant pathway for schizophrenia (p=0.004). The lack of 
pathway studies in literature is probably because the methodology on pathway analysis is not 
standardized (Wang et al., 2007, O'Dushlaine et al., 2009), and a pathway might be too generic 
for interpretation and application since it contains multiple genes.       
3.1.4 Objectives 
Identification of the genetic risk factors for schizophrenia would help in understanding the 
etiology of schizophrenia development. GWAS is a powerful hypothesis free approach to 
identify the genetic risk factors. However, findings from GWAS have not been consolidated, the 
data of GWAS have not been fully utilized, and the scope of GWAS is usually limited to case 
control design. In view of these deficiencies, the objectives of the part of thesis were to:     
1) identify genetic risk factors for schizophrenia in Chinese population based on GWAS design, 
2) identify genetic risk biological pathways for schizophrenia in Chinese population, 
3) identify the genetic risk factors for earlier onset of schizophrenia in Chinese population.    
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By recruiting genetic homogenous Chinese schizophrenia patients and healthy controls, and by 
implementing standardized diagnostic criteria, inconsistencies in genetic risk factors of 
schizophrenia may be reduced in our GWAS case control study. By using pathway analysis, 
GWAS data should be better utilized and more consistent risk pathways for schizophrenia may 
be identified. By studying risk factors for earlier onset of schizophrenia, the scope of GWAS 
analysis should be expanded.  
3.2 Methods 
3.2.1 Study design and sample collections 
In identifying the genetic risk factors (i.e. SNPs) that are associated with schizophrenia, a case 
control design was used. The cases were the schizophrenia patients recruited for the study of 
demographic risk factors in chapter 2, and the healthy controls were recruited from the local 
community by invitation. Blood of patients were drawn after obtaining written informed consent 
and were subsequently stored in Singapore Tissue Network. DNA was extracted from the blood 
and genotyped using Illumina 1M Duo Chips in Genome Institute of Singapore (GIS). A total of 
923 cases and 1,046 healthy controls of Chinese ethnicity were recruited and genotyped. To 
validate the results, we used the results from an independent schizophrenia GWAS study in 
Singapore involving 891 cases 996 controls. The recruiting criteria of the independent 
validation study sample were the same as the current GWAS except that all subjects were 
English speaking and their age were less than 50 years old.  
We also extracted the 923 cases out from current GWAS study and explored the genetic risk 
factors (i.e. SNPs) that were associated with early onset of schizophrenia.  
3.2.2 Data processing 
3.2.2.1 Data coding and storage 
Each subject was assigned a unique series code to maintain anonymity. Outcome variables and 
covariates (e.g. gender) were coded in the same way as described in the Methods Section in 
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Chapter 2. Genotype of each SNP was coded as the number of minor allele (i.e. 0, 1, 2) and 
missing data was coded as -1. The dataset was stored in a server in GIS and all data were 
processed under the Linux system.  
3.2.2.2 Quality control of genotyped data  
To ensure the reliability of the genotyped data, quality control procedures were implemented. 
Control procedures can be classified into sample control procedures and SNPs control 
procedures. In sample quality control procedure, samples were removed from analysis if a 
subject’s SNPs missing rate was more than 2%, if a subject’s heterozygosis was significantly 
higher than others with FDR value less than 0.01, if a subject’s 1st or 2rd degree of relatives were 
also present in the study sample, or if a subject’s first principle component statistics was more 
than two standard deviation away from the center of the Chinese population in Hapmap project 
in Principle Component Analysis. In SNPs quality control process, SNPs were excluded if their 
missing rate was more than 2%, if the minor allele frequency was less than 5%, if they did not 
follow Hardy Weinberg distribution with p value less than 5×10
-8
, or if they located in sex 
chromosome or mitochondria chromosome or conserved region. After the quality control 
process, a total of 82 subjects and 393,792 SNPs were removed, leaving 891 cases and 996 
controls with 753,234 SNPs for GWAS analysis. The same quality control steps were applied in 
the independent validation study sample. After quality control, 829 cases and 973 controls with 
706,626 SNPs were used in analysis.     
In examining the SNPs that were associated with earlier onset of schizophrenia, a separated 
quality control procedures were applied only to the 923 cases, since only cases were used in 
analysis. The sample quality control procedures were the same as described above. In SNPs 
quality control process, SNPs with missing rate more than 2%, or with minor allele frequency 
less than 2%, or with location in sex chromosome, mitochondria or conserved region were 
removed from analysis. The minor allele frequency criterion was relaxed from 5% to 2% 
because rare homogenous genotype was treated as the heterozygous genotype in analysis (see 
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next subsection: statistical analysis of GWAS). After the control procedures, a total of 29 
subjects and 300,721 SNPs were removed, leaving 887 schizophrenia subjects with 837,350 
SNPs for analysis. 
3.2.3 Statistical analysis  
3.2.3.1 Statistical analysis for GWAS  
In identifying the risk SNPs for schizophrenia based on case control design, the allele frequency 
of each SNP that had passed the quality control between cases and controls were compared. 
Cochran-Amitage trend test was used in assessing the significance of the association. P value 
was computed for each SNP. If the p values of SNPs were less than less than 5× 10
-8
, they were 
considered to be of genome wide significance. Manhattan plot and QQ plot were used to present 
the overall distribution of p value. 
To validate the results, the p value and effect size of the top 100 SNPs was compared with an 
independent study which had 891 Chinese schizophrenia cases and 996 Chinese healthy 
controls. Since the independent study was genotyped by ZhongHua array which had only 50% 
of SNPs that overlapped with SNPs in the illumine 1M Duo array used in current study, the 
SNPs that were present in current study but not in the independent study were imputed using 
1000 genome Chinese reference population (Siva, 2008).  
 3.2.3.2 Statistical analysis for pathway analysis 
The SNPs list with p values and test statistics found out in our previous GWAS step (section 
3.2.3.1) were analyzed to elucidate the biological pathways that were significantly associated 
with schizophrenia. The modified gene set enrich analysis algorithm (GSEA) developed by 
Wang et al. (2007) was used to identify the biological pathways that were enriched by 
significant genes identified in GWAS study. This algorithm measures the overall degree of 
significance of the genes in a pathway. The higher the degree of significance of the genes, the 
more significant the pathway will be. The algorithm of GSEA can be summarized into 3 steps. 1) 
Link the SNPs identified in GWAS to known human genes based on physical position of the 
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SNPs and genes, and assigns the test statistics of the SNPs to the linked gene as the gene test 
statistics. 2) Link the genes to known biological pathways based on pathway definition (i.e. 
definition of the gene set that belongs to a pathway). 3) Compute the significance of the 
pathway and adjust for multiple testing. The details of the application of these three steps in 
current analysis are described below:   
1) Link SNPs to genes and assign test statistics to them. SNPs are defined to belong to a gene if 
the physical positions of the SNPs are within 5kb upstream and 5kb downstream of the 
expression region of a known gene. The position of the SNPs was obtained from the documents 
of the microarrays used in genotyping. The gene expression position was obtained from UCSC 
table browser by choosing the same genome assembly as the microarray SNPs annotation. The 
maximum test statistics of SNPs within a gene was treated as the test statistics of the gene. A 
total of 22,023 genes were identified and assigned with test statistics.  
2) Link genes to pathways. In order to link genes to pathways, the definition of pathways (i.e. 
which genes are in the pathways) have to be specified. There are multiple pathway definition 
systems available, such as Molecular signature database (MSigDB), 
(http://www.broadinstitute.org/gsea/msigdb/index.jsp), Kyoto Encyclopedia of Genes and 
Genomes (KEGG), (www.genome.jp/kegg/), Database for Annotation, Visualization and 
Integrated Discovery (DAVID) , (http://david.abcc.ncifcrf.gov/),  Biocarta 
(http://www.biocarta.com/) and Gene Map Annotator and Pathway Profiler (GenMAPP), 
(http://www.genmapp.org/). Each of them has a different set of pathway definition. We used 
MsigDB canonical pathway definitions in this current study since its pathway definition is 
constructed by incorporating and combining the pathway definitions from multiple other 
pathway definition sources (e.g. KEGG, Biocarta). However, due to this way of construction, 
different pathways in the pathway definition may overlap with each other. In severe cases, two 
pathways may be identical but treated as different pathways and labeled differently since they 
are from different pathway definition sources. Due to this consideration, we also used KEGG 
pathway definition in our analysis. The definitions of pathways in KEGG are constructed based 
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on the evidence from validated biological experiments. Therefore, the pathway definition is 
more reliable and the genes in a KEGG pathway have more related biological functions. 
Moreover, KEGG pathway is a single source of pathway definition system. Therefore, different 
pathways are less overlapped and are relatively more distinct from each other. We followed the 
same method used by Wang et al. (2007) to control the quality of pathway by excluding the 
pathways that include more than 200 genes or less than 20 genes from analysis. As a result, a 
total of 536 pathways from MSigDB and 211 pathways from KEGG were used in analysis.   
3) Computed the significance of the pathways. All the genes identified in Step 1 were ranked 
from largest to smallest according to their test statistics. A normalized enrichment score (NES) 
was then computed for each pathway in the pathway definition. This score represents the degree 
of enrichment of significant genes in the pathway. Higher score signals that more genes in the 
pathway have larger test statistics. The algorithm of computing NES and the algorithm of 
computing the significance of NES are described below:  
Once the gene list identified in Step 1 was ranked, a enrichment score (ES) of a pathway was 
computed based on the formula, 
       
   
       
       
 
  
       
     
 
    
       
                      
 
   
    
where S represented a particular pathway, and Gj* represented a particular gene j* in the 
pathway S, and r(j*) represented the test statistics of a gene. NR and NH are constant for a 
particular pathway. P was taken as 1, which was recommended by Wang et al. (2007). To test 
the statistical significance of the ES, a permutation approach was used since the theoretical 
distribution of ES was unknown. In this study, the disease status was permuted for 10,000 times 
to compute the p values. Once permutation was performed, ES of each pathway was normalized 
by the mean and standard deviation of ES across permutations, so that the normalized ES (NES) 
were comparable between pathways with different gene set size. The formula to calculate NES 
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was:     
                  
          
  
                                                                        
Since there were multiple pathways, multiple hypothesis testing had to be controlled. We used 
two ways to control for multiple testing. 1) False discovery rate (FDR) (Reiner et al., 2003): 
FDR computes the probability of false positive given that the pathway is declared as a positive. 
A pathway with FDR less than 0.05 are considered as significant after controlling for multiple 
testing. In this thesis, FDR was computed according to permutation results as     
                             
                              
, which was specified by Reiner et al. (2003). 2) Family-wise 
error rate (FWER): FWER is Bonferroni adjustment of nominal p values, and it is a common 
way to control multiple testing. Pathway with FWER less than 0.05 are considered as significant 
after controlling for multiple testing. In current study, FWER was calculated as      
 
                 
                    
, which was suggested by Wang et al. (2007). In current study, we 
computed both FDR and FWER, but FWER less than 0.05 were used as the cut off criteria for 
conservative purpose. The R code for the entire pathway analysis is shown in the Appendix: 
code for pathway analysis. 
To validate the results of current pathway analysis, we applied the same analysis method on the 
ranked SNP p value of the independent study and compared the pathway results.  
3.2.3.3 Statistical analysis for age at onset  
The analysis was the same as described in Chapter 2 except that SNPs information rather than 
demographical information of subjects were used as independent variables. The duration from 
birth to the onset of schizophrenia (i.e. age at onset) was considered as the time of life before 
onset of schizophrenia. At each SNP position, two (MM, Mm) or three (MM, Mm, mm) 
genotype could be observed (M is major allele, m is the minor allele). If the genotyped 
frequency of mm (i.e. two minor alleles) was less 1%, Mm and mm were treated as a single 
genotype. Cox proportional hazard model (PHM) was used to estimate the effect size and 
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significance of each SNP (Cox, 1972). Since gender was found to be a significant risk factor for 
age of onset in Chapter 2, gender was always controlled as covariate in the model. Logrank test 
based on Kaplan Meier curve and Wald’s test from Cox PHM model without adjusting for 
gender as covariate were also computed for comparison purpose. We considered p value less 
than 5.0×10
-8
 as the criteria for genome wide significance.  
We also tried to build a predictive model of age at onset using the significant SNPs identified. 
All SNPs with p value less than 1.0 × 10
-4
 were used as a basis for feature selection to identify a 
subset of SNPs to predict onset age. We applied Lasso algorithm to identify the subset of SNPs 
that have high predictive power on age at onset (Tibshirani, 1996). The following paragraph is a 
description of the Lasso feature selection algorithm in Cox PHM model.  
Cox model specifies the relationship between hazard and independent variables 
                  
   , where z is the observed data, and β are the coefficients for 




     . In the Lasso algorithm, a penalized function       
 
    is added 
to the log-likelihood function, where d is the number of independent variables. Therefore, for a 
given value of λ, the coefficients (i.e.   ) could be estimated to be the set of values that 
maximized the penalized log-likelihood function 
 
 
         
 
   . In this estimation process, 
the coefficients of variables (i.e. SNPs) that are not important in determining the dependent 
outcomes (onset age) would be shrink to 0. Therefore, the set of variables with non-zero 
coefficients after the estimation process are considered as important variables in determining the 
outcomes. The tuning parameter λ of the penalty term was set to minimize generalized cross 
validation (GCV) value in current thesis (Craven and Wahba, 1979), and the coefficients were 
estimated based on the codes and methods developed by Zhang et al. (2007) (Zhang and Lu, 





3.2.3.4 Statistical software 
GWAS association analysis was performed using software Plink under Linux system. Pathway 
analysis and age at onset analysis were performed in R.2.10 under windows system.  
3.2.4 Role played in this study 
Since the genotyping of the subjects was outsourced to external party (i.e., Genome Institute of 
Singapore), I was involved in liaising with the external party, data quality control, data analysis 
and manuscript writing. In liaising with the external party, I responded all the queries of the 
sample from the external party, and sent as well as received data from them. In data quality 
control, I audited, identified and corrected all discrepancies between genetic data and recorded 
data in questionnaire (e.g., gender information). In data analysis, I performed all the data 
processing and data analysis by writing R programs under Linux system. In manuscript writing, 
I wrote all parts of the first draft of manuscript.  
 
3.3 Results  
3.3.1 GWAS analysis  
To identify the significant SNPs that are associated with schizophrenia, the allele frequency of 
each SNP was compared between cases and controls using Cochran-Armitage test. As shown in 
the Manhattan plot (Figure 3.1) and QQ plot (Figure 3.2, the x-axis represent a uniform 
distribution of p value), no SNPs has reached genome-wide significance after corrections for 
multiple testing (p≤5.0×10-8). The most significant SNP was rs185221 in chromosome 5 
(p=3.00×10
-6
, OR=1.52, Table 3.1). The 6
th
 most significant SNP rs252802 is LD with rs185221, 
and reached a p value of 4.19×10
-6
. These two SNPs are located in intron region of gene ephrin-
A5, a cell membrane anchored receptor, which plays an important role in late stage of neuron 
system development and differentiation by preventing binding of axon with astrocyte. Among 
the remaining 18 SNPs, 5 SNPs are located in the gene region of SBNO1, 4 SNPs are located in 
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the gene region of MPHOSPH9, 3 SNPs are located in the gene region of SETD8, and 2 SNPs 
are located in region FAM38B (Table 3.1). As shown in Figure 3.3, gene MPHOSPH9, SBNO1 
and SETD8 are adjacent to each other (Chr12:122,200k-122,500k) and the SNPs in these three 
genes are separated into two LD blocks, with SNPs in MPHOSPH9 locate in one block and 
SNPs in genes SBNO1 and SETD8 locate in another block. MPHOSPH9 is a gene involving the 
replication of DNA in M phase of cell cycle; SBNO1 is a gene involving in signalling 
transduction during the interaction between physical adjacent cells; SETD8 is a gene involving 
cell cycle regulations. None of these genes have been reported to be associated with 
schizophrenia. The function of FAM38B is not known.  


















Table 3.1 The list of the top 20 most significant SNPs in GWAS. 








 CHISQ P 
Odds 
Ratio 
rs185221 5 Ephrin-A5 G/A 328/1454 258/1734 21.82 3.00E-06 1.52 
rs3803001 12 SBNO1 G/A 526/1256 456/1536 21.5 3.55E-06 1.41 
rs4759407 12 MPHOSPH9 A/G 570/1212 500/1492 21.49 3.56E-06 1.40 
rs600419 18 FAM38B A/G 559/1223 766/1226 21.4 3.73E-06 0.73 
rs3759111 12 MPHOSPH9 A/G 569/1211 500/1492 21.34 3.84E-06 1.40 
rs252802 5 Ephrin-A5 G/A 307/1475 239/1751 21.18 4.19E-06 1.52 
rs28595660 12 None A/C 524/1258 455/1537 21.15 4.25E-06 1.41 
rs28414347 12 None C/A 524/1258 455/1537 21.15 4.25E-06 1.41 
rs28613486 12 SETD8 A/G 524/1258 455/1537 21.15 4.25E-06 1.41 
rs3759113 12 MPHOSPH9 C/A 570/1210 502/1490 20.92 4.79E-06 1.40 
rs28587386 12 SETD8 A/G 525/1257 457/1535 20.87 4.92E-06 1.40 
rs3825141 12 SBNO1 A/C 524/1258 456/1536 20.83 5.02E-06 1.40 
rs9795593 12 None G/A 521/1261 453/1539 20.71 5.34E-06 1.40 
rs28501453 12 SETD8 A/G 524/1256 457/1535 20.71 5.36E-06 1.40 
rs8095590 18 FAM38B G/A 561/1219 765/1223 20.51 5.93E-06 0.74 
rs10846519 12 SBNO1 A/G 521/1261 454/1538 20.51 5.95E-06 1.40 
rs7297649 12 SBNO1 G/A 521/1261 454/1538 20.51 5.95E-06 1.40 
rs4460848 12 MPHOSPH9 A/G 572/1210 505/1487 20.5 5.96E-06 1.39 
rs7959415 12 SBNO1 G/A 520/1260 453/1537 20.5 5.96E-06 1.40 
GA011195 12 None A/G 521/1255 453/1529 20.5 5.98E-06 1.40 
1 
The total number of minor/major alleles in the cases. 
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Figure 3.3 LD structures of the SNPs in Chromosome 12 region 122,200k-122,500k.  
 
 
To validate the GWAS results, we compared the p value of the top 100 SNPs in the current 
GWAS study with the p value of these SNPs in an independent analysis including 835 cases and 
981 controls. The top 20 SNPs out of the 100 SNPs and an addition 7 SNPs that reached p less 
than 0.1 in the independent study are shown in Table 3.2. Only 7 SNPs out of the top 100 SNPs 
reached p value less than 0.1 in the independent study, and only 3 SNPs reached a nominal 
significance (p<0.05, highlighted in red). Among these 3 SNPs, only rs11622397 had a known 
associated gene RPS6KA5, which involves in the phosphorylation of transcription factor CREB. 
This gene has not been reported to be associated with schizophrenia before, and its implication 
to schizophrenia is unknown. The highly significant and biologically plausible SNPs rs185221 
and rs252802, which are located in gene Ephrin-A5, did not reach the level of significance in 
the independent study (p = 0.47 and 0.61 in independent study). In fact, none of the top 20 most 
significant SNPs in current GWAS reached a p value less than 0.4 in the independent study. The 
disagreement of results between the two studies suggests that schizophrenia is not a disorder 




Table 3.2 Comparison of p value and effect size in current GWAS study with an independent 
study.    
SNP ID CHR Genes Current Study Independent study 
   P value  OR P value  OR 
rs185221 5 Ephrin-A5 3.00E-06 1.52 0.469 * 1.07 * 
rs3803001 12 SBNO1 3.55E-06 1.41 0.523 * 1.05 * 
rs4759407 12 MPHOSPH9 3.56E-06 1.40 0.559 * 1.05 * 
rs600419 18 FAM38B 3.73E-06 0.73 0.982 * 1.00 * 
rs3759111 12 MPHOSPH9 3.84E-06 1.40 0.585 * 1.04 * 
rs252802 5 Ephrin-A5 4.19E-06 1.52 0.607 1.05 
rs28595660 12 None 4.25E-06 1.41 0.499 1.05 
rs28414347 12 None 4.25E-06 1.41 0.532 1.05 
rs28613486 12 SETD8 4.25E-06 1.41 0.509 1.05 
rs3759113 12 MPHOSPH9 4.79E-06 1.40 0.569 * 1.05 * 
rs28587386 12 SETD8 4.92E-06 1.40 0.465 1.06 
rs3825141 12 SBNO1 5.02E-06 1.40 0.523* 1.05 * 
rs9795593 12 None 5.34E-06 1.40 0.500 * 1.06 * 
rs28501453 12 SETD8 5.36E-06 1.40 0.446 * 1.06 * 
rs8095590 18 FAM38B 5.93E-06 0.74 0.763 0.98 
rs10846519 12 SBNO1 5.95E-06 1.40 0.490 * 1.06 * 
rs7297649 12 SBNO1 5.95E-06 1.40 0.490 * 1.06 * 
rs4460848 12 MPHOSPH9 5.96E-06 1.39 0.621 * 1.04 * 
rs7959415 12 SBNO1 5.96E-06 1.40 0.490 * 1.04 * 
GA011195 12 None 5.98E-06 1.40 0.500 * 1.06 * 
rs11119983 1 ATF3 7.34E-05 0.73 0.059 * 1.18 * 
rs11622397 14 RPS6KA5 2.94E-05 0.67 0.044 0.81 
rs11625792 14 None 2.85E-05 0.67 0.063 * 0.82 * 
rs12889954 14 SYNE2 2.85E-05 0.65 0.078 0.83 
rs13279037 8 None 9.02E-05 0.77 0.027 0.85 
rs3016384 11 None 5.27E-05 0.77 0.035 0.86 
rs6682064 1 ATF3 5.93E-05 0.73 0.057 1.17 







3.3.2 Pathway analysis   
3.3.2.1 Identification of significant pathways 
To identify the pathways that were significantly enriched by risk genes for schizophrenia, we 
applied GSEA algorithm on the list of 753,234 SNPs identified in current GWAS analysis. 
KEGG and MsigDB pathway definition, which defined the genes in a particular pathway, were 
used in analysis. KEGG pathway definition system is a single pathway definition system and its 
pathways are constructed based on biological experimental evidence. MsigDB pathway 
definition system is a multiple sources pathway definition system, and its pathways are simply 
collections of pathways defined in different pathway definition sources, including KEGG 
pathway, Biocarta pathway, Reactome pathway and SIG clinical pathway.  Therefore, compared 
with MsigDB, the number of pathways defined in KEGG is smaller (211 pathways in KEGG vs. 
536 pathways in MsigDB), but the pathways are more reliable and there is less overlap of genes 
between different pathways. Therefore, we considered the results from KEGG pathway 
definition as the primary source of results, but the results based on MsigDB definition were also 
presented for comparison purpose.   
The top 10 most significant pathways according to KEGG and MsigDB pathway definition are 
shown in Table 3.3A and Table 3.3B. P values, FDR and FWER were computed based on 
10,000 times permutation of gene labels. To adjust for multiple testing corrections, we used 
FWER less than 0.05 as the cutoff criteria for significance. A total of 6 pathways out of the 211 
pathways defined in KEGG reached the level of significance (Table 3.3A). They were axon 
guidance pathway, focal adhesion pathway, arrhythmogenic right ventricular cardiomyopathy 
(ARVC) pathway, dilated cardiomyopathy pathway, calcium signaling pathway, and cell 
adhesion molecules (CAMs) pathway. These 6 pathways were also among the top 10 most 





Table 3.3 Top ten significant pathways based on FWER value. 
A. Top ten significant pathways based on KEGG pathway definition. 
Pathway Names (Code) N 
1
 ES NES p value FDR FWER 
Axon guidance (hsa04360) 112 0.59 5.03 <0.0001 <0.0001 <0.0001 
Focal adhesion (hsa04510) 178 0.51 3.91 0.0001 0.0024 0.0047 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
(hsa05412) 
66 0.59 3.73 0.0002 0.0033 0.0099 
Calcium signalling pathway 
(hsa04020) 
153 0.51 3.60 0.0001 0.0043 0.0166 
Dilated cardiomyopathy 
(hsa05414) 
76 0.56 3.35 0.0007 0.0095 0.0439 
Cell adhesion molecules (CAMs) 
(hsa04514) 
123 0.51 3.34 0.0006 0.0084 0.0465 
Cerebellar long-term depression 
(Ltardive dyskinesia) (hsa04730) 
63 0.57 3.30 0.0004 0.0086 0.0554 
Hypertrophic cardiomyopathy 
(HCM) (hsa05410) 
74 0.56 3.29 0.0006 0.0080 0.0586 
Long-term potentiation 
(hsa04720) 
63 0.56 3.12 0.0011 0.0135 0.1052 
ECM-receptor interaction 
(hsa04512) 
74 0.54 3.00 0.0013 0.0186 0.1553 
1 
The number of genes in the corresponding pathway.  
B.  Top ten significant pathways based on MSigDB canonical pathway definition.  
Pathway names N 
1
 ES NES p value FDR FWER 
KEGG: axon guidance 
112 0.59 4.87 0.0000 0.0000 0.0000 
REACTOME: transmission 
across chemical synapses 113 0.60 5.44 0.0000 0.0000 0.0000 
REACTOME: neurotransmitter 
receptor binding and 
downstream transmission in the 
postsynaptic cell 72 0.60 4.04 0.0000 0.0018 0.0049 
KEGG: focal adhesion 
178 0.51 3.94 0.0000 0.0022 0.0082 
KEGG: arrhythmogenic right 
ventricular cardiomyopathy arvc 66 0.59 3.69 0.0002 0.0060 0.0258 
KEGG: calcium signaling 
pathway 153 0.51 3.65 0.0000 0.0059 0.0300 
REACTOME: axon guidance 
140 0.51 3.46 0.0002 0.0124 0.0725 
KEGG: dilated cardiomyopathy 
76 0.56 3.39 0.0003 0.0148 0.0952 
KEGG: cell adhesion molecules 
(CAMs) 123 0.51 3.32 0.0003 0.0172 0.1210 
KEGG: long term depression 
63 0.57 3.27 0.0005 0.0185 0.1409 
1 
The number of genes in the corresponding pathway.  
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3.3.2.2 Validation of significant pathways 
To validate the significance of the 6 pathway identified in current study, we applied the same 
algorithm on the ranked list of 706,626 SNPs, which we obtained from the collaborating group, 
according to p value computed in the independent study. If the significance of these 6 pathways 
was not due to random effect, they should remain significant in the independent study. As 
shown in Table 3.4, all the 6 pathways reached nominal significance in the independent study. 
In addition, two pathways, ARVC and CAMs, passed multiple corrections in both studies 
(FWER<0.05). ARVC pathway includes genes responsible for disorder arrhythmogenic right 
ventricular cardiomyopathy, which is an inherited heart muscle disease that may result in 
arrhythmia, heart failure, and sudden death. CAMs pathway includes cell surface adhesion 
molecules that are responsible for cell-cell interaction, cell migration and differentiation. 
Particularly, during early development of the nervous system, CAMs are responsible for axons 
elongation towards their targets and are responsible for establishing and maintaining synapses 
adhesions. In the remaining 4 pathways, which did not pass the multiple testing corrections in 
the independent study, the axon guidance pathway is of most interest. This pathway includes 
mainly genes that guide the growth and growth direction of axons at early neuron development 
stage. In addition, the guidance of growth of axon by genes in axon guidance pathway is also 
mediated by genes in CAMs pathway, which assists in the elongation and migration of axon. 
Considering that schizophrenia is a neuron development disorder and axon is a major part of 
neuron cells and plays a critical role in signal transmission and processing, the identification of 
axon guidance pathway suggests that axon development dysfunction could contribute to 






Table 3.4 Validation of the 6 significant pathways in an independent study based on KEGG 
pathway definition. 
Pathway Current Study Independent Study  
 P value FDR FWER P value FDR FWER 










 ARVC 0.0002 0.0033 0.0099 0.0002 
 
0.0114 0.0214 
Calcium signalling 0.0001 0.0043 0.0166 0.0014 
 
0.0258 0.2046 






 CAMs 0.0006 0.0084 0.0465 <0.0001 <0.0001 <0.0001 
 
3.3.3 Age at onset analysis  
3.3.3.1 Identification of significant SNPs for onset age 
To identify SNPs that are responsible for earlier onset of schizophrenia, we treated age at onset 
as duration of life before onset of schizophrenia, and modeled the association between onset age 
and SNPs using Cox PHM. Since gender was found to be a significant risk factor for earlier 
onset in Chapter 2, we controlled gender as a covariate in the modeling. We considered the 
Wald test p value for the effect size (i.e. coefficient) of SNPs as the p value for each SNP. P 
value computed based on Kaplan Meier test and PHM without adjusting for gender were also 
computed for comparison purpose.  
As shown in the Manhattan plot and QQ plot (Figure 3.4 and Figure 3.5).  No SNPs have 
reached the genome wide significance (p<5.0×10
-8
). The most significant SNP was rs7113887 
(p = 8.69×10
-8
), which locates in the intron of gene CNTN5 in region11q22.1-11q22.3. The 
significance of this SNP was not changed by the type of tests and it was shown up as the most 
SNPs in all the three type of tests (Figure 3.4). The effect size of this SNP 1.86, signaling that 
patients with genotype GG or GA have 1.86 times higher risk to get schizophrenia in a unit of 
following up time than the patients with genotype AA (in this case, GA and AA was combined 
as one category since the frequency of AA was less than 1% ). The cumulative percentage of 
schizophrenia patients against age among patients with GG genotype and patients with GA or 
76 
 
AA genotype is shown in Figure 3.6. It could be seen clearly that patients with GA or AA got 
schizophrenia much faster than patients with GG genotype, particularly at young age (before 25 
years old).  
Figure 3.4 Manhattan plot of p value from PHM and Kaplan Meier (KM) logrank test with/o 















Figure 3.5 QQ pot of significance of all SNPs based on KM adjusted for gender. 
 
 
Figure 3.6 Comparison of age at onset for patients with genotype GG and GA/AA at rs7113887. 
  























































There are 9 SNPs in strong linkage disequilibrium with the most significant SNP rs7113887 
(r>0.7 based on Hapmap Chinese population), and all of them are located in the intron of 
CNTN5. The significance of these 9 SNPs in the context of gene CNTN5 and the recombination 
rate in the gene region are shown in Figure 3.7. As shown, all the SNPs in linkage 





 (Figure 3.7).     
Figure 3.7 SNPs in LD with rs7113887 in context of gene CNTN5. 
 
Among all SNPs tested, the second most significant SNP was rs16884782 (p=2.25×10
-7
, Table 
3.5). This SNP has the largest effect size among all SNP test (effect size = 2.8), but there are no 
nearby genes at the physical position of the SNP. Moreover, none of the nearby SNPs had p 
value less than 1.0×10
-4
, disregarding linkage disequilibrium. Therefore, the significance of this 
SNP is more likely due to random effect. In the remaining SNPs, nine SNPs had p values less 
than 1.0×10
-6
. Out of them, 2 SNPs locate in gene CNTN5, 3 SNPs in GCNT3, 1 SNP in 
PPP1R9A, 1 SNP in GMDS and 2 SNPs with no associated genes (Table 3.5).    
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SNP in gene CNTN5





Table 3.5 Eleven SNPs with p value less than 1.0×10-6 based on KM adjusted for gender. 











rs7113887 3/82/799 G / A 8.69×10
-8
 1.86 CNTN5 Axon formation 
rs16884782 27/857 G / A 2.25×10
-7
 2.80 None  
rs7181069 47/303/534 A / C 1.98×10
-6
 1.31 GCNT3 Mucin biosynthesis  
rs854541 145/433/306 A / G 2.81×10
-6
 1.27 PPP1R9A Actin cytoskeleton 
reorganization 
rs10790499 4/84/796 A / G 3.87×10
-6
 0.59 CNTN5 Axon formation 
rs11218601 4/84/796 G / A 3.87×10
-6
 1.69 CNTN5 Axon formation 
rs7740069 7/125/751 A / C 4.06×10
-6
 0.65 GMDS Synthesis of GDP-
fucose 
rs6708936 1/53/830 A / G 5.84×10
-6
 0.53 None  
rs3743119 55/323/506 C / A 8.42×10
-6
 0.78 GCNT3 Mucin biosynthesis  
rs3743120 55/322/507 C / A  8.72×10
-6
 0.78 GCNT3 Mucin biosynthesis  
rs17545059 9/131/744 A / G 8.95×10
-6
 0.69 None  
1
 The genotype frequency specified the number of patients in each genotype category. The genotype 
categories were separated by slashes and orders of genotype was two minor alleles / one minor allele and 
one major allele / two major alleles. All genotypes in the study sample were showed, but in analysis, 
when the frequency of the double minor allele patients was less than 1%, they were combined with 
heterozygous patients and were treated as one category.     
 
3.3.3.2 Building a model to predict onset age 
To identify a subset of SNPs that can predict onset age with high power, we selected the top 81 
SNPs with p value less than 1.0×10
-4
 as the basis for feature selection. Twenty-two SNPs were 
in strong correlation with others SNPs in the list (r>0.9) and were removed from feature 
selection. Lasso algorithm was applied to the remaining 59 SNPs to identify the best subset of 
SNPs with high prediction power. As shown in Figure 3.8, coefficient of 15 SNPs shrunk to 
zero during the process by setting the tuning parameter (λ) to minimize generalized cross 
validation value, leaving 44 SNPs remaining in the model (the detail algorithm was presented in 
Methods session, 3.2.3.3 Statistical analysis for age at onset ). The IDs of this set of 44 SNPs 
and their coefficient and p values are shown in Table 3.6.  
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Figure 3.8 Shrinkage of coefficient (β) of the 59 SNPs duration the selection of subset of SNPs 



















































beta coefficient (all colour)
GCV
tuning point
Explanation of selection process: During the selection, lambda (λ) was chosen as the value 
which minimized the global cross validation value, at which point the prediction power of the 
model would be the highest among all possible λ. This value of λ is called turning point. Once λ 
was settled, the coefficient of not important SNPs would be estimated to be 0 (shrink to 0 in the 
process), and the remaining SNPs with non-zero coefficient were considered as the best subset of 
SNPs with high prediction power.  
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Table 3.6 Selected SNPs in Lasso modelling and their coefficients. 
SNP ID Coefficients Effect size P value 
rs10152637 0.84 2.32 4.24E-05 
rs10206380 0.64 1.90 1.40E-04 
rs10282321 0.86 2.37 1.17E-04 
rs10468024 0.33 1.39 1.17E-05 
rs10497400 -0.73 0.48 2.22E-04 
rs10498466 0.71 2.03 6.15E-05 
rs10790499 -1.41 0.24 1.50E-06 
rs10805326 0.38 1.46 1.66E-04 
rs11099401 0.62 1.87 3.48E-04 
rs12144133 -0.61 0.54 8.10E-05 
rs12986153 -1.24 0.29 3.29E-05 
rs1370251 0.43 1.54 5.36E-05 
rs1498688 0.30 1.35 1.63E-04 
rs1678632 -0.64 0.53 8.48E-05 
rs16884782 0.18 1.20 9.71E-07 
rs17086746 -0.47 0.62 2.77E-04 
rs17545059 -0.48 0.62 1.90E-04 
rs2076941 -0.78 0.46 1.98E-04 
rs2118036 0.19 1.21 4.45E-04 
rs2131858 0.83 2.29 1.16E-04 
rs2235959 -0.70 0.49 1.63E-04 
rs2755213 -1.00 0.37 2.78E-05 
rs3095755 0.74 2.09 1.25E-04 
rs35429726 -0.10 0.90 2.80E-03 
rs3743119 -0.92 0.40 1.07E-04 
rs3851043 0.03 1.03 8.28E-10 
rs4413992 -0.48 0.62 9.19E-05 
rs4659995 1.15 3.15 3.62E-05 
rs4666096 -0.95 0.39 4.43E-05 
rs4691630 0.03 1.03 1.07E-02 
rs486786 0.69 2.00 8.58E-05 
rs6708936 -1.29 0.28 1.06E-06 
rs7197292 -0.97 0.38 7.32E-05 
rs735183 0.41 1.50 1.08E-04 
rs7740069 -0.81 0.45 3.06E-05 
rs7812433 0.70 2.02 5.66E-05 
rs7850199 0.71 2.03 1.79E-04 
rs8011669 1.01 2.75 8.00E-05 
rs8033183 -0.80 0.45 4.63E-05 
rs842049 0.77 2.17 8.43E-05 
rs854541 1.10 3.00 1.32E-05 
rs897185 -0.51 0.60 6.32E-05 
rs9448767 0.78 2.17 2.56E-04 
rs9566257 -0.22 0.80 8.32E-04 
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To further examine the predictability power of the 44 SNPs, we followed a procedure of 
examination of predictability introduced by Van Houwelingen et al. (2006). Basically, a 
prognostic index (PI) was introduced to each subjects in the study sample. PI is defined as PI = 
X1β1+X2β2+…+X44β44, where βi stands for the estimated coefficients in Lasso model and Xi 
stands for the genotype of the patients of SNP i. If the prediction model is good, it would be 
expected that the group of subjects with higher PI values would get schizophrenia faster 
compared with the group of patients with lower PI (i.e. distribution of onset age of subjects with 
higher PI should be steeper). We therefore classified our study sample into four groups 
according to the four quarters of computed PI values of each subjects, and compared the actual 
cumulative distribution of onset among the four groups. As shown in Figure 3.9, the actual 
distributions of age at onset for the four groups were well separated according to PI values. For 
subjects with PI value in the first quarter (mean PI=-0.28), 24% of them get schizophrenia 
before 30 years old, but 91% of the subjects with PI in the fourth quarter (mean PI=0.26) got 
schizophrenia before 30 years old. This result signals that the risk profile of onset age can 
potentially be determined by the genotype of the 44 SNPs. 
Figure 3.9 Comparison of age at onset among the four groups of subjects with different PI. 
 
















































first quarter, 214 subjects, mean PI=-0.28
second quarter, 213 subjects, mean PI=-0.06
third quarter, 213 subjects, mean PI=0.08
forth quarter, 213 subjects, mean PI=0.26




Due to the high inheritability of schizophrenia, genetic factors play a critical role in the etiology 
of schizophrenia (Gottesman et al., 1987). To identify the specific genetic risk factors at 
molecular level (SNPs, genes, pathways) is important for the understanding of the biological 
mechanism for schizophrenia development. Therefore, a large number of studies have been 
conducted to find out the genetic risk factors. However, due to the great inconsistencies in 
literature, no congruence has been reached on the genetic risk factors for schizophrenia. The 
inconsistencies in literature could be due to the intrinsic characteristics that schizophrenia is a 
complex disorder contributed by a large number of genetic risk factors with small effect size. 
However, heterogeneous study population, non-standardized phenotyping, small sample size 
and inadequate analyzing methods may also contribute to the inconsistency. Therefore, in order 
to improve the quality and reproducibility of our study, we recruited a large homogenous study 
samples (891 Singapore Chinese Schizophrenia patients and 996 healthy controls) and used 
both GWAS and pathway analysis to elucidate the underlying genetic risk factors of 
schizophrenia. In addition, we also investigated the genetic risk factors for early onset 
schizophrenia, which expand the scope of conventional GWAS. We did not find any SNPs that 
passed genome wide significance in our GWAS on schizophrenia, but we found that ARVC and 
CAMs pathway were significantly associated with schizophrenia. In GWAS on age at onset, we 
also failed to found a SNP with genome wide significance, but gene CNTN5, which involves in 
neuron development, emerged as the top significant gene. The results on GWAS, pathway and 
age at onset analysis are discussed in the following three sections. 
3.4.1 GWAS analysis  
None of the SNPs tested have passed the genome wide multiple testing correction in current 
analysis (p≤5.0×10-8). These results are comparable with previous GWAS on schizophrenia 
(Need et al., 2009, Yamada et al., 2011), and suggest that schizophrenia is not a disorder caused 
by a few substantial SNPs. In our two stage GWAS, only 3 of the top 100 SNPs reached a 
nominal significance (p value ≤ 0.05) in the independent study. The disagreement of the two 
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stages implies that most of the SNPs among the top 100 SNPs are due to random effect, and the 
current study does not have enough power to detect the SNPs with real effect. Increasing sample 
size and sample homogeneity is one way to increase the power of the study. However, given a 
study sample, analysis methods can also be modified to increase the power and the consistency. 
It has been reported that schizophrenia is contributed by genes that are concentrated in 
biological pathways (Levinson, 2003). Therefore, analyzing all the genes in a biological 
pathway as one unit may result in higher power and consistency. The following section 
therefore discusses the results from pathway analysis.   
3.4.2 Pathway analysis  
3.4.2.1 Significant results  
ARVC pathway and CAMs pathway were found to be significant in current study sample and in 
the validation study sample. ARVC pathway includes genes responsible for disorder 
arrhythmogenic right ventricular cardiomyopathy, which is an inherited heart muscle disease 
that may result in arrhythmia, heart failure, and sudden death. It is not known how this pathway 
is associated with schizophrenia. A possible hypothesis could be that the oxygen delivered to 
brain is insufficient during brain development stage because of heart problems. Interestingly, 
numerous studies have found that schizophrenia patients have higher incidence, morbidity and 
mortality rate from cardiovascular disorders compared with general population (Hennekens et 
al., 2005, Curkendall et al., 2004, Hussar, 1965, Jin et al., 2011). A review of the association 
between schizophrenia and cardiovascular heart disorders found that the relative risk is 1.5, 
suggesting that schizophrenia patients have 1.5 time higher risk to get cardiovascular disorders 
than others (Hennekens, 2007).  The explanation for the high risk of heart disorders have been 
attributed to the usage of antipsychotics (Daumit et al., 2008). However, the identification of 
ARCV pathway in our study shown that schizophrenia patients may have already got some 
dysfunctions in the heart disorder related genes, which might be the reason for the high risk of 
heart disorders among schizophrenia patients.  
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CAMs pathway was the other significant pathway found in our study. This pathway includes 
cell surface adhesion molecules that are responsible for cell-cell interaction, cell migration and 
differentiation. During the development of neuron cells, CAMs play a part in axons elongation 
towards their targets and are responsible for establishing and maintaining synapses adhesions. 
Dysfunctions in CAMs pathway will result in absurd alteration in neuron cell growth orientation. 
In agreement with our results, CAMs have also been reported as a significant pathway in other 
studies based on GWAS results from schizophrenia. O’Dushlaine et al. (2011) reported 5 
significant pathways among 255 constructed pathways based on SNP ratio test, which were 
glycan structures biosynthesis, cell cycle, SNARE, cell adhesion molecules (CAMs), and tight 
junction pathways. Importantly, CAMs pathway is the only pathway that has passed multiple 
testing corrections in their study. This agreement on CAMs pathway across study population 
and study mythology suggests that CAMs functions are important in schizophrenia development. 
Since CAMs pathway plays an important role in axon elongation and synapse contact during 
neuron cell development, the mechanism of its effects on schizophrenia could be through axon 
growth and synapse contact dysfunction. A third pathway, axon guidance pathway, is also of 
our interest. It did not reach significance level in the independent study, but it was the most 
significant pathway in the current study. The biological function of this pathway is to guide the 
growth and growth orientation of axons at early neuron development stage. Since CAMs 
pathway also plays a role in neuron development, these findings strongly support the neuron 
development hypothesis of schizophrenia aetiology (Insel, 2010).  
Our pathway results are different from those pathways identified by Jia et al. (2010). The most 
significant pathway in their study is the glutamate metabolism pathway, with NES score = 2.59 
and as nominal p value = 0.004, followed by TGF-beta signaling pathway, and TNFR1 pathway.  
However, these pathways did not emerge as significant in our database. It could probably due to 
the fact that the genetic dataset used in their study was based on European ancestry samples, 




3.4.2.2 Strengths and limitations of methodology  
The strengths of the methodology in identifying the significant pathway lie on the gene set 
enrichment algorithm. This algorithm is different from the counting algorithm used in most 
pathway analysis software (e.g. IPA, David pathway). Counting algorithm counts the number of 
genes belonging to a particular pathway in a ranked gene list (e.g. top 100 genes). It then 
compares percentage of the gene in the pathway (e.g. 10 out of the top 100 genes belong to a 
pathway “P”, the percentage will be 10%) with the expected percentage if the pathway is not 
associated with the disorder. The expected percentage is the total number of genes in the 
pathway as a percentage of total human genes (e.g. the pathway contains 100 genes and human 
have 30000 genes in total, the percentage would be 3.3%). Therefore, counting algorithm 
requires a submission of ranked gene list, and the final results are influenced by how many top 
genes are submitted. In contrast, the GSEA algorithm uses the rank of the entire genes from 
GWAS analysis, and concentration of pathway genes on the top of the entire gene rank is 
measured. Despite this strength, application of GSEA on GWAS data also has some limitations. 
The major limitation comes from the fact that it is difficult to assign a score to a gene based on 
SNPs statistics in the gene. The conventional way, which is also the approach taken in current 
study, is to assign the maximum test statistics of the SNPs within the physical region of the 
genes to be the statistics of the genes. However, it is also not known whether maximum test 
statistics of SNPs can represent the significance of the genes. If multiple independent SNPs in a 
gene contribute to the risk of getting schizophrenia, the maximum statistics of SNPs may not 
fully represent the significance of the gene. In addition, the presence of LD structure in a gene 
also further complicates the problems. One study have attempted to incorporate LD structure in 
pathway analysis (Hong et al., 2009), but the methods have not been applied in other studies.  
3.4.2.3 Significance and limitation of the study 
Two pathways, CAMs and ARVC, were found to be significantly associated with schizophrenia 
in our study. Among them, CAMs have been previously reported as a significant pathway for 
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schizophrenia (O'Dushlaine et al., 2011). Since CAMs also play a part in neuron cell 
development, the identification and confirmation of this pathway support the hypothesis that 
schizophrenia is a disorder of neuron development. The other pathway, ARVC, is novel 
pathway that has never been reported as genetic risk factor for schizophrenia before. The 
identification of this pathway provides an alternative explanation for the observation that 
schizophrenia patients get higher risk for cardiovascular diseases. Despite the significance of the 
findings in this current study, it has to be noted that there are multiple genes in each pathways. 
Therefore, although pathway results provide useful information to understand the biological 
mechanism of schizophrenia, the resolution of the finding is not high enough to have clinical 
implications.   
3.4.3 Age at onset analysis  
3.4.3.1 Significant results  
We found that SNP rs7113887 in intron region of gene CNTN5 is the most significant SNP that 
is associated with age at onset of schizophrenia. CNTN5 belongs to the contactin subfamily, 
which is highly expressed in amygdala and occipital cortex regions in brain, and plays a role in 
the development of the nervous system (Katidou et al.,2008; Kamei et al., 2000). In-vitro 
experiments have found that CNTN5 promoted axon outgrowth (Ogawa et al., 2001). In-vivo 
experiments have also shown that it played a key role in maturation of glutamatergic synapses 
and auditory development (Toyoshima et al., 2009; Li et al., 2003). Recent GWAS have also 
revealed that CNTN5 was related to a couple of psychiatric disorder: Genome-wide association 
and linkage analysis in Framingham have shown that SNP rs952700 in intron of CNTN5 was 
associated with cognitive test scores (p= 5.7 × 10-6) (Seshadri et al., 2007); SNP rs10501927 in 
intron of CNTN5 has been reported to be associated with Alzheimer disorder and multiple 
magnetic resonance imaging characteristics (FDR p<0.05) (Biffi et al., 2010); SNP rs2155907 
near gene CNTN5 has also emerged as one of the top 10 significant SNPs in a genome-wide 
association study of schizophrenia, although it did not reach pass genome-wide significance 
criteria (Glessner et al., 2010); Moreover, copy number variation of CNTN5 was found to be 
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associated with Autism in family based genome-wide study (Burbach & van der Zwaag, 2009; 
Saus et al., 2010). Other members in contactin subfamily including CNTN3, CNTN4 and 
CNTN6, which shared similar homology with CNTN5, have also been found to be associated 
with autism spectrum disorder (Mefford et al., 2008; Roohi et al., 2009). Furthermore, CNTNs 
associated proteins (i.e. CNTNAPs), which functions by forming complex with CNTNs as 
receptor-signaling units to mediate neuron–glial cell interactions, neuronal migration and 
dendritic orientation (Corfas et al., 2004), have also been shown to be associated with autism 
and schizophrenia (Burbach & van der Zwaag, 2009). Lastly, CNTN5 is located in region 
11q21-11q22.2. This region contains multiple genes for schizophrenia and neuronal disorder (St. 
Clair et al.,1990; Maziade et al., 1995), and patients with deletion or translocation of this region 
have been reported to suffer from mental disorders (Carnevale et al., 1987; Jacobsen et al., 
1973). Taking all evidence together, CNTN5 could influence the onset of schizophrenia via its 
role in nervous system development.    
CNTN5 contains two mis-sense SNPs in exons region at rs1216183 and rs1944169 (Safran et al., 
2010). However, neither of the SNPs in exons of CNTN5, or SNPs in LD with them, reached 
nominally significant p value in this study (p<0.05). Moreover, the nine SNPs that are in strong 
LD with rs7113887 all locate in introns of CNTN5. Therefore, how are the SNPs in introns of 
CNTN5 are associated with schizophrenia is not clear, since genetic information in introns is 
not expressed. One possible explanation could be that the identified SNPs in introns alter the 
gene expression of CNTN5 through gene protein interactions or gene-gene interactions, but 
biological experiments are required to identify the exact mechanism.  
We also derived a model based on 44 SNPs to predict the distribution of age at onset. The 
model was built based on Lasso algorithm by minimizing GCV value, such that it could have a 
high power to predict the future unknown population rather than fitting the current study sample 
data. Results have shown that the model could classify the study samples into different risk 
groups, especially for those whose onset of schizophrenia was before 30 years of age. Therefore, 
it suggests that these 44 SNPs can be potentially used as screening SNPs set. Subjects found to 
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have high prognosis index would have higher probability of developing schizophrenia at 
younger age.  
3.4.3.2 Strengths and limitations of study design  
The strengths of this current study to elucidate the risk factors for early onset include the 
following. 1) Only cases were used in analyzing the risk genetic factors for the onset age of 
schizophrenia. The advantage of this design is that selection of controls is avoided. Healthy 
controls may not be really healthy in the way that they may still have the risk genes for 
schizophrenia but have not yet manifest the disease phenotype. If the proportion of the 
genetically unhealthy controls in the controls is high, it will be difficult to find out genuine risk 
genetic factors based on case control study design. Therefore, this study design has avoided the 
selection bias associated intrinsically with the selection of controls. 2) The outcome variable 
was age at onset of schizophrenia, which is reliable and easy to obtain. Even if the obtained 
onset age is different from the actual onset age, the results and conclusion of current study will 
not be changed because the Cox proportion hazard model we used in analysis does not require 
the accuracy of the figures themselves, but rather the rank of the figures. 3) Our study sample is 
homogeneous, as all of them are Singapore Chinese whose forebears mostly emigrated from 
Southern China.  Moreover, the diagnostic criteria and procedures for schizophrenia were 
standardized in our study so that the variation in selection of schizophrenia patients was 
minimized, which also reduced the potential heterogeneity. 4) We also controlled for gender as 
a covariate in the analysis, which we found to be the most influential factors for age at onset in 
our analysis on demographic risk factors in Chapter 2. Therefore, in our analysis, the variation 
of age at onset could be largely attributed to variation of genetics of patients, and the results 
could be more reliable.   
The main limitation of our study design is that only those that have schizophrenia in the time 
period 2005-2008 were recruited. The question is that whether the study sample can represent 
the patients who will get schizophrenia after the time period (i.e. after year 2008) in Singapore. 
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We would believe that this would be the case based on the following considerations. 1) 
Schizophrenia is a disorder with long history and its incidence and prevalence is stable across 
time and locations. Therefore, there is no reason to believe that people who developed 
schizophrenia in the future are different from people who get schizophrenia today. 2) Our study 
sample is large. We recruited 923 schizophrenia patients, which is the largest Chinese 
schizophrenia sample as far as we know. Even after the quality control steps, 887 patients, 
which represent 96% of the patients recruited, was used in analysis. Considering that the total 
Chinese schizophrenia patients in Singapore - based on the 1% prevalence and 70% of Chinese 
in the general population - is around 35,000, our study sample accounts for about 2.6% of the 
entire population. Based on these two considerations, we believe that our study sample can 
represent both the current and the potential further schizophrenia Chinese patients in Singapore. 
Another limitation of current study is that the predictive model we built can only be applied to 
those who will definitely develop schizophrenia some time in their life, because the model was 
built based on the subjects who have already developed schizophrenia. However, in practice, it 
is difficult to identify the population who will develop schizophrenia in future. 
3.4.3.3 Significance of the study 
The significance of our study is that it is the first study to identify the genetic risk factors for 
onset age of schizophrenia from a genome wide analysis perspective. We also identified a 
candidate gene CNTN5 with high statistical significance (p= 8.69×10
-8
), which is the first 
genome wide association study on schizophrenia that report a neuron system related gene with 
high statistical significance. Moreover, since CNTN5 also involves in axon formation, this 
result indirectly supports our finding in pathway analysis that axon guidance is an important 
pathway in schizophrenia development. Lastly, by employing analysis on age at onset, we 





The aims of this part of thesis were to identify the genetic risk factors for schizophrenia. 
Especially, we aimed to identify the significant risk SNPs and pathways for schizophrenia 
occurrence, and to identify the risk SNPs for onset age of schizophrenia. In order to improve the 
power of the study and to reduce the potential inconsistencies, we recruited homogenous 
Singapore Chinese schizophrenia patients and standardized diagnostic process. Unfortunately, 
in despite of these efforts, we did not find any SNPs that were significantly associated with 
schizophrenia. These results suggest that schizophrenia is not a simple disorder caused by a few 
influential SNPs. Therefore, given a study sample, conventional GWAS might not be the best 
way to identify the genetic risk factors. Based on this consideration, we treated each biological 
pathway as a single unit and employed GSEA algorithm to find out the significant risk pathways. 
It was shown that ARVC and CAMs pathway were significantly associated with schizophrenia 
and remained significantly in the independent study. Among these two pathways, CAMs play 
role in neuron cells development and it has been reported as a significant pathway for 
schizophrenia before, while ARVC is novel pathway involving in heart disorder and has not 
been reported. The identification of these pathways helps in understanding the etiology of 
schizophrenia development. However, the clinical relevance of pathway is not clear because a 
pathway is generic and contains multiple genes. We have also explored the risk SNPs for onset 
age of schizophrenia, which is a prognostic indicator of schizophrenia. By using Cox PHM 
modeling, we found out that SNP rs7113887 in gene CNTN5 was the most significant SNP 
associated with age at onset. This is the first GWAS on schizophrenia that found a neuron 
related genes. The incorporating of this clinical aspect of schizophrenia (i.e. age at onset) into 
GWAS framework also expands the scope of conventional GWAS study. Considering all 
evidence, our results support that schizophrenia is a disorder of neuron development since both 
the identified pathways (CAMs) and genes (CNTN5) are involved in neuron development. 
Additional studies are required to further refine the specific markers in the pathways and the 
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genes, and biological function study of the pathways and genes are also necessary to further 
elucidate the mechanism on how they contribute to the development of schizophrenia.  

















Chapter 4 Outcomes of schizophrenia: Tardive dyskinesia 
4.1 Introduction 
4.1.1 Background  
Schizophrenia patients usually develop a variety of co-morbidities as the disorder progresses. 
One of the common and severe co-morbidity is tardive dyskinesia. Tardive dyskinesia is a 
movement disorder, which is characterized by repetitive, involuntary and purposeless facial, and 
to a less extend, body and limbs movements, such as tongue protrusion, rapid eye blinking, and 
lips smacking (Chouinard et al., 1988, Freedman, 1973). The diagnosis of tardive dyskinesia is 
based on the overall severity of the movement disorder, which is measured by the instrument 
Abnormal Involuntary Movement Scale (AIMS) (Gharabawi et al., 2005). AIMS rate 12 items 
of symptoms, which aim to measure the extent of involuntary movements of facial, trunk, and 
extremities, and also the awareness of the movements by the subjects. Based on the total score 
of the instruments, a subject could be classified as tardive dyskinesia according to Glazer-
Morgenstern criteria or Schooler-Kane criteria (Glazer et al., 1993, Schooler and Kane, 1982). 
Glazer-Morgenstern criteria require the total score of item 1 – item 7 rated greater than 3 points 
and at least one item rated greater than 2 points. The Schooler-Kane criteria is more restrictive 
in diagnosing tardive dyskinesia, and require at least one item rated greater than 3 points or at 
least 2 items rated more than 2 points. Due to its restrictiveness, Schooler-Kane criteria is also 
more widely used to diagnose tardive dyskinesia (Tsai, 2007).  
The exact mechanism for tardive dyskinesia development is not known for certain, but it is 
believed to be caused by prolonged usage of antipsychotic medications, since the dyskinesia 
symptoms are found to be strongly associated with a history of antipsychotic usage (Klawans et 
al., 1980). Schizophrenia patients are usually under life time antipsychotic treatment, and 
therefore the prevalence of tardive dyskinesia among schizophrenia patients is very high. It has 
been estimated that one third of them will develop tardive dyskinesia in their life time (Jeste et 
al., 1999, Saltz et al., 1991). Together with the consideration that tardive dyskinesia could 
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significantly reduced the quality of life of schizophrenic patients (Browne et al., 1996), the 
burden of tardive dyskinesia on the whole schizophrenia population would be high. In order to 
fully understand the burden of tardive dyskinesia, the incidence, prevalence, and risk factors of 
tardive dyskinesia among schizophrenic patients have to be studied. The following section 
reviews the current understandings and progresses in research of incidence, prevalence and risk 
factors of tardive dyskinesia among schizophrenia patients.  
4.1.2 Review of prevalence, incidence and risk factors of tardive dyskinesia  
4.1.2.1 Prevalence  
Numerous studies have reported a high prevalence of tardive dyskinesia among schizophrenia 
patients. Yassa & Jeste (1992) reviewed 76 studies published since 1989, and found that the 
overall prevalence of tardive dyskinesia was 24.2% among psychiatric patients. Pandurangi & 
Aderibigbe (1995) reviewed 25 prevalence studies in non-western countries up to 1993, and 
found that the estimated average prevalence for Asian population was 17.2%. Although this 
prevalence is substantially higher than tardive dyskinesia prevalence among patients without 
antipsychotic treatments, which is estimated to be around 5% (Kane et al., 1986, Kane and 
Smith, 1982), it is generally lower than the tardive dyskinesia prevalence reported in western 
populations (Pandurangi and Aderibigbe, 1995).  One postulated explanation is the supposedly 
lower dosage of antipsychotics used in the Asian populations (Yamamoto et al., 1979, Lin and 
Finder, 1983).  
Among individual studies, the reported prevalence varies from as low as 2.5% (Kua et al., 1982) 
to as high as 40.6% (Chong et al., 2002). There are a few possible reasons for the variations in 
the reported figure. Firstly, different studies may use different symptom measurement 
instruments and diagnostic criteria for tardive dyskinesia, which may contribute to the inter-
study variation in prevalence. Secondly, sample selection difference may also contribute to the 
difference in reported prevalence. As reported by Yassa & Jeste (1992), Asian patients had 
lower prevalence of tardive dyskinesia than North American, European, and African patients. 
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Thirdly, criteria to select samples in different studies may be different. Some studies use 
relatively more homogeneous selection criteria (e.g. schizophrenia patients only), whereas other 
use less strict criteria (e.g. all psychiatric patients under antipsychotic treatment). This variation 
may contribute to the variations of reported prevalence.  
In Singapore, a prevalence study has been conducted 10 years ago by examining the proportion 
of tardive dyskinesia patients among a schizophrenia patients using AIMS criteria (Chong et al., 
2002), and the prevalence was found to be 40.6%. The sample included Chinese, Malay and 
Indian population. It could be necessary to examine the prevalence again to see whether there is 
any change in the prevalence in the past ten years.  
4.1.2.2 Incidence  
Incidence of tardive dyskinesia, however, is not as well studied as the prevalence. This is 
because the status of tardive dyskinesia is ascertained at the time of assessment, but the exact 
time of onset of tardive dyskinesia is difficult to be determined, which, in theory, can be any 
time before the assessment. In order to study incidence, the time of the onset, or a reasonably 
narrowed time interval of the onset, have to be determined. To obtain this information, 
prospective follow-up study with regular assessment of tardive dyskinesia status at a reasonable 
interval is required. In despite of these difficulties, a few studies have tried to assess the 
incidence of tardive dyskinesia. Two early studies conducted by Kane et al. (1984) and Hal & 
William (1993) both showed that the estimated incidence rate of tardive dyskinesia was 5% 
based on a five-year prospective study. Chakos et al. (1996) followed 118 newly diagnosed 
schizophrenia patients for 4 years with 6 monthly assessments, and found that the cumulative 
proportion of tardive dyskinesia in their sample was 6.3% after 1 year of follow-up, 11.5% after 
2 years, 13.7% after 3 years, and 17.5% after 4 years, giving an average incidence rate of 4.4%, 
which confirmed the rate reported by Kane et al. (1984). However, all these incidence studies 
are based Caucasian population, and similar prospective studies of Chinese schizophrenia 
patients are rare. 
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4.1.2.3 Risk factors 
There are a number of factors that have been reported to be associated with tardive dyskinesia. 
Among them, antipsychotic usage, advanced age and female gender are the most well studied 
risk factors for tardive dyskinesia. Considering all evidence in literature, antipsychotic usage 
and senior age are more consistent risk factors, while female gender is less consistent. However, 
there are some confusion on the relative contributions of antipsychotic usage and senior age to 
tardive dyskinesia, because longer antipsychotic usage is highly correlated with older age. The 
following paragraphs review the effects of antipsychotic usage, senior age and gender on tardive 
dyskinesia.   
Antipsychotic usage is considered as a risk factor because tardive dyskinesia is strongly 
associated with a history of antipsychotic treatments (Margolese et al., 2005). A meta-analysis 
consisting of 21 studies showed that the lifetime incidence rate of tardive dyskinesia was 2.9 
times higher for patients exposed to prolonged antipsychotic treatments than patients under no 
antipsychotic treatments (Morgenstern et al., 1987). Higher dosage of antipsychotic usage has 
also been reported to be positively associated with higher incidence rate of tardive dyskinesia 
(Reith et al., 1993). In addition, antipsychotics with different dopamine receptor antagonism 
potency have different effects on the risk of getting tardive dyskinesia. Especially, patients 
receiving second generation antipsychotics, which have lower dopaminergic antagonism effects, 
were found to have a lower risk of developing tardive dyskinesia (0.9% VS. 3.8%) (Tenback et 
al., 2005, Margolese et al., 2005). Based on all these evidence, it can be seen that variation in 
the duration of treatments, dosage, and dopaminergic antagonism potency of antipsychotics all 
affect the risk of getting tardive dyskinesia, suggesting that antipsychotic usage is a risk factor.   
However, a number of studies have also shown that antipsychotic usage may not be the major 
driven factor for tardive dyskinesia. It has been reported that tardive dyskinesia can occur 
spontaneously with no antipsychotic treatments (Pappa and Dazzan, 2009), suggesting that 
antipsychotic usage is not necessary for tardive dyskinesia development. Furthermore, cases 
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after only short term treatment of antipsychotics (2-3 months) have also been reported, 
especially for elderly patients (Chouinard et al., 1980, Chouinard et al., 1982), suggesting that 
prolonged exposure is not necessary for tardive dyskinesia either. Moreover, the relationship of 
antipsychotics dosage and tardive dyskinesia has not been firmly established yet. Exacerbated 
tardive dyskinesia symptoms with reduction of dosage of antipsychotics has been reported (van 
Berkel et al., 2007), and several studies have even found a reverse relationship between 
antipsychotics dosage and tardive dyskinesia symptoms severity (Pi et al., 1992, Chiu et al., 
1993). Considering these evidences together, it seems neither prolonged duration nor high 
dosage of antipsychotic treatments is necessary for tardive dyskinesia development. Therefore, 
antipsychotic usage may not be the major driven factor for tardive dyskinesia.  
Another risk factor for tardive dyskinesia is senior age. Senior age has been consistently 
reported as a risk factor for tardive dyskinesia in literature. It was also commented as the only 
risk factor confirmed by most of authors (Smith and Baldessarini, 1980). A large number of 
studies conducted in western countries have suggested a significant association between tardive 
dyskinesia and advanced age, by showing that the mean age of tardive dyskinesia psychiatric 
patients were significantly older than that of patients with no tardive dyskinesia (Smith and 
Baldessarini, 1980, Smith et al., 1979, Simpson et al., 1978, Yassa and Nair, 1988, Pandurangi 
and Aderibigbe, 1995), and the risk of  tardive dyskinesia for elderly patients(≥ 40 years old) is 
much higher than younger patients (Jeste and Wyatt, 1981, Kane et al., 1986). However, in 
despite of the consistency, there are still some difficulties in interpretation of the effects of 
advanced age. This is because advanced age is also correlated with longer exposure to 
antipsychotic treatments. Therefore, there is a possibility that the association between advanced 
age and tardive dyskinesia is confounded by longer exposure of antipsychotics. A number of 
studies have attempted to segregate the effects of age and antipsychotic exposure by controlling 
antipsychotic exposure statistically in analysis. Results showed that age still exerted a large 
effect on tardive dyskinesia after controlling for antipsychotic exposure (Woerner et al., 1991), 
suggesting that age is not confounded by duration of antipsychotic exposure.  
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Female gender is another reported risk factor for tardive dyskinesia. Yassa et al. (1992) 
reviewed 76 studies on gender differences in prevalence of tardive dyskinesia and estimated that 
the prevalence was 21.6% in men and 26.6% in women, suggesting women have higher risk to 
develop tardive dyskinesia. However, among the 76 studies reviewed, 54 failed to find a 
significant difference between males and females, suggesting that the gender effects in tardive 
dyskinesia are not consistent. Moreover, the mean age in females in the 76 reviewed studies 
were generally 5-10 years older than that of males, suggesting that the association between 
gender and tardive dyskinesia could be confounded by the underlying gender difference in age. 
Because of these considerations, gender is not universally accepted as a risk factor for tardive 
dyskinesia. 
Interaction between gender and age has also been reported. A few studies tabulated age and 
gender and investigated the prevalence of tardive dyskinesia in each category. Results showed 
that there was a pattern of increasing prevalence of tardive dyskinesia with advancing age in 
women but there was no such pattern in male. This result suggests a possible interaction 
between gender and age (Smith et al., 1979, Brandon et al., 1971). However, a formal statistical 
test failed to found a significant interaction (Kane et al., 1986).  
4.1.3 Objectives   
Tardive dyskinesia is a severe co-morbidity of schizophrenia, which could significantly reduce 
the life quality of patients. Understanding of its prevalence and incidence and how 
schizophrenia patients develop tardive dyskinesia is important to assess and to potentially 
reduce the burden on schizophrenia patients. Although a large numbers of studies have 
examined the prevalence, the variation in the reported prevalence is large. This variation could 
be due to variation of tardive dyskinesia diagnostic criteria, study population, and sample 
composition. The number of studies on the incidence rate, however, is small, because follow-up 
and regular assessment is required to study incidence. With respect to risk factors, antipsychotic 
usage (duration and dosage), advanced age, and female gender have been reported as risk 
factors for tardive dyskinesia. However, the possible confounding effects between antipsychotic 
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exposure duration and advanced age have not been examined adequately. Moreover, there is 
also a lack of congruence on the effects of gender on tardive dyskinesia among schizophrenia 
patients. In view of these issues, the main objectives of this part of thesis were to:  
1) examine the prevalence and incidence of tardive dyskinesia among Singapore Chinese 
schizophrenia patients;  
2) identify the risk factors for tardive dyskinesia and examine the possible confounding effects 
between antipsychotic exposure duration and advanced age;  
3) select a set of important risk factors and build a predictive model for tardive dyskinesia.  
The prevalence and incidence discovered in current study may help in assessing the burden of 
tardive dyskinesia among schizophrenia patients in Singapore. In addition, since the sample in 
current study consisted of only Chinese schizophrenia, our figures could provide a specific 
reference for other group to verify and compare with. Furthermore, since a prevalence study of 
tardive dyskinesia among Singapore schizophrenia patients have been investigated 10 years ago 
(Chong et al., 2002), results from current study may help in assessing whether there is any 
change in tardive dyskinesia prevalence in the last ten years. Moreover, by investigating the risk 
factors and building a predictive model of tardive dyskinesia, the effects of antipsychotic usage, 
senior age, and gender on tardive dyskinesia among Singapore Chinese schizophrenia patients 
could be identified, which could verify and contribute to current understanding of risk factors of 
tardive dyskinesia. Lastly, by specifically examining the possible confounding effects between 
antipsychotic duration and age, the confusions on the relative contribution of antipsychotic 





4.2 Methods  
4.2.1 Study design  
4.2.1.1 Patient recruitments and assessments  
Subjects recruited in this study were also used in the study in Chapter 2 (notes: additional 
subjects were recruited in study in Chapter 2, and thus the Chapter 2 study had more 
schizophrenia patients). Therefore, the recruitment procedure was the same as in Chapter 1. In 
brief, schizophrenic patients were recruited during the year 2005 – 2008 in Institute of Mental 
Health, and both inpatients and out patients were recruited. Diagnosis of schizophrenia was 
established with the Structured Clinical Interview for DSM, and the severity of dyskinesia 
symptoms were assessed using the AIMS. Both assessments were carried out by registered 
medical doctors in Institute of Mental Health. The reliability of the diagnosis of the 
schizophrenia and AIMS was not measured, but as they were experience clinical doctors, the 
reliability of the assessment results should be trustable. AIMS contain a total of 12 5-scale items, 
which aim to measure the severity of the movement disorder in various part of the body. Items 
1-4 measure orofacial movements which include facial expression, lips and perioral area, jaw 
and tongue movement; items 5-6 measure upper (e.g. hands) and lower (e.g. legs) extremities 
movements; item 7 measure trunk movements (e.g. neck, shoulder, and hips); items 8-10 
measure overall movements, patients’ incapacity due to movement and patients’ awareness of 
movements. These 10 items are rated on a 5 point anchored scale, with minimal score 0 and 
maximum score 4. Item 11-12 are yes-no scaled items related to teeth and dentures movement. 
Specifically, patients were diagnosed to have tardive dyskinesia if at least two of the three 
subtotal scores (orofacial movements (items1-4), extremities movement (items 5-6), and trunk 
movement (item7)) were more than 2, or at least one the three subtotal score was more than 3.  
The inclusion and exclusion criteria were the same as in Chapter 2. Patients were included into 
the study if they were of Chinese ethnicity and if they met the DSM-IV criteria for 
schizophrenia. The patients were considered to be of Chinese ethnicity if their parents and 
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grandparents were declared as Chinese. Patients were excluded from the study if they have 
organic brain disorder, epilepsy or mental retardation. A total of 790 schizophrenia patients 
consented to participate the study and passed these inclusion and exclusion criteria. The data of 
them were used in final analysis. The number of subjects was near to the targeted sample size of 
1,000. As multi-variables were collected, and the study was not designed to study a single 
variable, the target sample size was determined such that it was statistically sufficient to study 
most the variables.     
4.2.1.2 Covariate data collections and data coding  
The demographic information including birth date, age, gender, and familial psychiatric history 
were collected during the interview. Other information on the patients including medication 
profile and diabetes status was collected from patient hospital records. Some variables were 
computed from existing variables. BMI was computed as weight divided by height square; 
antipsychotics dosage was computed as Chlorpromazine equivalent dosage based on the 
conversion factor described in Chapter 2; antipsychotic exposure period was computed by 
summation of the duration of antipsychotic treatments based on hospital records. Continuous 
variables were categorized in logistic regression in model building, and the categorization was 
performed in the same way as the categorization performed by Chong et al. (2002) for 
comparison purpose. Covariates types and coding are shown in Table 4.1. Data qualification 
control procedures were performed in the same way as described in Chapter 2 Methods to 
ensure the data were correct. 
4.2.1.3 Consent  
Together with the addition schizophrenia patients used in Chapter 2, the study was approved by 
Independent Review Board in Singapore, and all participants need to sign informed consent 
form in order to participate into the study if they were more than 14 years old. If they were 




Table 4.1 Covariate types and their coding. 
Variables  Data type treated in analysis Coding (→ means coded as) 
Age (years old)  
Age at onset (years old) 
Ordinal variable  
≤39     → 1  
40-49 → 2 
50-59 → 3 
≥60    → 4 
Gender Binary 
Male     →1 
Female → 2 
Duration of antipsychotic 
exposure (years)  
 
Ordinal variable  
≤5 → 1 
5-10 → 2 
> 10 → 3 
BMI (Kg/m
2
) Continuous - 
Current antipsychotics dosage 
(typical or atypical, dosage was 
converted into Chlorpromazine 
equivalent dosage) (mg) 
Ordinal  
<150 → 1 
15-300 → 2 
300-600 → 3 




stabilizer) (mg)  
Binary 
Users → 1 
Non users → 0 
Current smokers Binary 
Yes →1 
No → 0 
Diabetes Binary 
Yes →1 
No → 0 
Family history Binary 
Yes →1 
No → 0 
PANSS positive and negative 
score 
Ordinal  
=7 → 1 
8-10 → 2 
11-14 → 3 
> 15 → 4 
PANSS general score Ordinal 
< 18 → 1 
18-20 → 2 
21-23 → 3 
> 23 → 4 
EPSE  Binary 
Yes →1 





4.2.2 Statistical analysis 
4.2.2.1 Analysis of prevalence and incidence  
The prevalence of tardive dyskinesia was computed by dividing the total number of tardive 
dyskinesia patients by the total number of patients with schizophrenia recruited. The average 
incidence of the study sample was computed as the total number tardive dyskinesia patients 
divided by the total person years of the study sample. The total person years was computed as 
the sum of each person’s duration of illness from onset of schizophrenia to the date of 
assessment. We also examined the occurrence of tardive dyskinesia as a function of time after 
onset of schizophrenia. Specifically, we consider tardive dyskinesia as an event, and we plotted 
the proportion of the schizophrenia patients with tardive dyskinesia against the years that had 
passed since onset of schizophrenia. Therefore, the rate of developing tardive dyskinesia after 
onset of schizophrenia can be visualized as the slope of the curve.  
4.2.2.2 Predictive model building  
A variable selection procedure was performed to identify a subset of the variables for predicting 
of tardive dyskinesia. In this study, Lemeshow purposeful variable selection algorithm (Bursac 
et al., 2008, Hosmer and Lemeshow, 2000) in the framework of logistic regression was 
implemented to identify the important variables. The procedure of selection process was 
summarized below:  
1) Performed single variable analysis. Each of the 18 variables was tested for association with 
tardive dyskinesia. Variables with nominal p value less than or equal to 0.25 was selected for 
model building. Variables with p value more than 0.25 were considered insignificant for the risk 
of getting tardive dyskinesia and were excluded from model building.  
2)  A full logistic model based on the selected variables in step 1 was built, and coefficients and 
the p values of each of variable in presence of all other variables were computed.  
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3) We examined the variables with least significant in the full model built in step 2 (i.e. variable 
with maximum p value). This variable was removed from the model if removing the variable 
would not change the value of the coefficients of remaining variables by more than 20% and the 
model without the variable would not be significantly different from the model with the variable 
based on log-likelihood tests (log likelihood p must be more than 0.05).  
4) If the variable we examined in step 3) was removed, we would continue to examine the next 
least significant variable among the remaining variables. The same criteria defined in step 3) 
were applied to see whether this variable was removable or not. If the variable was not removed, 
we would continue to examine the second least significant variable to see whether they were 
removable based on the same criteria.   
5) Continue step 4) until all variables with p value more than 0.25 have been examined.  
6) In all above steps, current age and duration of antipsychotic exposure were kept inside the 
model because these two were the variables we were interested in.  
7) The final model would be built after all previous steps had been performed.   
4.2.2.3 Antipsychotics and age  
To identify the potential confounding between duration of antipsychotic usage and advanced 
age, we used the most basic epidemiological approach in identifying confounders by classifying 
the age and duration of antipsychotic exposure and examining trend of the proportion of tardive 
dyskinesia patients across categories. If proportion of tardive dyskinesia patients increases with 
age category while keeping duration of antipsychotic exposure constant, and if proportion of 
tardive dyskinesia patients does not increase with duration of antipsychotic exposure category 
while keeping age category constant, then the age would confound the apparent effect of 
duration of antipsychotic exposure (i.e. age is the confounder, and antipsychotic exposure 





All analyses were performed using STATA 10.0.  
4.2.3 Role played in this study 
Since the sample used in this study was the part of the sample used in the study in Chapter 2. I 
played the same role as the role I played in study in Chapter 2.  
 
4.3 Results 
4.3.1 Descriptive statistics of study sample  
The descriptive statistics of the study sample and the comparison between schizophrenia 
patients with tardive dyskinesia and without tardive dyskinesia is shown in Table 4.2. As shown, 
age, age at onset, cumulative antipsychotic exposure duration, antipsychotic usage dosage, 
diabetic status, and EPSE were found to be significantly associated with tardive dyskinesia 
(p<0.05). The high significance of age and antipsychotic exposure duration (p<0.001) suggest 
that these two factors are possible important risk factors for tardive dyskinesia. This finding 
agrees with the literature that age and duration of antipsychotic exposure are the two most 
significant risk factors. However, as shown in Table 4.3A, the correlation coefficient between 
age and  antipsychotic exposure duration was also high (r=0.61) , suggesting that there could be 
a potential confounding effect between these two factors. The onset age of schizophrenia was 
also highly significant (p<0.001, Table 4.2), and schizophrenia patients with tardive dyskinesia 
had 3.4 years earlier onset than that of schizophrenia patients with no tardive dyskinesia. It is 
possible that early onset schizophrenia patients have some biological risk factors which increase 
risk of getting tardive dyskinesia. However, it is also possible that earlier onset schizophrenia 
patients tends to have longer antipsychotic exposure (r = - 0.31, Table 4.3A), which increases 
the risk of developing schizophrenia. Counter to intuition that high dosage of antipsychotics 
would be associated with tardive dyskinesia, results showed that antipsychotics dosage was 
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negatively associated tardive dyskinesia. Schizophrenia patients with tardive dyskinesia used 
less antipsychotic at the time of assessment based on hospital record (349.8mg vs. 487.7mg, 
p<0.001, Table 4.2). EPSE was also highly associated with tardive dyskinesia (p<0.001, Table 
4.2). This significant association could be because EPSE measures the severity of Parkinson 
disorder like symptoms, which are similar to tardive dyskinesia symptoms to some extent. 
Diabetes status was found to be associated with tardive dyskinesia status (p=0.028, Table 4.2). 
The possible explanation could be that diabetes and tardive dyskinesia shared similar risk 
factors or being diabetes deteriorates and fastens the development of tardive dyskinesia. Other 
















Table 4.2 Statistics of variables of study sample, tardive dyskinesia patients and non tardive 
dyskinesia patients. 











Continuous variables Mean (SD) Mean (SD) Mean (SD) p value
1
 
Age, years 48.3 (12.9) 58.1 (10.9%) 45.7 (12.2) <0.001 
BMI, (kg/m
2
) 23.3 (4.7) 22.8 (4.7) 23.4 (4.6) 0.159 
Age o f onset, yrs 28.1 (9.8) 30.8 (10.8) 27.4 (9.4) <0.001 
Cumulative antispychotics 
exposure, yrs 
17.1 (11.7) 22.5 (12.1) 15.6 (11.1) <0.001 
Current antipsychotics 
dosage, mg 
458.8 (469.1) 349.8 (415.5) 487.7 (478.4) <0.001 
PANSS Score     
           Positive 10.1 (3.8) 10.3 (3.9) 10.0 (3.8) 0.464 
           Negative 11.5 (5.1) 12.2 (5.1) 11.4 (5.0) 0.051 
General 21.1 (5.1) 21.6 (4.9) 20.9 (5.1) 0.115 
Categorical variables N (%) 
2
 N (%) 
2





Gender    0.574 
              Male 519 (65.7) 106 (63.9) 413 (66.2)  
              Female 271 (34.3) 60 (36.1) 211 (33.8)  
Current smokers     0.737 
              Yes 232 (29.4) 47 (28.3) 185 (29.6)  
              No 558 (70.6) 119 (71.7) 439 (70.4)  
Diabetes mellitus    0.028 
              Yes 59 (7.5) 19 (11.4) 40 (6.4)  
              No 731 (92.5) 147 (88.6) 584 (93.6)  
EPSE    <0.001 
              Yes 228 (28.9) 91 (54.8) 137 (22.0)  
              No 562 (71.1) 75 (45.2) 487 (78.0)  
Antidepressants    0.150 
              Present 160 (20.3) 27 (16.3) 133 (21.3)  
              Absent 630 (79.7) 139 (83.7) 491 (78.7)  
Anticholinergics     0.249 
              Present 537 (68.0) 119 (71.7) 418 (67.0)  
              Absent 253 (32.0) 47 (28.3) 206 (33.0)  
Benzodiazepines    0.950 
              Present 229 (29.0) 48 (28.9) 181 (29.0)  
              Absent 560 (71.0) 118 (71.1) 442 (71.0)  
Mood stabilizers    0.112 
              Present 179 (22.7) 30 (18.1) 149 (23.9)  
              Absent 611 (77.3) 136 (81.9) 475 (76.1)  
1
 Simple t test with equal or unequal (subjected to equality of variance test) for continuous variables, and 
chi square test for categorical variables.  
2 
Number in the bracket were the percentage of the patients in each of the subcategory.  
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Table 4.3 Correlation coefficients among continuous variables and categorical variables. 
A. Pearson correlations of continuous variables.  










Age 1.00       
BMI -0.04 1.00      
Onset Age 0.37 -0.02 1.00     
Antipsychotic 
exposure 
0.61 0.00 -0.31 1.00    
PANSS Positive -0.14 0.02 -0.11 -0.06 1.00   
PANSS Negative 0.20 -0.17 -0.08 0.12 0.20 1.00  
PANSS General 0.05 -0.08 -0.09 0.03 0.46 0.59 1.00 
 
B. Spearman correlations of categorical variables.  








Gender 1.00        
Smoke -0.31 1.00       
EPSE -0.05 0.02 1.00      
Diabetes 0.11 -0.07 0.02 1.00     
Anti-
depressants 
0.11 -0.08 -0.04 0.05 1.00    
Mood   
stabilizer 
0.02 -0.06 0.05 0.01 0.03 1.00   
Benzo-diazepine 0.02 0.04 0.02 0.10 0.10 0.07 1.00  
Anti- 
cholinergic 
0.00 0.06 0.15 0.02 0.06 0.13 0.17 1.00 
 
4.3.2 Prevalence and incidence of tardive dyskinesia 
The prevalence of tardive dyskinesia among study sample was 21.0% in our study sample (166 
out of 790 subjects). This prevalence is much less than that of 10 years ago in Singapore, when 
the prevalence was 40.6% (Chong et al., 2002). We have also examined the change in the 
prevalence of tardive dyskinesia with time after the onset of schizophrenia. The relationship is 
shown in Figure 4.1. The rate of developing tardive dyskinesia was low in the first few years 
after onset (i.e. the slope was flat, and almost all of them (100%) do not have tardive 
dyskinesia). However, with time, the rate gradually accelerated (i.e. slope became steeper). 
Thirty years after onset of schizophrenia, about 25% of patients had developed tardive 
dyskinesia (75% remained as non tardive dyskinesia patients), and after 50 years following the 
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onset of schizophrenia, the majority of schizophrenia patients (>85%) would develop tardive 
dyskinesia. The average rate of getting tardive dyskinesia in our study sample was 36/yr/1000 
persons (CI: 31-42/yr/1000), suggesting that 3.6% of schizophrenia patients would get tardive 
dyskinesia in one year of follow up after onset of schizophrenia.    
Figure 4.1 The relationship between proportion of schizophrenia patients without tardive 
dyskinesia and duration of years since onset of schizophrenia. 
 
   
4.3.3 Predictors of tardive dyskinesia  
To identify a set of important risk factors that could predict the status of tardive dyskinesia, we 
used the all the covariates that had a p value less than 0.25 in the single variable analysis (Table 
4.2) and implemented Lemeshow variable selection algorithm (Bursac et al., 2008, Hosmer and 
Lemeshow, 2000). The variables selected out by the algorithm and their effect sizes are shown 
in Table 4.4. In selection process, age at onset, BMI, antidepressants and mood stabilizer were 
removed from the model, suggesting that these factors were not important in determining 
tardive dyskinesia status in the presence of other covariates. Among the remaining covariates in 
the model, the most significant covariate was age (p<0.001). The odds for patients over 60 years 
old to develop tardive dyskinesia was 12 times more than patients under 40 years old in the 
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presence of all other covariates (Table 4.4). Cumulative antipsychotic exposure duration, which 
was highly significant in single variable analysis, did not reach nominal significance in the 
presence of other covariates on average (p=0.520, Table 4.4). The insignificance of 
antipsychotic exposure duration indicates that the apparent effects of antipsychotic exposure 
duration in single variable analysis could be possibly confounded by other factors. Age would 
be the most possible confounder of antipsychotic exposure, because it was highly correlated 
with exposure duration (r=0.61, Table 4.3A) and it was significantly associated with tardive 
dyskinesia, even in presence of other covariates in the final model (Table 4.4). EPSE was 
another highly significant covariate in the final model, suggesting that its association with 
tardive dyskinesia is independent of other covariates. All the remaining covariates did not reach 
nominal significance on average (p<0.05) and their effects size were small (odds ratio <2.0, 






















OR CI (95%) p value
3
 
Age, yrs     <0.001 
             ≤39 208 11 (5.30) 1   
             40-49 213 26 (12.2) 2.02 0.94-4.32 0.071 
             50-59 209 46 (22.0) 3.52 1.64-7.54 0.001 
             60-69 121 60 (49.6) 12.20 5.43-27.30 <0.001 
             ≥70 39 23 (59.0) 13.60 4.83-38.10 <0.001 
Cumulative antipsychotic 
exposure, yrs 
    
0.520 
             <5 123 8 (6.50) 1   
             5-10 127 15 (11.8) 1.97 0.73-5.39 0.181 
             >10 540 143 (26.5) 2.42 1.04-5.60 0.039 
Diabetes     0.112 
              Absent 731 147 (20.1) 1   
              Present 59 19 (32.2) 1.67 0.89-3.16 0.112 
Cumulative antipsychotic 
dosage, mg 
    
0.063 
              <100 149 48 (32.2) 1   
              100-500 416 86 (20.7) 1.01 0.60-1.72 0.961 
              >500 225 32 (14.2) 0.59 0.32-1.11 0.107 
Anticholinergics     0.139 
              Absent 253 47 (18.6) 1   
              Present 537 119 (22.2) 1.41 0.89-2.22 0.139 
PANSS negative score     0.101 
              ≤7 238 35 (14.7) 1   
              8-10 180 36 (20.0) 0.82 0.45-1.47 0.501 
             11-14 185 51 (27.6) 1.14 0.64-2.02 0.660 
              ≥15 187 44 (23.5) 0.68 0.35-1.31 0.250 
PANSS general  score     0.222 
              ≤16 139 18 (13.0) 1   
              17-19 238 50 (21.0) 1.51 0.77-2.96 0.227 
              20-22 186 42 (22.6) 1.26 0.62-2.55 0.524 
              ≥23 227 56 (24.7) 1.84 0.88-3.81 0.103 
EPSE     <0.001 
              Absent 562 75 (13.3) 1   
              Present 228 91 (39.9) 3.14 2.08-4.74 < 0.001 
1
Number of individual in the category. 
2
Number of patients with tardive dyskinesia in the category 
(proportion). 
3





To examine the predictability of the final model, we plotted the ROC curve based on the model 
developed. As shown in Figure 4.2, the area under the ROC curve was 0.8, which suggests that 
the model could adequately predicts tardive dyskinesia status of our study sample.  
Figure 4.2 ROC curve based on the multivariable logistic model developed. 
  
4.3.4 Confounding effects of age and duration of antipsychotic exposure    
To examine the possible confounding effects between age and duration of antipsychotic 
exposure, we used the most traditional way of examining confounders by classifying the age 
and antipsychotic exposure duration and examined the trend of change in the proportion of 
tardive dyskinesia patients. As shown in Figure 4.3, when keeping duration of antipsychotic 
exposure constant, the proportion of tardive dyskinesia patients generally increased as the age 
category increases. However, when keeping age category constant, there was no pattern that 
proportion of tardive dyskinesia patients increased with the increase of antipsychotic exposure 
categories. This result implies that the apparent effect of cumulative exposure duration of 
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Figure 4.3 . Proportion of tardive dyskinesia patients among schizophrenia patients 
categorized by age and antipsychotic exposure duration. 
 
 
4.4 Discussion  
4.4.1 Prevalence and incidence of tardive dyskinesia 
Twenty-one percent of schizophrenia patients were found to have tardive dyskinesia in this 
study. This prevalence was substantially less than the prevalence reported 10 years ago in 
Singapore among schizophrenia patients, when the prevalence was 40.6% (Chong et al., 2002).  
Although clinicians and diagnostic criteria might have changed in the past 20 years, the current 
study design is fairly comparable to the study conducted by Chong et al. (2002) since the same 
recruitment location (IMH), the same target population (Singapore schizophrenia patients) and 
the same diagnostic instruments (AIMS) were used. The reduction in prevalence from 40.6% to 
21.0% could be due to the fact that current study sample was younger (48 years old on average 
vs. 53 years old on average). However, based on our the chart of change of tardive dyskinesia 
proportion in current study (Figure 4.1), 5 years difference (i.e. from 53 years old to 48 years 
old, assuming the average duration after onset is also 5 years) would result in a change of 5% 
tardive dyskinesia patients. By correcting this sample age difference using the figure, the 
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prevalence 10 years ago (40.6%-5%=35.6%) is still substantially larger than current prevalence. 
Rater difference between current study and studies 10 years ago might also contribute to 
difference in prevalence. However, considering that both studies used the same instrument to 
identify tardive dyskinesia in the same hospital (IMH), and the principle investigator of the 
study conducted 10 years ago (i.e., Chong Siow Ann) was the leader of current study, it is 
believed that the influence rater difference is not much. Therefore, the reduction of prevalence 
could partially reflect that prevalence of tardive dyskinesia patients among Singapore Chinese 
schizophrenia patients has been reduced. A possible explanation could be that there are more 
awareness of tardive dyskinesia and less usage of typical antipsychotics (i.e. more EPS effects) 
than 10 years ago with a shift towards a greater use of the second generation (i.e. atypical) 
antipsychotics. One indirect way to investigate this hypothesis is to investigate the association 
between typical or atypical antipsychotics usage with tardive dyskinesia cross-sectionally within 
current dataset. The results support this hypothesis, because 29.3% pure typical antipsychotics 
user (with no atypical antipsychotics medication, N=538) had tardive dyskinesia, while only 
17.3% pure atypical antipsychotics user (with no typical antipsychotics usage, N=208) had 
tardive dyskinesia (p = 0.001). However, this result is subject to reverse causality confounding 
due to cross section nature of study design, and it is difficult to draw causal conclusion that 
atypical antipsychotics usage is the reason for the drop of tardive dyskinesia prevalence in 
Singapore. Nonetheless, this result still suggests that atypical antipsychotics users had lesser 
tardive dyskinesia risk.   
The incidence of tardive dyskinesia among Chinese schizophrenia patients was estimated to be 
36/yr/1000 persons (CI: 31-42/yr/1000 persons) after onset of schizophrenia (i.e. 3.6%). This 
figure is lower than the incidence rate identified based on Caucasian population with a reported 
incidence rate of 4-5% (Kane et al., 1984, Reith et al., 1993, Chakos et al., 1996). However, in 
the estimation of incidence rate, the total person years was computed by summation of time 
period from onset of schizophrenia to the time of assessment for each subject. For the 
schizophrenia patients who were classified to have tardive dyskinesia at the time of assessment, 
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the actual onset of tardive dyskinesia should be sometime earlier than the assessment date. 
Therefore, the actual duration of life without tardive dyskinesia (duration from onset of 
schizophrenia to onset of tardive dyskinesia) was less than the person years used in analysis in 
current study (i.e. duration from onset of schizophrenia to the date of assessment). The reason 
we used person year from onset of schizophrenia to assessment is because the actual time of 
onset of tardive dyskinesia is impossible to be determined since our study was a cross section 
study. The effect of using our approximation is that the actual incidence rate should be larger 
than our estimated incidence rate (average incidence rate =
                
                  
; the actual total 
person years is smaller than the total person years used in calculation in current study; therefore 
the actual incidence rate is higher than the reported incidence in current study). Hence, the 
actual incidence of developing tardive dyskinesia among Chinese schizophrenia patients should 
be higher than 36/yr/1000 person, and the actual curve of tardive dyskinesia proportion as a 
function of years since onset of schizophrenia should be lower than what we plotted in Figure 
4.1. Taking this correction into consideration, the actual incidence rate among Singapore 
Chinese schizophrenia patients could be comparable to the reported incidence (4-5%) among 
Caucasian schizophrenia patients (Kane et al., 1984, Reith et al., 1993, Chakos et al., 1996). In 
order to measure the incidence rate accurately, a prospective follow-up study with regular 
assessment of tardive dyskinesia status is needed. The smaller the assessment interval, the more 
accurate the estimated incidence would be.     
4.4.2 Risk factors and prediction model  
In single variable analysis, a number of covariates were found to be significantly associated 
with schizophrenia, including age, age at onset, cumulative antipsychotic exposure, 
antipsychotics dosage, diabetic status, and EPSE. Patients with tardive dyskinesia were 
prescribed significantly lower antipsychotic dosage than schizophrenia patients without tardive 
dyskinesia. Antipsychotics, especially typical antipsychotics, have severe EPS effect, and it is 
believed to be the cause of tardive dyskinesia. Therefore, it would have been thought that higher 
dosage is associated with tardive dyskinesia. This counter intuitive association is not unique to 
117 
 
our study, since it has also been reported 10 years ago in Singapore as well as a number of 
studies in Hong Kong and Europe (Chong et al., 2002, Pi et al., 1992, Chiu et al., 1993). A 
possible explanation of this observation could be that clinicians prescribe less antipsychotic to 
schizophrenias with tardive dyskinesia symptoms to avoid deteriorating the symptoms. Another 
worth mentioning finding is that gender, which has been reported by some studies as risk factors 
for tardive dyskinesia (Yassa and Jeste, 1992), did not show up to be significant in our single 
variable analysis (p=0.57, Table 4.2). Considering that majority of the studies (54 out of 76 
studies) reviewed by Yassa & Jeste (1992) on gender and tardive dyskinesia yielded negative 
results, the lack of effect of gender on tardive dyskinesia in our study could reflect that gender 
does not affect tardive dyskinesia development. In addition, in chapter 2, we found that 
significantly more females were prescribed atypical antipsychotics than males. We postulate 
that this could be due to females having more dyskinesia symptoms, which in turn lead to 
switch of typical to atypical antipsychotics. However, since the results here showed no 
difference across gender in tardive dyskinesia, suggesting that the higher rate of atypical 
antipsychotic among females is not due to differential rate of dyskinesia across gender. EPSE 
was also significantly associated with tardive dyskinesia symptoms. This is probably because 
EPSE also measure Parkinson symptoms like movement symptoms, which correlate with the 
symptoms of tardive dyskinesia movement disorders.      
To identify the important and relatively independent risk variables for tardive dyskinesia, a 
variable selection algorithm was implemented and a model was built. In building the 
multivariable logistic model, age at onset, BMI, antidepressants and mood stabilizer were 
removed, implying that these variables are not important in determining tardive dyskinesia in 
presence of other variables. Among them, age at onset was highly significant in single variable 
analysis. The removal of age at onset suggests that its apparent significance at single variable 
analysis is confounded by another factor or a combination of other factors. In the final model, 
the most influential and significant covariate is age, signaling that advanced age is the most 
important risk factor for tardive dyskinesia. The effect size of age in current study was higher 
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than the effect size found by Chong et al. (2002) in Singapore, where the odds ratio for age 
group 40-49, 50-59, 60-69, and ≥ 70 were 1.58, 5.01, 9.28 and 8.20, respectively (current study 
were 2.02, 3.52, 12.20, 13.60 for the same age categories). The lower effect size could be due to 
the fact that both Chinese and Malay schizophrenia patients were used in logistic model in study 
conducted by Chong et al. (2002), while in this study only Chinese patients were included in the 
analysis. As shown by Chong et al. (2002), Malay had less risk of developing tardive dyskinesia 
than Chinese, which may be the reason for their lower overall effect size of age. The effect size 
of age in our model is also comparable with the study conducted on European population by 
Jeste et al. (1981) and Kane et al. (1986), where risk of getting tardive dyskinesia was found to 
be 4 times higher for schizophrenia patients over 40 years old than the patients under 40 years 
old. The congruence of significance and effects of age across time and locations further 
confirms that age is a one of the most important risk factor for tardive dyskinesia. On the other 
hand, duration of antipsychotic exposure, which was highly significant in single variable 
analysis, did not reach nominal significance in the final model. The insignificance of 
antipsychotic exposure duration in multivariable model was also observed by Chong et al. 
(2002). One study has also reported that age remained significant in multivariable model but not 
antipsychotic exposure duration (Woerner et al., 1991). Taking all these into consideration, the 
apparent effect of antipsychotics duration in single variable analysis is highly likely to be 
confounded. Considering that duration of antipsychotic exposure is highly correlated with age in 
our study sample, age could be the underlying confounder.   
The predictability of the built model was reasonably good considering that the area under the 
ROC curve was 80%, and an optimal cut off point can be achieved with good sensitivity and 
specificity. However, the curve was plotted based on the study sample data, which is also the 




4.4.3 Confounding effects of age and duration of antipsychotic exposure    
We used a traditional method to examine the confounding effects of age and duration of 
antipsychotic exposure. At any fixed level of duration of antipsychotic exposure, increasing of 
age was associated with increasing proportion of tardive dyskinesia. However, if age category 
was fixed, there was no such association between increasing of duration of antipsychotic 
exposure and increasing of proportion of tardive dyskinesia. These results directly suggest that 
the effect of antipsychotic exposure duration is confounded by age. Taking into account that 
tardive dyskinesia can occur without any antipsychotic exposure (Pappa and Dazzan, 2009), the 
reason why patients subjected to longer antipsychotic exposure have higher risk of tardive 
dyskinesia is more likely to be due to the effect of advanced age.  
4.4.4 Limitations and significance of current study  
The main limitation of this study is its cross-sectional design. Since there was no follow up and 
re-assessment of tardive dyskinesia status at a regular interval, all the tardive dyskinesia onset 
times are left censored (i.e. actual onset time is earlier than the assessment time). Therefore, the 
incidence rate we computed and plotted is a lower boundary of the actual incidence rate. 
Moreover, because of the cross-sectional design, antipsychotics dosage was measured at the 
time of assessment of tardive dyskinesia. Therefore, the actual relationship between 
antipsychotics dosage and tardive dyskinesia status could not be established due to possible 
reverse causality.  
The significance of this study is the confirmation that age is the most significant and influential 
risk factor for tardive dyskinesia among schizophrenia patients. We also used a traditional 
approach to examine the possible confounding effects between age and duration of 
antipsychotic exposure, and found that the apparent effect of duration of antipsychotic exposure 
on tardive dyskinesia is confounded by age. These findings suggest that senior age, rather than 
prolonged usage of antipsychotics, is the main reason for development of tardive dyskinesia 
comorbidity among schizophrenia patients.  
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4.5 Conclusions  
The current study aimed to examine the prevalence and incidence of tardive dyskinesia among 
Singapore Chinese schizophrenia patients, and to identify the risk factors including confounding 
factors for tardive dyskinesia. We found out that the prevalence of tardive dyskinesia was 21.0% 
and the average incidence was 36/yr/1000 person years (i.e. 3.6%). The prevalence was smaller 
than what was reported 10 years ago in Singapore, indicating that tardive dyskinesia among 
Chinese schizophrenia patients is reduced in the past 10 years. Our computed incidence rate, 
however, was an under estimation of the real incidence rate, and therefore the 3.6% incidence 
rate serves a lower boundary of the incidence rate of tardive dyskinesia among Chinese 
schizophrenia patients in Singapore. We also found that age, age at onset, antipsychotic 
exposure duration, antipsychotics dosage, diabetes, and ESPE were significantly associated with 
tardive dyskinesia. However, in the presence of other covariates, only age and EPSE remained 
to be nominal significant, indicating that age is one of the most important risk factors for tardive 
dyskinesia. Antipsychotic exposure duration, which is generally believed to a significant risk 
factor for tardive dyskinesia, turned out to be insignificant in the presence of age, suggesting 
that the apparent effect of antipsychotic exposure duration could be confounded. Since 
antipsychotic exposure duration was highly correlated with age in our study sample, we 
examined the confounding effects of these factors using classification analysis. Results indicate 
that the effects of antipsychotic exposure duration are confounded by advanced age. This 
finding has clinical implications by establishing the higher risk of tardive dyskinesia among 
older people with schizophrenia.   
By studying the prevalence, we revealed a change of prevalence of tardive dyskinesia among 
Singapore Chinese schizophrenia patients in the past 10 years, which provides useful 
information to policy makers. By investigating the risk factors of tardive dyskinesia, we showed 
that age was the most important risk factor and that the effect of antipsychotic exposure duration 
was confounded by age. This result provides medical workers with useful information for their 
professional practice. However, despite the significances, application of current study is limited 
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by its cross section nature. Particularly, incidence rate is under estimated and the real effects of 
antipsychotic dosage on tardive dyskinesia could not be studied since medication information 
was collected at the time of recruitments. Therefore, the current study can be improved by 
incorporating a follow-up study of newly onset schizophrenia patients and assessing their 
tardive dyskinesia status as well as collecting time series data at regular interval. In such a way, 
prospective analysis can be performed and the validity and generalization power of the study 














Chapter 5 Outcomes of schizophrenia: offspring school 
performance   
5.1 Introduction 
5.1.1 Background and literature review 
Being schizophrenic not only adversely affects the patients themselves but also their family 
members. Particularly, offspring of people with schizophrenia are negatively affected in a 
number of ways, which are expressed as social and cognitive disadvantages as compared with 
their peers. A number of studies have shown that the offspring of schizophrenia patients have 
lower IQ (Kremen et al., 1998), greater attention deficit (Erlenmeyer-Kimling and Cornblatt, 
1992), higher incidence of speech impairment (Jones et al., 1994), and more difficulties in 
social adjustment (Walker et al., 1993). In addition, the school performance of children from 
schizophrenia families has also been reported to be poorer than children from non-schizophrenia 
families (Fisher et al., 1980). Especially, the offspring were also commented by teachers to have 
lower motivation, more behavioural problems (Janes et al., 1983), and poorer mathematical 
reasoning ability (Ayalon and Merom, 1985). Although the number of studies on offspring 
school performance from schizophrenia families is small, the consistency of the results suggests 
that the school performance of offspring from schizophrenia families is poorer than their peers. 
Schizophrenia patients might be blamed for not providing sufficient parenting to their children, 
which leads to the poor school performance. However, the exact mechanism for poor school 
performance of offspring in schizophrenia families has seldom been studied. Therefore, the 
blame for schizophrenia parents is not justified.  
There are at least two possibilities for the underlying mechanism for poor school performance 
of children from schizophrenia families. 1) Offspring from schizophrenia families live in an 
unfavourable familial environment. For example, schizophrenic parents are unable to provide 
adequate parenting and to satisfy the needs of the children, which adversely affect the 
development of cognitive and social functions of children. Moreover, patients with 
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schizophrenia often have cognitive impairments, lower social economic status and poorer 
education (Tandon et al., 2009, Goldberg and Morrison, 1963), which may indirectly affect 
children school performance via poor family education. Due to these poor familial environments, 
offspring from schizophrenia families may have a poorer school performance than their peers. 2) 
The offspring’s poor school performance might also be caused by the risk genetic factors shared 
by schizophrenic parents and offspring. These inherited genetic factors may affect offspring 
cognitive functions, which results in a poor school performance. A twin study from the United 
Kingdom found that 60% of the variation in school performance was explained by genetic 
influences (Haworth et al., 2008), implying that the poor school performance can potentially be 
caused by the inherited genetics from schizophrenic parents. If this possibility is true, 
schizophrenic parents should not be blamed for poor parenting. 
It is necessary to know which one of the two possibilities is the actual underlying mechanism. 
This is not only because the blame to schizophrenic parents needs to be justified but also 
because poor school performance has been proposed as a predictor for development of 
schizophrenia in later life. A number of studies have been specifically designed to investigate 
the predictability of poor school performance at primary or secondary school on development of 
schizophrenia in early adulthood (Cannon et al., 1999, MacCabe et al., 2008, van Oel et al., 
2002). However, the presumption of these studies is that the poor school performance of the 
recruited subjects is due to the risk genes for schizophrenia, because the occurrence of 
schizophrenia is largely determined by genetic risk factors. This presumption does not have 
solid foundation at current stage because of a few reasons. Firstly, the evidence on poor school 
performance of offspring from schizophrenia families is not strong enough. This is because the 
number of studies and sample size of each study is small (about 100 subjects in the cited 
studies), and because different studies used different measures of school performance (e.g. 
teachers’ feedback on the students, students examination grade), which makes it difficult to 
compare the results across studies. Secondly, it is not known whether poorer school 
performance is caused by the risk genetics inherited from schizophrenia patients. Only if the 
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poor school performance is caused by genetics could school performance be a possible predictor 
for schizophrenia as schizophrenia is largely a genetic determined disorder. Because of these 
two reasons, the validity of the presumption for the studies on predictability of school 
performance on schizophrenia is not solid. As a result, studies to confirm the poorer school 
performance of offspring of schizophrenia patients and studies to investigate the mechanisms 
for the poorer school performance are important.  
However, in parent-offspring studies, it is difficult to disentangle the effects of genetics and the 
effects of family environment. It is because the association between family environment and 
family genetics, which is termed as gene environment correlation (Jaffee and Price, 2007). In 
current study, it means that poor family environment is always associated with schizophrenia 
risk genes running in schizophrenia families. Traditionally, children of twin (COT) study design 
have been used to separate the genetic and environmental effects (Gottesman and Bertelsen, 
1989). In this design, the difference in rates of disorder between children of affected and 
unaffected monozygotic co-twins (MZ) is compared with the rate difference between children 
of affected and unaffected dizygotic co-twins (DZ). If genetics do not play a role in the 
development of the disorder, the difference in rate of disorder between children of affected and 
unaffected MZ should be the same as the difference in rate between children of affected and 
unaffected DZ. This is because the only difference between MZ pair and DZ pair is the extent of 
sharing of genetic components within the pairs. Conversely, if the difference is not equal, it 
would suggest a role of genetics in the development of the disorder. Due to the difficulties in 
collection of discordant MZ and DZ twins, the application of COT design is limited. To 
overcome this limitation, children of sibling (COS) design have been developed recently based 
on the same principle as COT (D'Onofrio et al., 2009b, D'Onofrio et al., 2009a, Harden et al., 
2007, Rutter et al., 2001). In COS design, the intergeneration association (i.e. parental disorder 
and offspring behaviour) strengths are compared between discordant sibling pairs that have 
decreasing genetic relatedness (e.g. full-sibling, half-sibling, full-cousin, half-cousin and 
unrelated individuals). If behaviours of offspring are purely determined by family environment 
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(i.e. independent of family genetics), the association strength would be the same across 
comparison groups, because the only difference between the comparison groups is the genetic 
distance within the groups. Conversely, if the behaviours of offspring are purely determined by 
the inherited genetics, the association strength should become weaker and weaker when the 
kinship within the pair become nearer and nearer (i.e. genetics become more and more similar 
within comparison pairs).   
Although a few studies have studied the association between parental schizophrenia status and 
offspring poor school performance, very few studies have specifically investigated the 
mechanism behind this association. Therefore, the mechanism is largely unknown at present 
stage. However, some studies have investigated the intergeneration association of other parent 
traits and offspring behaviours. Kuja-Halkola et al. (2010) used a COS design to investigate the 
mechanism for the association of mother smoking and offspring stress coping ability. Results 
showed that the poor stress coping ability of children was actually due to the genetics that 
inherited in the families and was not related to the smoking status of mother. D'Onofrio et al. 
(2010) has also found out that the apparent intergeneration association between mother smoking 
status and poor offspring academic achievement was confounded by family genetics using COS 
design. Taking these findings into account, it is possible that the intergeneration association 
between parental schizophrenia status and offspring poor school performance is due to family 
genetics but not family environment.  
5.1.2 Objectives 
Offspring from schizophrenia families have been reported to have poorer school performance 
compared with their peers. However, the mechanism underlying this association is largely 
unknown. Understanding this mechanism is important for schizophrenic parents and for the 
consolidation of the validity for predictive study of school performance. Therefore, the specific 
objectives of current study were to:   
1) confirm the intergeneration association between schizophrenia families and offspring poor 
school performance and  
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2) investigate the mechanism underlying the association.  
We used the data from Swedish national registers to investigate the association, and we used 
COS design to examine the mechanism.  The results of present study may consolidate the 
foundation for studying school performance as a predictor for schizophrenia and may relieve 
schizophrenic parents from blames for not taking care of their children.  
5.2 Methods 
5.2.1 Study design  
The design of the study was to link multiple Swedish longitudinal population-based registers to 
investigate the association and the mechanism of the association between schizophrenia families 
and offspring school performance. To investigate the association, national school register and 
national hospital records register was linked. Therefore, the examination grade of children at 
school and their parental schizophrenia status could be obtained and analyzed. To investigate 
the mechanism, each subject was linked to the multi-generation register. Therefore, the family 
structures of the offspring could be identified, and COS design could be implemented to 
separate genetic effects and environmental effects. The difference in school performance and 
the intergeneration association strength within discordant unrelated pairs, half cousin pairs, full 
cousin pairs, half sibling pairs, and full sibling pairs were compared to see how the difference 
and association strength changed across comparison groups. The detailed description of the 
national registers and the statistical analysis methods are presented in the following sections.  
5.2.2 Swedish national registers  
Multiple Swedish national longitudinal registers were merged using the unique national 
identification number which is given to all Swedish citizens at birth or immigrants on arrival to 
the country. The registers used in current study were:  
The National School Register (NCR): Education in Sweden is free of charge and compulsory for 
children with age between 7 and 16 years (9 years). The Swedish National School Register 
includes educational achievements (scores in multiple subjects and a summary grade) for all 
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students from the final year of compulsory school (class 9) since 1988 (Lambe et al., 2006). The 
registry comprised 1,439,215 individuals with available summary grade from 1988 to 2006. 
The Multi-Generation Register: This register includes the identity number of the biological 
parents of each individual born in Sweden since 1932 or individuals immigrated to Sweden 
together with their parents before age 18 years old. Based on this information, the structure of 
the families can be identified. 
The Hospital Discharge Register: This Register includes details of all individuals who have 
episodes of psychiatric hospitalization in Sweden since 1973.  Data from a few private providers 
of inpatients care are also included.  
Other national registers: The Education Register includes information of the highest level of 
education obtained by each individual since 1990 (Education in the Swedish population, 1993).
 
The Total Population Register holds the gender and date of birth of each individual since 1961.    
Using the Multi-Generation Register, individuals were connected to their relatives (e.g., siblings 
and cousins) via their parents and grandparents. The entire dataset includes 1,439,215 offspring 
in 810,968 nuclear families nested in 640,035 extended families.   
5.2.3 Processing of variables   
5.2.3.1 Exposure 
The family was classified as schizophrenia families if at least one of the biological parents of 
the offspring were classified as schizophrenic patients. The diagnosis of schizophrenia of 
parents was extracted from national hospital discharge register. If the subjects had two or more 
separate hospitalization records with discharge diagnosis of schizophrenia (ICD-8/9: 295, ICD-
10: F20, excluding latent schizophrenia [ICD-9: 295.5 and ICD-10: 295F]), they were classified 
as schizophrenic patients. The reason for choosing two or more inpatient admissions as the cut-
off criteria was to increase diagnostic specificity (Lichtenstein et al., 2006). Offspring was 




From 1988 to 1997, a summary 5-step grade (1-5) was given reflecting the student’s average 
grade. From 1998 onwards, students were given an overall grade (0-320) based on their 16 best 
subject grades. Offspring summary grades were standardized and normalized for each period 
using Blom transformation (van den Oord et al., 2000). The normalized summary grade was 
used as a measure of the overall school performance of offspring. Since this study included 
students graduating between 1988 and 2006, both grade systems were used. 
5.2.3.3 Covariates 
The highest educational level of the parents of schizophrenia family was extracted from the 
Education Registry in 2004. The highest educational level of father and mother was defined as 
the family educational levels. In case where the family educational level information was 
missing for one parent, information from the parent with available data was used. If the 
education level for both parents was missing, the education level of the family was treated as 
missing data. Offspring gender was obtained from the Total Population Register.  
5.2.4 Statistical analysis    
In order to investigate the association between parental schizophrenic disorder and offspring 
school performance, linear regression on unrelated offspring was used to avoid clustering of 
data.  Both parental education level and offspring gender were included in the model as 
covariates.   
Parents with schizophrenia could affect offspring school performance by passing on certain 
genetic characteristics to their offspring and/or contribute to environmental risks (Plomin et al., 
1977). To determine whether it is genetic or environmental factor that affected offspring school 
performance, analyses within extended families of different genetic relatedness where offspring 
were differently exposed to parental schizophrenia were performed. The different type of 
extended family types are displayed in Figure 5.1. Genetic relatedness is measured by the 
percentage of co-segregation for each class of relatives. Paternal (maternal) half-cousin data 
included half-cousin who had the same grandfather (grandmother) but different grandmother 
(grandfather) in one each extended family (Figure 5.1a, 5.1b). Full cousin contains full cousins 
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who had the same grandfather and grandmother in one each extended family (Figure 5.1c). 
Paternal (maternal) half-sibling data contains paternal (maternal) half siblings in each extended 
family who had the same father (mother) but different mother (father) (Figure 5.1d, e) (Full 
siblings shared the same mother and father. Therefore it was not possible to examine the 
influence of exposure to schizophrenic parents on full sibling pairs). Index of extended family 
was by the grandmother, and index of nuclear families were by the children of grandfather and 
grandmother. The analyses of the structure family data included two main parts (genetic effects 
and environment effects), which are described below:  
1) We evaluated the effects of genetics by stratifying association analysis according to genetic 
relatedness. We wanted to explore the effect of variability in genetic relatedness within one 
extended families on the association strength. Since index of extended families were  
grandmother, the relationship between offspring in extended family could be either maternal 
half-cousin, full cousin or half siblings. Therefore, within-family effects of exposure to 
schizophrenia status on offspring school performance across maternal half-cousin, full-cousin 
and half-sibling were compared (Figure 5.1). 
2) We evaluated the importance of the environmental effects in two ways. (a) We compared the 
mean school performance between unrelated offspring with schizophrenic mother and with 
schizophrenic father. Since the mother is the primary caregiver in Sweden (Funder, 1991),  the 
family environment would be more detrimental if the mother (as compared to father) had the 
diagnosis, and thus offspring of schizophrenic mothers would perform worse at school than 
offspring of schizophrenic fathers. (b) We explored if variability in offspring family 
environment similarity moderated the association strength within the extended family. The 
analysis was the same as investigating genetic influence, but instead of stratifying according to 
offspring genetic relatedness we stratified according to family environmental relatedness of 
offspring. We, therefore, contrasted the association strength between paternal and maternal half-
sibling pairs and between paternal and maternal half-cousin pairs (Figure 5.1). The rationale is 
that a vast majority (91%) of children in Sweden continue to live with their mother after 
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parental divorce or separation (Fakta, 1994). Therefore, although the genetic relatedness of 
paternal half-sibling pairs is the same as genetic relatedness of maternal half-sibling pairs, the 
family environment would be more similar within maternal half-sibling pairs (as compared to 
paternal half-sibling pairs) since they stayed with the same mother (paternal half-sibling were 
brought up by different mothers). As half-cousin are the offspring of half-sibling, maternal half-
cousin would be more similar in family environment (as compared to paternal half-cousin) since 
they were brought up by maternal half-sibling. If family environment plays an important role in 
the association, variability in environment similarity would moderate the association strength.    
Since the family data were clustered (families were nested in extended families), hierarchical 
linear modelling (HLM) was used to adjust for covariates and the clustering of data (SAS Mixed 
procedure) (Harden et al., 2007). The within-family effect size of exposure to parental 
schizophrenia status on offspring school performance could then be estimated by the β-












Figure 5.1 Datasets used when comparing school performance in offspring of parents from 
schizophrenia families with that in relatives at varying genetic distance. 
5.2.5 Role played in this study  
In this study, I was involved in study design, data linkage, data analysis and manuscript writing. 
In study design, I performed literature review and wrote proposal for this study. In data linkage, 
I obtained and linked the data of different national registry based on national identification 
number. In data analysis, I performed all the data processing and all the data analysis by writing 
SAS programs. In manuscript writing, I wrote all parts of the first draft of manuscript.    
 
5.3 Results 
5.3.1 Intergeneration association between schizophrenia families exposure and 
offspring school performance 
Descriptive characteristics of the study sample are shown in Table 5.1. The proportion of the 
offspring who had at least one schizophrenic parent  was 0.25% (3,654 out of 1,442,869 
subjects). This prevalence is less than the 1.0% prevalence of schizophrenia in general 
population. We also evaluated the effects of exposure to schizophrenia families to offspring 
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school performance using linear regression. As shown in Table 5.2, the effect size of parental 
schizophrenia status on offspring school performance was -0.31 (p<0.0001) before controlling 
for covariates, suggesting that the performance of offspring from schizophrenia families is 0.31 
standard deviation lower than that of unrelated offspring from non-schizophrenia families. After 
adjusting for offspring gender and parental educational levels, the strength of the association 
was reduced to -0.18 (p<0.0001), implying that part of the association is contributed by the 
covariates. However, the association still remained highly significant. This high significance 
indicates that parental schizophrenia status could independently and strongly affect offspring 
school performance. 
Table 5.1 Description of characteristics of offspring from schizophrenia families and from non-
schizophrenia families. 
Variables  Unexposed offspring 
 
(N=1,439,215) 
 Exposed offspring 
 
(N=3,654) 
Gender       
 Male  736,513 51.2%  1,912 52.3% 
 Female  702,702 48.8%  1,742 47.7% 
Highest parental education      
 less than 9 years of education  32,212 2.2%  143 3.9% 
 9 years of education  74,879 5.2%  375 10.3% 
 1-2 years upper secondary education  476,646 33.1%  1,470 40.2% 
 3 year secondary education  229,922 16.0%  502 13.7% 
 
less than 3 years post secondary 
education 264,529 18.4%  488 13.4% 
 3+ years post-secondary education  332,325 23.1%  598 16.4% 
 Post-graduate education  25,086 1.7%  37 1.0% 








Table 5.2 Regression analysis of the effect of parental schizophrenia on offspring school 
performance. 
Model 1: Crude model without adjusting for covariates 
1
        
Effect  Estimate   
Standard 
Error P value  
Intercept  0.08  0.001  <.0001 
Exposure -0.31  0.019  <.0001   
Model 2: Model adjusted for covariates 
1
          
Intercept  1.09  0.008  <.0001 
Exposure -0.18  0.017  <.0001   
Gender       
 Male  -0.39  0.002  <.0001   
 Female  0  -  - 
Family Education       
 less than 9 years of education  -1.25  0.010  <.0001 
 9 years of education  -1.30  0.010  <.0001 
 1-2 years upper secondary education  -1.14  0.009  <.0001 
 3 year secondary education  -0.86  0.009  <.0001 
 less than 3 years  post secondary education -0.65  0.009  <.0001 
 3+ years post-secondary education  -0.35  0.009  <.0001 
  post graduate education  0    -    - 
1 
Based on the sample including 631,358 unrelated offspring. 
 
 
5.3.2 Effects of genetics on association strength  
To investigate the effects of genetics in mediating the intergeneration association strength (i.e. 
parental schizophrenia status and offspring school performance), we stratified the analysis by 
genetic relatedness and compared the association between half cousin pairs, full cousin pairs, 
and half sibling pairs. HLM was used to adjust for covariates and the cluster of data so that the 
average effect of parental schizophrenia on offspring school performance could be examined 
within one extended family. In such a way, variations between different families were adjusted. 
As summarized in Figure 5.2, within extended families, the association between parental 
schizophrenia and offspring school performance was the strongest when comparing 
differentially exposed half-cousin (β=-0.23, p=0.01) (N=65,126), lower when comparing full 
cousins (β=-0.13, p<0.0001) (N=917,678), and vanished when comparing half-sibling (β=0.04, 
p=0.31) (N=203,506). The detail results of HLM modelling are shown in Table 5.3. Since the 
only difference among half-cousin pairs, full-cousin pairs and half-sibling pairs are the extent of 
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sharing of genetics (genetics similarity), the results suggest that change in genetic relatedness 
within extended families greatly moderates the association strength between parental 
schizophrenia and offspring school performance.  
 
Figure 5.2 Association between parental schizophrenic disorder and offspring school 









































Effect size within extended family 
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Table 5.3 Hierarchical linear modelling of the effect of parental schizophrenia on offspring 
school performance in half-cousin, full cousin and half-sibling dataset. 
Model 1. Half-cousin comparison 
1
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Model 2. Full cousin comparison 
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Model 3. Half sibling-comparison 
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  Female 0         
  1 Based on the sample including 65,126 offspring. 
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Based on the sample including 917,678 offspring. 
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5.3.3 Effects of family environment on association strength.  
We examined the effect of family environment in mediating the observed effect on offspring 
school performance in two ways. 1) The mean of school performance of offspring with 
schizophrenic father and offspring with schizophrenic mother was compared. The hypothesis is 
that the offspring with schizophrenic mother would have had worse school performance than 
offspring with schizophrenic father if environment played an important role in the association. 
This is because mother is the primary care giver, and had more influence on their offspring 
compared with father. As shown in Table 5.4, no significant difference was found (mean 
difference=0.015SD, p=0.70). As a result, the interpretation is that family environment does not 
play an important role in affecting offspring school performance.  
Table 5.4 Comparison of school performance between offspring with schizophrenic mother and 
offspring with schizophrenic father. 
    
Number of 
offspring  Mean school performance (SD) Standard Error  
Offspring with schizophrenic 
mother 
 
 1073   -0.220   0.031 
Offspring with schizophrenic 
father  1666     -0.235     0.024 
Mean Difference     0.015    
p value 
1
        0.70 
p value (adjusted) 
2





Adjusted for offspring gender and parental education in linear regression.     
 
2) The association analysis was stratified according to offspring environmental similarity when 
genetic relatedness was controlled. Therefore, we compared the strength of the associations (β-
coefficient) between paternal half-sibling and maternal half-sibling pairs and between paternal 
half-cousin and maternal half-cousin pairs. The assumption here is that the within genetic 
relatedness (i.e. genetic similarity) is the same for paternal half-sibling (or paternal half-cousin) 
and maternal half-sibling (or maternal half-cousin) since the genetic distance is the same, but 
the within family environment similarity for paternal half-sibling (or paternal half-cousin) is 
less than maternal half-sibling (or maternal half-cousin) since the maternal half-sibling was 
raised by the same mother. As summarized in Figure 5.3, no negative association between 
schizophrenia in parents and school performance in offspring was found in neither paternal half-
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sibling (β=0.01, p=0.83) (N=98,166) nor maternal half-sibling pairs (β=0.06, p=0.27) 
(N=105,340). Moreover, the intergeneration association strength was comparable for paternal 
half-cousin (β=-0.21, p=0.01) (N=68,371) and maternal half-cousin (β=-0.23, p=0.01) 
(N=65,126). The results imply that variability in the environmental similarity in comparison 
groups does not affect the association strength if the genetic relatedness is held at the same level. 
Taking all evidence together, the evidence that family environment substantially affects 
offspring school performance is not sufficient. Therefore, the support to the hypothesis that the 
family environment plays an important role in the intergeneration association is little. The detail 
results of HLM are shown in Table 5.5 and Table 5.6.  
Figure 5.3 Association between parental schizophrenic disorder and offspring school 

















































Table 5.5 Hierarchical linear modelling of the effect of parental schizophrenia on offspring 
school performance in paternal and maternal half-cousin dataset. 
Model 1. Paternal half-cousin comparison 
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    Model 2. Maternal half-cousin comparison 
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  Female 0.00         
1 
Based on the sample including 68,371offspring. 
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Table 5.6 Hierarchical linear modelling of the effect of parental schizophrenia on offspring 
school performance in paternal and maternal half-sibling dataset. 
Model 1. Paternal half-sibling comparison 
1





Standard Error  P value  
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    Model 2. Maternal half-sibling comparison 
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  Female 0   
 
  
 1 Based on the sample including 98,166 offspring. 
2 




5.4.1 Effects of parental schizophrenia status on offspring school performance 
5.4.1.1 Intergeneration association between schizophrenia families exposure and offspring 
school performance 
We found that the average school performance for offspring from schizophrenia families was 
0.31SD lower than that of unrelated offspring from non-schizophrenia families, suggesting that 
parents with schizophrenia can adversely affect offspring school performance. This observation 
is consistent with previous observations that offspring from schizophrenia families perform 
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poorer than their peers (Fisher et al., 1980, Janes et al., 1983, Ayalon and Merom, 1985). 
Moreover, we verified that the intergeneration association between parental schizophrenia and 
offspring school performance was highly significant even after control for covariates. 
Considering the large sample size of our study sample, the negative influence of parental 
schizophrenia on offspring school performance is reliable.  
5.4.1.2 Mechanism of intergeneration association  
Offspring school performance could be affected through either family environmental or family 
genetic mechanisms. To disentangle the effects of genetic and environmental influences, the 
association analyses were stratified according to genetic and environmental relatedness. Genetic 
factors were found to greatly moderate the association as the effect size of association strength 
dropped 43.2% when genetic relatedness of the comparison pair increased from 6.25% in half-
cousin to 12.5% in full cousins. This observation implies genetic contributions on the 
association. However, when the analyses were stratified according to environmental relatedness 
while genetic relatedness was hold constant, no significant effects were found neither in 
paternal half-sibling nor in maternal half-sibling, and there was  only marginally difference  
between paternal half-cousin and maternal half-cousin. This result suggests that variation in 
within environmental similarity of comparison pairs would not affect the intergeneration 
association strength. In addition, no significant difference was found in mean school 
performance between offspring with a schizophrenic mother and schizophrenic father, despite 
that offspring with schizophrenic mother lived in more detrimental family environment. Taking 
all evidence together, these results provided little evidence for the association between family 
environmental influences and offspring school performance. Therefore, the interpretation is that 
the intergenerational association between parental schizophrenia and offspring academic 
performance is mainly due to genetic effects.  
5.4.1.3 Significance of results 
School performance is a complex trait, which is determined by both environmental and genetic 
factors (Lemelin et al., 2007). It has been studied as a pre-morbid predictor for later 
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development of schizophrenia in early or late adulthood. A twin study conducted in Dutch has 
suggested that underperformance at school might be one of the first prodromal signs of 
schizophrenia (van Oel et al., 2002).
 
A study in Sweden has also found an association between 
poor school performance and the risk of developing schizophrenia in later life (MacCabe et al., 
2008). In contrast, two Finnish studies suggested that there was no association between poor 
school performance and schizophrenia (Isohanni et al., 1998, Cannon et al., 1998). Even though 
there is no convergence on whether poor school performance is a predictor for later 
development of schizophrenia, the presumption of these studies would be best validated if 
school performance is influenced by schizophrenia risk genetics. This is because schizophrenia 
is largely determined by genetics. Our results suggest that academic underperformance of 
offspring to parents with schizophrenia are due primarily to genetics run in schizophrenia 
families. Therefore, our results validate the presumptions.  Moreover, our results imply that 
schizophrenic parents need not to blame themselves for their offspring poor school performance. 
This is because our results showed that family environment, which is associated with 
schizophrenia disorder (e.g. inability for providing good parenting), did not influence offspring 
school performance.   
5.4.2 Strengths and limitations of current study  
There are a number of strengths in our study. Firstly, a population-based study design was used. 
Since almost all offspring with schizophrenia parents were included in registry and were sued in 
analysis, the potential selection bias was reduced. Secondly, stratification analysis within 
children of sibling (COT) design framework to segregate presumably co-occurring genetic and 
environmental effects was implemented so that relative effect of genetic and environment could 
be studied. However, there were also a number of limitations present in our study. The 
prevalence of offspring with at least one parent with schizophrenia was only 0.25% in our study; 
which is lower than the 1% prevalence in general population (Tandon et al., 2008). One possible 
reason is that the reproductivity of schizophrenia patients is lower than that of general 
population (Nanko and Moridaira, 1993). Another possible reason is that we used a strict 
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criterion for schizophrenia classification, which required at least two separate inpatient episodes 
involving a schizophrenia discharge (Lichtenstein et al., 2006). Thus, some offspring from 
schizophrenia family were not included in our dataset, which may also contribute to this low 
prevalence in our study. In our study, little support was found to the hypothesis that 
environmental effects were important for the intergenerational transmission in this nation-wide 
population-based study including all offspring with schizophrenic parents. Thus, the most 
probable interpretation of the results is that environment does not play a substantial role in 
explaining the poorer school performance in offspring to parents with schizophrenia. However, 
this is not a proof that environment does not have an effect. It is possible that the effect is small, 
and current study is unable to detect it. Lastly, the offspring of schizophrenic parents in our 
study could not represent all schizophrenic families in Sweden. This is because fewer 
schizophrenic, compared to non-schizophrenic individuals, have children. However, since 
schizophrenic patients with more severe symptoms, which likely have stronger impact on 
offspring performance, are even less likely to have children, our estimation of the effect of 
parental schizophrenia on offspring school performance was probably conservative.     
5.5 Conclusions 
This study aimed to examine the intergeneration association between schizophrenic parents and 
offspring school performance and to investigate the mechanism of the association. It was found 
that school performance of offspring from schizophrenia families was significantly poorer than 
their peers who were from non-schizophrenia families.  This result is comparable to the 
previous findings from case control studies which showed poorer offspring school performance 
for children with schizophrenic parents. Therefore, the intergeneration association between 
schizophrenic parents and offspring poor school performance is verified by our study. It was 
further found that the relative school performance of offspring with schizophrenic parents to 
offspring with non-schizophrenic parents was influenced by the genetic relatedness. When the 
relatedness got closer from non-related comparison pairs to half-sibling, the relative school 
performance of offspring with schizophrenic parents to offspring with non-schizophrenic 
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parents get smaller and smaller. This result suggests that genetics substantially influence the 
school performance of offspring from schizophrenia families. This because the relative school 
performance should not change with the change of genetic distance if genetics are independent 
of school performance. In contrast, we did not find any supporting evidence that family 
environment, which the offspring were exposed to, could moderate the offspring school 
performance. In detail, 1) we did not found any difference in school performance between 
offspring whose mother was schizophrenic patients and offspring whose father was 
schizophrenic patients. Mothers are the primary care giver for their children, and therefore the 
exposed family environment for offspring with schizophrenic mother should be more 
unfavourable than offspring with schizophrenic father. Based on this rationale, offspring with 
schizophrenic mother should have poorer school performance than the offspring with 
schizophrenic father if exposed family environment could substantially influence school 
performance. Since no difference was found between offspring with schizophrenic mother and 
offspring with schizophrenic father, the evidence did not support a role of family environment. 
2) We stratified the half-cousin as maternal half-cousin and paternal half-cousin. The genetic 
distance of maternal half-cousin (6.25%) is the same as the genetic distance of paternal half-
cousin (6.25%). However, as mother is the primary care giver, we would expect the 
environment difference within maternal half-cousin was smaller than the difference within 
paternal half-cousin. Our results showed that the effect of parental schizophrenia status on 
offspring school performance was the same for maternal half-cousin and for paternal half-
cousin. Similar results were found for paternal half-sibling and maternal half-sibling. These 
results imply that variation of exposed family environment difference within comparison pairs 
could not alter the parental schizophrenia effects on offspring school performance. Therefore, 
these evidences did not support the role of family environment on offspring school performance. 
Taking all evidence together, the interpretation is that the poor school performance of offspring 
from schizophrenia families is due to the family genetics rather than the family environment.  
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The results from this study are significant in two aspects. 1) We established that poor school 
performance of offspring from schizophrenia families is due to inherited genetics. This 
establishment consolidate the foundation for the studies of poor school performance as a 
predictor of later schizophrenia onset. This is because schizophrenia is a genetics determined 
disorder, and any predictor for schizophrenia should have underlying genetics implications. 2) 
The current study results relieve schizophrenic parents from blaming themselves for not 
providing a good parenting to their children. In our study, we did not find any evidence that 
family environment, which in current study composes of schizophrenia associated family 
environment (e.g. inability to provide adequate parenting), could affect offspring school 
performance in schizophrenia families. Therefore, parents need not to feel guilty for their 
offspring poor school performance. Publics should not blame the schizophrenic parents either. 
This study is a national registry based cohort study and has employed all the offspring from 
schizophrenia families in Sweden. Therefore, the selection bias is low in current study, and the 
evidences are reliable. However, it also has a few limitations. The main limitation is that the 
study did not prove that environment does not have a role in offspring school performance in 
schizophrenia families. Our interpretation is based on the fact that we did not find any 
supporting evidence for the role of family environment. In reality, it is possible that 
environment has a role in offspring school performance in schizophrenia families, but the 
effects cannot be detected in current study design. To examine the pure effects of family 
environment on offspring school performance in schizophrenia families, a better design is 
adoption study of identical twins in schizophrenia families. The school performance of offspring 
living with their schizophrenic biological parents is compared with the co-twin living within 
their non-schizophrenic adopting parents, with covariates adjusted. However, considering that 
schizophrenia is not a common disease and that events of identical twin birth and adoption are 
both rare, this study design has practical difficulties in collecting enough samples. Until the time 
when better study design and analyzing methodologies are developed, the power to study the 
pure effects of environment is limited at current stage. 
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Chapter 6 Conclusions and future work  
6.1 Restatement of objectives 
Schizophrenia imposes a great of burden on both family and society. Therefore, the overall aim 
of this thesis was to contribute to elucidate the nature of this burden, such that the burden could 
potentially be reduced based on the additional knowledge contributed by this thesis.  
The burden includes both economic burden and non-economic burden. Economic burden 
mainly comes from high cost of medical treatments, and is largely determined by the prevalence 
and severity of schizophrenia in a population. The non-economic burden is related to negative 
outcomes of schizophrenia, such as co-morbidities and the negative influence on family 
members.  Co-morbidities, such as tardive dyskinesia, causes distress, disability and could 
compromise quality of life. Negative influence of schizophrenia on family members, such as the 
children in the family, adversely affect the life of the members and may even change their 
behaviors. Therefore, understanding the determinants for prevalence and severity and 
understanding the effects of the negative outcomes of schizophrenia would help to elucidate the 
nature of the overall burden of schizophrenia.  
Since schizophrenia is a chronic disorder with no cure at present, the prevalence of 
schizophrenia is largely determined by age at onset and incidence rate, which are affected by 
risk factors of schizophrenia. Numerous risk factors for early onset of schizophrenia and higher 
incidence rate have been reported, which can be classified into demographic risk factors, 
environmental risk factors and genetic risk factors. Demographic factors, including gender, 
family history and birth seasonality have been reported to be associated with earlier onset and 
higher incidence rate. However, negative studies have also been reported, and similar studies 
based on Chinese population are limited. Genetic risk factors have been considered as the most 
significant risk factors for schizophrenia but the findings are generally inconclusive. 
Considering these deficiencies, the first aim of this thesis was to understand the effects of the 
two types of risk factors of schizophrenia: demographic risk factors and genetic risk factors.  
146 
 
Negative outcomes of schizophrenia are related to co-morbidities and negative influence on 
family members. One of the most common co-morbidities of schizophrenia is tardive dyskinesia. 
Tardive dyskinesia is characterized by involuntary movements of bodies and extremities, which 
can negatively affect the quality of life of schizophrenia patients. However, the mechanism for 
tardive dyskinesia development among schizophrenia patients is still largely unknown. 
Schizophrenia also negatively affects the life of family members. The influence on their 
offspring school performance could be studied as a proxy for the influence of schizophrenia on 
family members. Children of schizophrenia patients are found to have poor school performance, 
which has been thought to be due to unfavorable family living environment, such as lack of 
good parenting and poor family education. However, the actual mechanism is not known and 
the unfavorable family environment may be confounded by associated schizophrenia family 
genetics. Considering these deficiencies, the second aim of thesis was to investigate the 
mechanism for the two negative outcomes of schizophrenia: tardive dyskinesia and poor 
offspring school performance.  
We attempted to achieve the first aim as described in Chapter 2 and Chapter 3 by investigating 
the association between demographic and genetic risk factors and schizophrenia. We attempted 
to achieve the second aim as described in Chapter 4 and Chapter 5 by exploring the mechanism 
for tardive dyskinesia and poor offspring school performance. In achieving two aims, the effects 
of demographic and genetic risk factors on schizophrenia onset could be identified, and the 
mechanism of the influences of schizophrenia on co-morbidities and their offspring could be 
understood. The following section reviews the four studies which aim to achieve these two aims 
and conclude based on the results from these studies.  
6.2 Conclusions and achievement of objectives    
In Chapter 2, the effects of gender, family history, and birth seasonality on schizophrenia onset 
age were investigated. We found that male gender and positive family history are significantly 
associated with the early onset of schizophrenia, but birth seasonality had no effect on 
schizophrenia. These results imply that a population with higher proportion of male gender and 
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family history of schizophrenia would have higher prevalence of schizophrenia, and 
consequently higher economic burden of schizophrenia, given other factors being equal. We 
further found that gender and family history interacted with each other in affecting age of onset. 
Of note, we found that the effect of a positive family history override the gender effects, 
because the males and females did not show any difference in age at onset when both has 
positive family history. These findings expand the current understanding of gender and familial 
effects on age at onset.  
In Chapter 3, we attempted to identify the genetic risk factors of schizophrenia. We found that 
no SNPs were significantly associated with schizophrenia based on a case control study design 
(p<5.0×10
-8
), which is consistent with all previous GWAS on schizophrenia. The failure of 
identifying significant SNPs suggests that schizophrenia is not a simple disorder that is caused 
by a few influential causal SNPs. Multiple risk SNPs, with small effects for each SNP, are likely 
to play a role in the development of schizophrenia. We therefore utilized a pathway analysis 
which treated all the genes in a pathway as one unit and examined the pathway effects on 
schizophrenia. Results showed that the ARVC pathway and CAMs pathways are significantly 
associated with schizophrenia. CAMs pathway has been specifically reported as risk pathway 
for schizophrenia, and it is involved in neuron cell, especially axon, developments. The ARVC 
pathway is a pathway relating to heart disorder and has not been previously implicated in 
schizophrenia. Although the mechanism for its association with schizophrenia is not known, 
identification of this pathway give an alternative explanation for the observation of high rate of 
heart failures among schizophrenia patients. We also investigated the genetic risk factors for 
early onset of schizophrenia. Results showed that a SNP in introns of CNTN5 reached a 
significance level of 1.0×10
-8
. CNTN5 is a gene that involves in axon development, which 
coincides with pathway findings. Moreover, CNTN5 and members in CNTN families as well as 
proteins that interact with CNTN5 have all been reported as risk factors of schizophrenia and 
bipolar disorders before. These cross validations further support the role of CNTN5 in 
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schizophrenia development. Since both identified pathways and genes are related to neuron 
development, our results support that schizophrenia is a disorder of brain development.   
In Chapter 4, we examined the prevalence, incidence, and risk factors of tardive dyskinesia. We 
found that one in five Singapore Chinese schizophrenia patients had tardive dyskinesia. This 
prevalence is much less than the prevalence ten years ago. We also found out that incidence rate 
was at least 36/1000 person years. These findings provide useful information for policy makers. 
We further examined the risk factors of tardive dyskinesia among the schizophrenia patients. It 
was found out that both advanced age and prolonged usage of antipsychotics were significantly 
associated with tardive dyskinesia. However, the effect of prolong usage of antipsychotics were 
confounded by senior ages. This is because higher proportion of tardive dyskinesia was found to 
be associated with older age when keeping duration of antipsychotic usage constant, while the 
proportion of tardive dyskinesia did not change with antipsychotics usage when keeping age 
category constant. This finding clarifies the mechanism for development of tardive dyskinesia 
among schizophrenia population by revealing the confounding effects of age.  
In Chapter 5, we investigated the association as well as the mechanism of the association 
between parental schizophrenia status and offspring school performance. It was found out that 
the offspring of schizophrenia patients had poorer school performance than their peers. This 
observation is in agreement with previous studies. We further investigated the mechanism of the 
association by stratification analysis and found out that variation in genetics substantially 
modulated the strength of intergeneration association. However, variation in family 
environment did not change the strength of the association. We, therefore, conclude that poor 
school performance of offspring of schizophrenic patients is due to the genetic factor rather than 
adverse family environment associated with schizophrenia patients. These findings relieve the 
schizophrenic parents from blaming themselves for not providing a good parenting due to 
schizophrenia symptoms. Moreover, current findings also reinforce the foundation for studying 
poor school performance as a predictor for later schizophrenia development. 
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Through these four studies, our aims in current thesis have been fulfilled. The effects of 
demographic risk factors as well as genetic risk factors on schizophrenia among Singapore 
Chinese population have been elucidated. The status, risk factors and mechanism for tardive 
dyskinesia as well as poor offspring school performance have been revealed. Therefore, the 
overall aim to contribute to elucidate the burden of schizophrenia has been achieved.   
6.3 Future work 
As with most research, the work described in this thesis has identified more areas of further 
work. These further researches should also seek to address some of the limitations of the studies 
described here. Considering their purposes, the future research has been grouped into three areas:  
1) Future studies to improve methodology. Since schizophrenia is not a very common disorder, 
obtaining large sample of schizophrenia patients is challenging. Therefore, given a limited 
sample size, a trade-off between power and resolution of findings is usually encountered in 
identifying the risk factors of schizophrenia. For example, grouping genes belonging to the 
same biological pathway could improve the power in detecting the real genetic risk factors. 
However, by doing so, the resolution of the study is lost to some extent, because each pathway 
includes multiple of genes. Moreover, considering that rare SNPs (i.e. SNPs with less than 5% 
prevalence in population) may contribute more risk to schizophrenia, they could be studied for 
association with schizophrenia in future. However, given a limited sample size, the rare alleles 
at multiple locations have to be combined in order to gain sufficient power to be detected. By 
doing so, the resolution of the test is also lost. Therefore, a new analysis method that can 
increase the power of detection yet minimize the loss of resolution is needed. These new 
analysis methods could help in the identification of risk factors of schizophrenia and increase 
the consistency of findings by reducing false positive results. 
2) Future studies to locate causal genetic risk factors. The foundation of genetic study of 
schizophrenia is built on the theory of LD, which states that alleles in physical proximity tend to 
inherit together from generation to generation. Therefore, all the risk SNPs identified in this 
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thesis cannot be claimed as causal SNPs as they may be the SNPs that are in LD with the real 
causal SNPs. In order to identify the real causal SNPs, a fine mapping procedure is required, in 
which all SNPs nearby, or in LD with, the identified SNPs would be sequenced and tested for 
association. The causal SNPs would be the one with the most significant effect. The challenge is 
that there are might be multiple SNPs that are in perfect LD, and all of them have the highest 
significance in association. In such a case, comparing the significance of the SNPs with perfect 
LD across study samples with different underlying LD structure (e.g. population from different 
origins) could help in identifying the casual SNP. This is because the causal SNP should remain 
significant disregarding LD structure, whereas the significance of the SNPs that are in LD with 
the causal SNP is affected by LD structure. Function studies of the most significant SNP are 
also needed to fully establish causality relationship.  
3) Future studies to elucidate the mechanisms of association. In identification of demographic 
risk factors in this thesis, we found that gender was associated with age at onset of 
schizophrenia. Estrogen in females has been hypothesized as the mediator for the association, 
but it was not tested in this thesis. In order to establish the role of estrogen, a biological 
experiment based on the schizophrenia animal model could be designed. If application of 
estrogen on the animal model reduces the schizophrenic symptoms, and withdraw estrogen 
leads to a relapse of schizophrenic symptoms, then the role of estrogen could be established. 
The challenge of the experimental design is that there is no good schizophrenia animal model 
due to the lack of clear conceptual framework for schizophrenia. However, as knowledge 
cumulates, good schizophrenia model may get developed, and the experiment could be 
performed. In identifying the genetic risk factors of schizophrenia, we found that gene CNTN5 
was associated with early onset of schizophrenia. However, since the significant SNPs all locate 
in introns of CNTN5, it is not clear how these SNPs play a role in schizophrenia development. 
A hypothesis would be that these SNPs influence the expression of the CNTN5. To test this 
hypothesis, the RNA expression amount could be compared between subjects with different 
151 
 
alleles in the introns. If the hypothesis is true, a significant difference in expression amount 
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R code for pathway analysis:  
Note: The following code is the core part of the code for GSEA analysis. The gene information 
including open reading frame position was downloaded from UCSC 
(http://genome.ucsc.edu/cgi-bin/hgGateway).  
setwd("C:/Users/AdminNUS/Desktop/redo pathway analysis/GSEA1B") 
#function master is the main function to compute test statistics for 
pathways. This main function includes a number of sub functions which 
were defined in the code blocks following the master function.  
 
master<-function() { 
 pathway<-read.table("kegbiogopathway.txt", header=T) 
 
 #SNP p value included the p values of the SNPs passing quality 





 #Convert gene labeling.  
  
 uniprot2ncbi<-read.table("201111212CJ4QDUXNP.tab", header=T) 
 snpinfo<-read.table("snpinfo.txt", header=T) 
 names(snpinfo)<-c("SNP", "CHR", "BP") 
 gene<-read.table("knowngene3.txt", header=F) 
 tempref2uni<-read.table("refseq2uniprot.tab", header=T) 
 tempunip2entr<-read.table("uniprot2entrez.tab", header=T) 
 
 names(tempunip2entr)<-c("To", "Toentrez") 
 temp<-merge(tempref2uni, tempunip2entr, by=c("To")) 
 gene2<-temp[,c("From","Toentrez")] 
 names(uniprot2ncbi)<-c("uniprot", "ncbi") 
 names(gene2)<-c("uniprot", "ncbi") 
 uniprot2ncbi<-rbind(uniprot2ncbi, gene2) 
 
 names(gene)<-c("id", "CHR", "Strand", "Start", "End", "uniprot") 






 newgene<-matchunincbi(ncbi=uniprot2ncbi, newgene=newgene)  
  
 matchsnp2gene(chr=22)  
 snpgene<-read.table("snpgene.txt") 
 names(snpgene)<-c("SNP", "CHR", "BP", "ncbi", "start", "end") 
 genestats<-snp2gene(snppvalue=snppvalue, snpgene=snpgene) 
 
 write.table(genestats, "genestats.txt", row.names=F, col.names=F, 
quote=F, sep="\t")  







 raw<-gsea(genestats=genestats, pathway=pathway[,c("gene", 
"pathway")], no.permu=10000) 
 pwpvalue<-result(raw=raw, min=20, max=200) 
 return(procs(pwpvalue=pwpvalue)) 
  
 keggpathway<-read.table("keggpathway.txt", header=F) 
 keggraw<-gsea(genestats=genestats, pathway=keggpathway, 
no.permu=10000) 





#step1 process gene position file  
procgene<-function(gene=gene) { 
 chr<-sort(as.character(names(table(gene$CHR)))) 
 chr2num<-c(1,1,10, 11, 12,13,14, 15, 16, 17,17,18, 19,19,2,20, 
21,22,3,4,4,4,5,6,6,6,6,6,6,6,6,7,8,9,9,0,0,0,0,0,0,23,24) 
  
 matchchr<-function(x) {which(chr==as.character(x[2]))}   
 index<-apply(gene, 1, matchchr)  
 
 newgene<-data.frame(uniprot=gene$uniprot, CHR=chr2num[index], 
start=gene$Start, end=gene$End) 





#step 2 matching uniprot gene to ncbi gene 
matchunincbi<-function(ncbi=uniprot2ncbi, newgene=newgene)  { 
 gene<-merge(newgene, ncbi, by="uniprot")  




#step 3 match chip snps to genes  
matchsnp2gene <- function(snp=snpinfo[,c("SNP", "CHR", "BP")], 
gene=newgene, chr) { 
 index<-snp$CHR=="0" | snp$CHR=="X" | snp$CHR=="Y" | snp$CHR=="M" 
 snp<-snp[!index, ]  
 snp$CHR<-as.numeric(as.character(snp$CHR))  
  
 index<-order(snp$CHR, snp$BP)  
 snp<-snp[index, ] 
 index<-order(gene$CHR, gene$start)  




 temp<-data.frame(SNP=NULL, CHR=NULL, BP=NULL, ncbi=NULL) 
 for(i in 1:chr) { 
  snplist<-snp[snp$CHR==i,] 
  genelist<-gene[gene$CHR==i, ] 
  for(j in 1: nrow(genelist)) { 
   index<-which((snplist$BP-genelist[j, 
"start"])*(snplist$BP-genelist[j, "end"])<=0) 
   if(length(index)>0) { 
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    write.table(data.frame(snplist[index, ], 
genelist[j,c("ncbi", "start", "end")]),file="snpgene.txt", quote=F, 
row.names=F, col.names=F, sep="\t", append=T)  
    print(i) 
    print(j) 
   } 
  }  
 }   
} 
 
#step4 link snppvalue to genes 
snp2gene<- function(snppvalue=snppvalue, snpgene=snpgene) { 
 




  maxchisq<-tapply(CHISQ, as.factor(ncbi), max)  
  genestats<-
as.data.frame(cbind(as.character(levels(as.factor(ncbi))), maxchisq)) 






   
#step 5 compute pathway statistics 
gsea<-function(genestats, pathway, no.permu) {  




 names(pathway)<-c("gene", "pathway") 
 pathway.list<-unique(pathway$pathway)  
 pathway.list<-as.character(pathway.list)  
 if(!is.character(pathway.list)) stop ("pathway.list is not 
characters")  
  




 for(j in 1:no.permu) { 
  if(j==1) { 
   stats<-statistics 
   g<-gene 
  } 
  else { 
   stats<-sample(statistics) 
   g<-gene 
  }  
   
  if(is.numeric(stats)) { 
   index<-order(stats, decreasing=T) 
   stats<-stats[index] 
   g<-g[index] 
  } 
  else stop("stats not numeric") 
   
  for(i in 1:length(pathway.list)) { 
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   geneset<-
as.character(pathway[pathway$pathway==pathway.list[i], "gene"]) 
   tag.indicator <- sign(g%in%geneset)      
   no.tag.indicator <- 1 - tag.indicator  
      N  <- length(g)  
         Nh <- sum(tag.indicator) 
   if(j==1) { 
    n<-c(n, Nh) 
   } 
      Nm <-  N - Nh  
   nNm<-1/Nm 
   Nr <- sum(stats[tag.indicator == 1]) 
   nNr<- 1/Nr 
   score <- cumsum(tag.indicator * stats * nNr - 
no.tag.indicator * nNm)  
   es[i,j] <- max(score) 
   print(j) 
   print(i) 
  } 
 } 
 detach(genestats) 
 return(list(pathway=pathway.list, es=es, n=n)) 
} 
   
result<-function(raw, min, max) { 
 es<-raw$es[,-1] 





 index<-(N>min & N<max) 
 es<-es[index, ]  
 ES<-ES[index] 
 pathway.list<-pathway.list[index]  






 row.sd<-apply(es, MARGIN=1, FUN=sd) 
 row.mean<-apply(es, MARGIN=1, FUN=mean) 
 nes<-matrix(nrow=nrow(es), ncol=ncol(es)) 
 NES<-NULL 
 for(i in 1:no.pathway) { 
  nes[i,] <- (es[i,] - row.mean[i])/row.sd[i] 
  NES[i]<-(ES[i]-row.mean[i])/row.sd[i]  
 } 
  




 max.nes<-apply(nes, MARGIN=2, FUN=max)  
 for(i in 1:no.pathway) { 
  p0<-sum(nes[i,]>=NES[i]) 
  p1<-sum(nes>=NES[i])/total  
  p2<-sum(NES>=NES[i])/no.pathway 
  pwqvalue[i]<-p1/p2 
  pwpvalue[i]<-p0/no.perm 
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  fwer[i]<-sum(max.nes>=NES[i])/no.perm 
 } 
 return(data.frame(pathway=pathway.list, N=N, ES=ES, NES=NES, 
pvalue=pwpvalue, FDR=pwqvalue, FWER=fwer))   
}   
 
procs<-function(pwpvalue) {  
 index<-order(pwpvalue$pvalue) 





















R code for analysis of age at onset:    
Note: The following is the core part of the code for analysis of age at onset. The key function to 











 score<-read.table("score.txt", header=T) 
 name<-genname() 
 gdag<-genderage()  
 calp(genderage=gdag, name=name, coln=coln, score=score) 
 data<-result() 
 return(data)   






 for(i in 1:length(alphabet)) { 









 rmsamples<-read.table("rm66samples.txt", header=T) 
 ageonset<-read.table("ageonset.txt", header=T)  
 index<-as.vector(ageonset$genotypeid)%in%as.vector(rmsamples[,1]) 
 ageonset<-ageonset[!index, ] 
 gender<-read.table("gender.txt", header=T) 
 gdag<-merge(ageonset,gender, by="genotypeid") 
 index<-(gdag$agonset==999) 
 gdag<-gdag[!index, ]  
 gdag$Gender<-as.numeric(gdag$Gender=="Male") 
 return(gdag)  
} 
 
concat = function(v) { 
 res = "" 
 for (i in 1:length(v)){ 








calp<-function(genderage, name, coln, score) { 
 wname<-paste("w", name, sep="") 
 co<-data.frame(genotypeid=coln) 
    
 for(i in 1:length(name)) { 
  Pkm<-NULL 
  Pcoxncor<-NULL 
  Pcox<-NULL 
  betacoxncor<-NULL 
  betacox<-NULL 
  SNP<-NULL 
  freq<-NULL 
  Pneg<-NULL 
  Pnegcor<-NULL 
   
  data<-read.table(name[i], row.names=1) 
  data<-t(data) 
  data<-cbind(co, data)  
  rownames(data)<-NULL 
   cname<-colnames(data)      
 
  for(j in 2:ncol(data)) { 
   temp<-merge(genderage, data[,c(1,j)], 
by="genotypeid")  
   x<-temp[,cname[j]]  
   index<-(x==-1)  
   temp<-temp[!index, ]  
   s<-Surv(temp$agonset, rep(1, nrow(temp))) 
   x<-temp[,cname[j]]  
    
   tb<-table(x) 
   if(length(tb)>1) {  
   if(length(tb)>=3) { 
    tb<-tb[c("0", "1", "2")]  
    if(min(tb)<=0.01*nrow(temp)) { 
     minname<-names(which(tb==min(tb)))  
     temp[x==as.numeric(minname), cname[j]]=1  
    } 
   }     
   tb<-table(x) 
   freq[j-1]<-concat(tb)     
      
   test<-survdiff(s~temp[,cname[j]]) 
   SNP[j-1]<-cname[j]  
   Pkm[j-1]<-1-pchisq(test$chisq, length(test$n)-1) 
      
   fit0<-summary(coxph(s~temp[,cname[j]]))  
   Pcoxncor[j-1]<-fit0$coef["temp[, cname[j]]", 
"Pr(>|z|)"] 
   betacoxncor[j-1]<-fit0$coef["temp[, cname[j]]", 
"coef"] 
 
   fit<-summary(coxph(s~temp[,cname[j]] + 
temp[,"Gender"]))  
   Pcox[j-1]<-(fit$coef)["temp[, cname[j]]", "Pr(>|z|)"] 
   betacox[j-1]<-fit$coef["temp[, cname[j]]", "coef"] 
   } 
 
   temp<-merge(score, data[,c(1,j)], by="genotypeid") 
   temp<-merge(temp, genderage, by="genotypeid")  
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   x<-temp[,cname[j]]  
   index<-(x==-1)  
   temp<-temp[!index, ]  
   x<-temp[,cname[j]]  
   tb1<-table(x) 
   if(length(tb1)>1) {  
   if(length(tb1)>=3) { 
    tb1<-tb1[c("0", "1", "2")]  
    if(min(tb1)<=0.01*nrow(temp)) { 
     minname<-names(which(tb1==min(tb1)))  
     temp[x==as.numeric(minname), cname[j]]=1  
    } 
   }     
   y<-as.matrix(temp[,2:8])  
   x<-temp[,cname[j]] 
   covar<-temp[,"Gender"] 
   fit<-summary(manova(y~x)) 
   Pneg[j-1]<-fit$stats["x", "Pr(>F)"] 
   fit<-summary(manova(y~x+covar))  
   Pnegcor[j-1]<-fit$stats["x", "Pr(>F)"] 
   } 
   print(j)  
  }   
 temp0<-data.frame(snp=SNP,freq=freq, 
pkm=Pkm,pcoxncor=Pcoxncor,betancor=betacoxncor, pcox=Pcox, 
beta=betacox, pneg=Pneg, pnegcor=Pnegcor)  
 write.table(temp0, wname[i], row.names=F,col.names=F, quote=F, 
sep="\t")  
 }  
} 
 
    
result<-function() { 
 data<-NULL 
 name<-genname()  
 wname<-paste("w", name, sep="") 
 for(i in 1:length(wname)) { 
  temp<-read.table(wname[i])  
  data<-rbind(data, temp) 
 } 
 colnames(data)<-c("snp", "freq", "pkm", "pcoxncor", "betancor", 
"pcox", "betacox", "pneg", "pnegcor")  
 index<-is.na(data$snp) 
 data<-data[!index, ] 
 return(data)  
} 
       
processresult<-function(result) {    
 rmsnp<-read.table("allrmsnp.txt", header=T) 
 rmsnp<-as.character(rmsnp[,1]) 
 index<-(result$snp)%in%rmsnp 





 cols<-c(rep(c("red", "green", "blue"), 7), "red") 
 chipsnp<-read.table("chipsnp.txt", header=T) 
 colnames(chipsnp)<- c("snp", "chromosome", "position") 




 index<-order(pvalue$chromosome, pvalue$position)  




 mp(temp, cex=0.6, pch=16, colors=cols) 
 axis(side=2, at=1:8, labels=1:8) 





 mp(temp, cex=0.6, pch=16, colors=cols) 
 axis(side=2, at=1:8, labels=1:8) 
 title("P value from PHM without adjusting for gender", cex=0.5) 





 mp(temp, cex=0.6, pch=16, colors=cols) 
 axis(side=2, at=1:8, labels=1:8) 





 mp(temp, cex=0.6, pch=16, colors=cols) 
 axis(side=2, at=1:8, labels=1:8) 






 mp(temp, cex=0.6, pch=16, colors=cols) 
 axis(side=2, at=1:8, labels=1:8) 
 title("P value from multivariate test adjusting for corvariates 
for negative symptoms", cex=0.5) 
}   
 
 
extractdata<-function(result, coln) { 
 index<-is.na(data$snp)   
 result<-result[!index, ]    
 snplist<-result[result$pcox<1.0e-04, "snp"] 
 name<-genname()  
 temp<-NULL 
 tempnames<-NULL 
 for(i in 1:length(name)) { 
  data<-read.table(name[i], row.names=1) 
  data<-t(data) 
  index<-colnames(data)%in%snplist 
  tempnames<-c(tempnames, colnames(data)[index]) 
  colnames(data)<-NULL 
  temp<-cbind(temp, data[, index]) 
  print(i) 
 } 
 colnames(temp)<- tempnames 




 return(temp)      
} 
#estimate the baseline hazard function and compared with PHM 
BETA<-beta.lasso*true.sd 













plot(km.f, conf.int=T, col=c("red","black","red"), xlab="age of onset", 
ylab=expression(hat(S)(t))) 
lines(time[2:length(time)], s0, type="s", col="black") 
legend(50, 0.9, c("KM curve", "95% confidence interval", "PHM 
predicted curve"), col=c("red", "red", "black"),border="white", 
lty=c(1,3,1)) 
title("comparison of actual age of onset and predicted age of onset 
based on 44 SNPs") 
  
 
#plot the coefficient curve as a function of beta 
par(mai=c(1.0,0.82,0.82,1.0)) 
c<-sample(colours(), size=1) 
plot(la, beta.s[,1], xlim=c(0,11), ylim=c(-0.8, 1), xlab="lamda", 
ylab="beta", type="p", cex=0.5, pch=16,col=c, axes=F) 
lines(la, beta.s[,1],col=c) 
for(i in 2:ncol(beta.s)) { 
 c<-sample(colours(), size=1) 
 points(la, beta.s[,i], type="p", pch=16,cex=0.5, col=c) 





#scale of gcv 
b0=(max(beta.s)-min(beta.s))/(max(GCV)-min(GCV)) 
gcv<-b0*GCV+a0 
points(la, gcv, type="l")  
 
tick=seq(5.7, 6.3, by=0.1) 
tick1=b0*tick+a0 
axis(side=4, at = tick1, labels = tick) 
axis(side=2, at=seq(-1,1,by=0.25), labels=seq(-1,1,by=0.25)) 
axis(side=1, at=c(0:11), labels=c(0:11)) 
box()  
abline(v=la[rank(GCV)==1], col="red", lty=3)  
mtext(text="GCV", side=4, line=2) 
title("Lasso variable selection", cex.main=0.9, line=1) 
legend(7.5, 1, c("beta coefficient (all colour)", "GCV", "tuning 
point"),pch = c(16,26,26), ncol=1, lty=c(1,1,3),cex = 
0.8,col=c("black","black","red")) 
 













 tmp<-data[index, ] 
 
 tmp<-merge(tmp[,c("snp", "pcox")], regionsnp, by="snp") 
 index<-order(tmp$pos) 
 tmp<-tmp[index, ] 
  






 recomb<-read.table("recombchr11.txt", header=T) 




 x11(width=8, height=6) 
 PAR<-par(mai=c(1.0,0.82,0.82,1)) 
 plot(tmp$pos, -log10(tmp$pcox), xlab="SNP postion at chromosome 
11", ylab="-log10(P value)", type="p", col=cols, pch=18, axes=F, 
ylim=c(0,8)) 
  
 tk<-seq(min(tmp$pos), max(tmp$pos), length.out=5) 
 axis(side=1, at=round(tk), labels=round(tk), cex.axis=0.8) 
 axis(side=2, at=0:8, labels=0:8) 
 lines(recb$start, rescale(from=recb$Rate_cM.Mb, to=c(0,8)), 
type="h", col="light blue") 
 tk<-rescale(from=seq(0,30,by=5), to=c(0,8)) 
 axis(side=4, at=tk, labels=seq(0,30,by=5)) 
 mtext(text="Recombination rate (cM/Mb)", side=4, line=2) 
 box() 
 legend(99350596, 8.2, legend=c("SNP in LD with rs7118338", "SNP 
in gene CNTN5", "other SNPs in the region"), pch=16,col=c("red","blue", 




#plot the the KM curve for different genetic profile  
 
BETA<-beta.lasso*true.sd 
BETA<-as.matrix(BETA, nrow=length(BETA), ncol=1) 
PI<-z%*%BETA  
 
hist(PI, xlab="prognostic index (PI)")  
box() 
time2<-time[-1] 









#lines(fit$time, fit$lower, type="s", lty=1, col="grey") 




lines(fit$time, fit$surv, type="s", col="blue") 
#lines(fit$time, fit$lower, type="s", lty=1, col="light blue") 




lines(fit$time, fit$surv, type="s", col="green") 
#lines(fit$time, fit$lower, type="s", lty=1, col="light green") 




lines(fit$time, fit$surv, type="s", col="red") 
#lines(fit$time, fit$lower, type="s", lty=1, col="pink") 
#lines(fit$time, fit$upper, type="s", lty=1, col="pink") 
mtext(side=1, text="Age of onset", line=2) 
mtext(side=2, text=expression(hat(S)(t)), line=2) 
legend(40, 0.95, ncol=1, legend=c("first quarter KM curve", "second 
quarter KM curve", "third quarter KM curve","forth quater KM curve"), 
lty=1, cex=0.7, col=c("black","blue","green","red")) 




 pdata<-merge(pdata,genderage(), by="genotypeid") 


















Attachment of abstract of pulished articles: 
1. Poor school performance in offspring of patients with schizophrenia: what are the 
mechanisms? 
Psychol Med. 2012 Jan;42(1):111 
BACKGROUND: Offspring of patients with schizophrenia exhibit poorer school performance 
compared with offspring of non-schizophrenic parents. We aimed to elucidate the mechanisms 
behind this association. 
METHOD:We linked longitudinal national population registers in Sweden and compared school 
performance among offspring of schizophrenic parents with offspring of non-schizophrenic 
parents (1 439 215 individuals with final grades from compulsory school 1988-2006). To 
investigate the mechanisms, we studied offspring of schizophrenic patients and controls within 
the same extended families. We investigated genetic effects by stratifying analyses of parent-
child associations according to genetic relatedness (half-cousins, full cousins and half-siblings). 
Environmental effects were investigated by comparing school performance of offspring of 
schizophrenic fathers and of schizophrenic mothers, respectively, and by stratifying the analyses 
according to environmental relatedness while controlling genetic relatedness (paternal and 
maternal half-cousins, paternal and maternal half-siblings). 
RESULTS:Offspring of parents with schizophrenia had poorer overall school performance than 
unrelated offspring of non-schizophrenic parents (-0.31 s.d.). Variability in genetic relatedness 
greatly moderated the strength of the within-family association (β=-0.23 within exposure-
discordant half-cousins, β=-0.13 within exposure-discordant full cousins, β=0.04 within 
exposure-discordant half-siblings), while no evidence was found that the environment affected 
offspring school performance. 
CONCLUSIONS: Genetic factors account for poorer school performance in children of parents 
with schizophrenia. This supports that cognitive deficits found in individuals with schizophrenia 
and their relatives might be genetically inherited. Early detection of prodromal signs and 
impaired functioning of offspring of patients with schizophrenia could lead to earlier and better 
tailored interventions. 
 
2. Gender differences in Singaporean Chinese patients with schizophrenia. 
Asian J Psychiatr. 2011 Mar;4(1):60 
The purpose of this study was to compare gender differences in age of onset of illness, clinical 
features and prescription patterns in Chinese schizophrenia patients in Singapore. A cross-
sectional study was conducted which recruited 903 subjects diagnosed with schizophrenia from 
the Institute of Mental Health between 2005 and 2008. Information on age of onset of 
schizophrenia, body mass index (BMI), psychiatric family history and current medication was 
collected via a standardised collection form. Symptom severity was assessed with Positive and 
Negative Syndrome Scale (PANSS). Differences in age of onset of schizophrenia illness, 
clinical features and prescription patterns were compared between gender groups. Among 
sporadic schizophrenia cases, female subjects demonstrated a bimodal distribution in age of 
onset of illness, and had a significantly later age of illness onset compared with male subjects. 
For subjects with family history of psychiatric disorder, no significant gender differences were 
found in age of onset of illness. Female subjects had significantly higher BMI, higher 
proportion of diabetes mellitus, lower negative symptom scores and were prescribed more 
atypical antipsychotics and antidepressants compared with male subjects. Male subjects after 
age 50 were prescribed a lower antipsychotic dose, but this difference was not observed in 
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female subjects. In conclusion, we found differences in age of onset of schizophrenia, severity 
of negative symptoms and prescription patterns between the male and female gender groups in 
Chinese schizophrenia patients in Singapore. These differences were consistent with findings 
from Caucasian population, and could possibly be explained by influences of oestrogen. 
 
3. The prevalence of tardive dyskinesia in Chinese Singaporean patients with schizophrenia 
J Clin Psychopharmacol. 2010 Jun;30(3):333 
Tardive dyskinesia (TD) is a form of neuroleptic-induced movement disorder characterized by 
involuntary movements. With a lack of effective treatment strategies, risk factors based on 
epidemiological studies should be identified in order to prevent the occurrence of TD. In this 
study, we sought to recruit an independent sample to establish the point prevalence of TD, and 
to examine the risk factors associated with it. A total of 790 schizophrenia patients were 
recruited in Singapore Institute of Mental Health, and socio-demographic, medication, and 
severity of TD were collected and assessed. One hundred and sixty-six (21.0%) patients were 
found to have TD. Logistic regression of 8 variables including age, duration of cumulative 
neuroleptic exposure, diabetes mellitus, current neuroleptic dose, anticholinergic use, EPSE 
status, PANSS negative and general psychopathology score suggest that age and EPSE were 
significant risk factors of TD. These findings suggest that older schizophrenia patients have 
higher risk for TD, and clinicians could consider this factor in prescribing antipsychotics. 
